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Abstract
The association between primary care quality and health-care
use, costs and outcomes for people with serious mental illness:
a retrospective observational study
Rowena Jacobs ,1* Lauren Aylott ,2,3 Ceri Dare ,2 Tim Doran ,3
Simon Gilbody ,3,4 Maria Goddard ,1 Hugh Gravelle ,1 Nils Gutacker ,1
Panagiotis Kasteridis ,1 Tony Kendrick ,5 Anne Mason ,1 Nigel Rice ,1
Jemimah Ride ,1 Najma Siddiqi 3,4,6 and Rachael Williams 7
1Centre for Health Economics, University of York, York, UK
2Expert by experience
3Hull York Medical School, York, UK
4Department of Health Sciences, University of York, York, UK
5Primary Care and Population Sciences, Aldermoor Health Centre, University of Southampton,
Southampton, UK
6Bradford District Care NHS Foundation Trust, Bradford, UK
7Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency,
London, UK
*Corresponding author rowena.jacobs@york.ac.uk
Background: Serious mental illness, including schizophrenia, bipolar disorder and other psychoses, is
linked with high disease burden, poor outcomes, high treatment costs and lower life expectancy. In the
UK, most people with serious mental illness are treated in primary care by general practitioners, who
are financially incentivised to meet quality targets for patients with chronic conditions, including
serious mental illness, under the Quality and Outcomes Framework. The Quality and Outcomes
Framework, however, omits important aspects of quality.
Objectives: We examined whether or not better quality of primary care for people with serious mental
illness improved a range of outcomes.
Design and setting: We used administrative data from English primary care practices that contribute
to the Clinical Practice Research Datalink GOLD database, linked to Hospital Episode Statistics,
accident and emergency attendances, Office for National Statistics mortality data and community
mental health records in the Mental Health Minimum Data Set. We used survival analysis to estimate
whether or not selected quality indicators affect the time until patients experience an outcome.
Participants: Four cohorts of people with serious mental illness, depending on the outcomes examined
and inclusion criteria.
Interventions: Quality of care was measured with (1) Quality and Outcomes Framework indicators
(care plans and annual physical reviews) and (2) non-Quality and Outcomes Framework indicators
identified through a systematic review (antipsychotic polypharmacy and continuity of care provided by
general practitioners).
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Main outcome measures: Several outcomes were examined: emergency admissions for serious mental
illness and ambulatory care sensitive conditions; all unplanned admissions; accident and emergency
attendances; mortality; re-entry into specialist mental health services; and costs attributed to primary,
secondary and community mental health care.
Results: Care plans were associated with lower risk of accident and emergency attendance (hazard
ratio 0.74, 95% confidence interval 0.69 to 0.80), serious mental illness admission (hazard ratio 0.67,
95% confidence interval 0.59 to 0.75), ambulatory care sensitive condition admission (hazard ratio
0.73, 95% confidence interval 0.64 to 0.83), and lower overall health-care (£53), primary care (£9),
hospital (£26) and mental health-care costs (£12). Annual reviews were associated with reduced
risk of accident and emergency attendance (hazard ratio 0.80, 95% confidence interval 0.76 to 0.85),
serious mental illness admission (hazard ratio 0.75, 95% confidence interval 0.67 to 0.84), ambulatory
care sensitive condition admission (hazard ratio 0.76, 95% confidence interval 0.67 to 0.87), and
lower overall health-care (£34), primary care (£9) and mental health-care costs (£30). Higher general
practitioner continuity was associated with lower risk of accident and emergency presentation (hazard
ratio 0.89, 95% confidence interval 0.83 to 0.97) and ambulatory care sensitive condition admission
(hazard ratio 0.77, 95% confidence interval 0.65 to 0.92), but not with serious mental illness admission.
High continuity was associated with lower primary care costs (£3). Antipsychotic polypharmacy was not
statistically significantly associated with the risk of unplanned admission, death or accident and emergency
presentation. None of the quality measures was statistically significantly associated with risk of re-entry
into specialist mental health care.
Limitations: There is risk of bias from unobserved factors. To mitigate this, we controlled for observed
patient characteristics at baseline and adjusted for the influence of time-invariant unobserved patient
differences.
Conclusions: Better performance on Quality and Outcomes Framework measures and continuity of
care are associated with better outcomes and lower resource utilisation, and could generate moderate
cost savings.
Future work: Future research should examine the impact of primary care quality on measures that
capture broader aspects of health and functioning.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Services
and Delivery Research programme and will be published in full in Health Services and Delivery Research;
Vol. 8, No. 25. See the NIHR Journals Library website for further project information.
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Plain English summary
Serious mental illness (SMI), such as schizophrenia and bipolar disorder, can have a devastatingimpact on individuals and their families. If people with serious mental illness receive high-quality
care from their general practitioners, they may live longer and be in better health. They may also need
less costly hospital care.
The Quality and Outcomes Framework pays general practices more money if they review the health
needs of their patients with serious mental illness at least once per year. General practices also receive
money if they put in place a care plan for patients with serious mental illness. However, the Quality
and Outcomes Framework covers only some aspects of care. Our study identified other measures not
included in the Quality and Outcomes Framework that may benefit patients: (1) ensuring that patients
are not prescribed two or more antipsychotic drugs unless appropriate (polypharmacy) and (2) patients
seeing the same general practitioner every time they attend the practice (continuity of care).
Using electronic patient records from general practices, we test whether or not better-quality primary
care is linked to better outcomes for patients with serious mental illness, including fewer unplanned
hospital admissions, fewer accident and emergency attendances, less use of specialist mental health-care
services and fewer premature deaths. We also test whether or not better-quality primary care saves
money for the NHS.
We found that patients with a care plan and those who are reviewed annually have fewer unplanned
hospital admissions, fewer accident and emergency attendances and lower overall health-care costs.
Seeing the same general practitioner also helps to reduce unplanned hospital admissions and accident
and emergency attendances for patients with some types of health complaints. We did not find that
receiving two or more antipsychotic drugs leads to worse outcomes.
We conclude that care plans, annual reviews and continuity of care are good measures of quality of
primary care. They can help keep patients out of hospital and reduce overall health-care costs.
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Scientific summary
Background
Serious mental illness is a set of chronic conditions, including schizophrenia, bipolar disorder and other
psychoses. It is linked with high disease burden, poor health outcomes, high treatment costs and lower
life expectancy. The UK population prevalence of bipolar disorder is around 1–2% and the lifetime
prevalence of schizophrenia is around 1%. Total monetary costs in England in 2012 were £6.0B for
bipolar disorder and £11.8B for schizophrenia and psychoses, mainly from costs to public services,
informal care and lost labour market output. Most people with a serious mental illness are treated
chiefly in primary care by their general practitioner.
Research questions
High-quality primary care has the potential to improve the health and well-being of patients with
serious mental illness and to reduce health-care utilisation and costs. We examined the association
between the quality of primary care for people with serious mental illness and seven outcome
measures:
1. emergency hospital admissions for serious mental illness
2. preventable admissions – emergency admissions for ambulatory care sensitive conditions
(conditions for which better-quality care should reduce the probability of an emergency
hospital admission)
3. all unplanned admissions
4. attendance at accident and emergency departments
5. mortality
6. re-entry into specialist mental health services
7. costs incurred for people with serious mental illness in primary and secondary care, and in
community mental health services.
Outcomes 1–6 were analysed in terms of ‘time to event’.
Methods
Quality measures
The Quality and Outcomes Framework incentivises general practitioners for meeting quality targets for
patients with certain chronic conditions, including serious mental illness. We studied two patient-level
quality indicators from the mental health domain of the Quality and Outcomes Framework: (1) whether
or not a patient with serious mental illness had a care plan and (2) whether or not they had received an
annual physical health review.
As the Quality and Outcomes Framework quality measures cover only some aspects of quality, we
undertook a systematic literature review to identify other measures of primary care quality for which
indicators could be available in routine administrative data. This led us to choose two non-Quality and
Outcomes Framework patient-level quality indicators: (1) continuity of consultations with the same
general practitioner and (2) antipsychotic polypharmacy.
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We used three widely applied indices of general practitioner care continuity. The extent of dispersion
across different general practitioners involved in the patient’s care was measured using the Continuity
of Care Index. The density of visits to a single general practitioner was measured with the Usual
Provider of Care Index and the pattern of visits across general practitioners was measured with the
Sequential Continuity Index.
We defined antipsychotic polypharmacy as the concurrent use of two or more antipsychotic substances
for at least a 30-day period. As a check on the robustness of this, we also considered longer and shorter
periods (thereby respectively reducing and increasing the amount of polypharmacy).
Data
We used a retrospective observational study design and followed four cohorts of primary care patients
with serious mental illness. We drew our patient samples from primary care practices in England that
contribute to the Clinical Practice Research Datalink GOLD database. Clinical Practice Research
Datalink linked the general practice records of patients with (1) their records in the Hospital Episode
Statistics admitted patient care data and attendances at accident and emergency departments,
(2) community mental health service records in the Mental Health Minimum Data Set and (3) mortality
data from the Office for National Statistics. The Clinical Practice Research Datalink classified practices
as rural or non-rural. We provided the Clinical Practice Research Datalink with data on the distances
from all English general practices to the nearest hospital and nearest mental health inpatient facility,
and the Clinical Practice Research Datalink attached four categorical indicators of these distances to
the practices in our sample.
In addition to the quality and outcome measures, we constructed a set of covariates for each patient
from the electronic patient records. Covariates included age (19–35, 36–45, 46–55, 56–65, > 65 years),
sex, number of Charlson Comorbidity Index comorbidities, depression, smoking status, alcohol status,
type of serious mental illness diagnosis (e.g. schizophrenia) and time since their first serious mental
illness diagnosis. For each patient, the Clinical Practice Research Datalink attached a categorical
measure of deprivation from the Index of Multiple Deprivation rank of the small area (lower-layer
super output area) in which the patient lived.
Hospital Episode Statistics hospital admission data covered the period of 1 April 2000 to 31 March
2014. Accident and emergency data were available for the period of 1 April 2007 to 31 March 2014.
We used data from the Mental Health Minimum Data Set for the period of 1 April 2011 to 31 March
2014, as earlier data were in an alternative format.
The start of the observation period for a patient was the latest of the following: 365 days after their
date of registration with the practice, 1 January of the year after the patient turned 18 years of age
or the date of their serious mental illness diagnosis. The end of the observation period was the earliest
of the following: the end of their registration with the practice, date of death or 31 March 2014.
The four sample sizes for analyses varied because of differences in data availability on key characteristics
and outcomes, and inclusion criteria for each specific analysis. For the analyses of the associations of
unplanned hospital admissions and accident and emergency attendances with care plans, annual reviews
and continuity, data were available for 19,324 individuals. For models in which the quality measure was
polypharmacy, patients had to have had at least one record of an antipsychotic drug and the sample
size was 17,255 patients for unplanned admissions and mortality, and 13,247 patients for accident and
emergency attendance. We had data on 9907 patients for models of re-entry to specialist mental health
services. The models of NHS cost used samples of 16,485 patients. The analysis samples were drawn
from 214 or 215 general practices.
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Statistical methods
We used survival analysis to examine the relationship between quality and all of the outcomes, except
NHS costs. Hospital admissions, accident and emergency attendances, re-entry to specialist mental
health services and mortality are events for which occurrence should be reduced or delayed by higher-
quality primary care. We therefore used survival models to investigate whether or not the time to first
occurrence of the outcome of interest was associated with the quality measure.
We used discrete-time survival analysis, which is appropriate when time to an event is recorded in
discrete intervals rather than continuous time, for our analyses of continuity of care. This was because
the measures of continuity were based on consultations with general practitioners within a 12-month
period. We divided time into 3-month blocks and investigated the association between quality
indicators in the prior 12 months (four blocks) and occurrence of the outcome in a 3-month period.
We fitted a complementary log–log proportional hazards model for each outcome. The hazard function
is the probability that the outcome event occurs during a particular (usually very small) period, given
that it has not occurred before the start of the period and that the individual is still observed in the
data. We were interested in the effect of the quality measures (which vary from period to period) on
the hazard rate. We also allowed the hazard function to vary between 3-month periods by specifying
dummy variables for each 3-month period so that the hazard function is constant within each period,
but can vary across periods. This allows for greater flexibility in the modelling.
Although we included observed characteristics of individuals in the model, it is possible that the hazard
of the outcome is affected by unobserved patient characteristics, which may also be correlated with
the observed quality indicators. These are often referred to as unobserved confounding factors and
their omission from a model can lead to biased estimates of the treatment of interest. In models in which
the outcome is a linear function of the explanatory variables, it is possible to control for unobserved
time-invariant patient factors by including a dummy variable for each individual. This is often termed
a fixed-effects model. This does not, however, extend to models in which the outcome is a non-linear
function of the explanatory variables, which is the case for our models. Instead, we adopted an alternative
procedure.We assumed that the effect of the unobserved patient characteristics is random and follows
a normal distribution. The mean of this random error can be modelled as a function of the mean of the
observed time-varying patient characteristics. These variables capture confounding by unobserved
time-invariant patient factors (e.g. long-standing illness, health-seeking behaviour) that affect both primary
care quality and health-care utilisation, and approximate a fixed-effects approach. As the three continuity
measures were highly correlated, we estimated three separate models to investigate their association
with outcomes.
We also investigated the association between polypharmacy and the occurrence of three outcomes:
(1) unplanned hospital admissions (all cause), (2) accident and emergency attendances and (3) mortality.
We again estimated survival models, but as we did not study continuity of care as a quality indicator in
these models, we estimated continuous-time survival models instead. These models have the advantage
of examining the exact timing of events, which provides more precise inference than can be obtained
with a discrete-time survival model.
For the analysis of the relationship between primary care quality and NHS costs incurred for people
with serious mental illness, we calculated costs of primary care, general hospital care (including
accident and emergency) and specialist mental health care (including inpatient- and community-based
care) for each quarter in each year for each patient. We then constructed a panel data set of repeated
observations on each patient.
As patient health-care costs are highly skewed, with a long right tail and a non-trivial proportion of
zero costs, we estimated two-part models. The first part models the probability of non-zero costs
using a probit model. The second part models the level of cost for those with positive costs using a
generalised linear model with a gamma variance function and log-link function. These were chosen on
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the basis of specification tests for best fit to data. The models contained three quality measures
(care plan, annual review and general practitioner continuity), plus patient and practice characteristics.
To allow for unobserved patient factors correlated with cost and quality, we assumed that they had
random effects with a mean for each patient, which was determined by the mean of their observed
characteristics.
For the survival analysis, models of unplanned hospital use, accident and emergency attendances,
re-entry to specialist mental health services and mortality, we report hazard ratios (the proportional
change in the underlying hazard of the outcome for a unit change in the quality measure). The quality
variable increased the outcome if its hazard ratio is > 1 and reduced it if the hazard ratio is < 1.
Patient and public involvement
Two members of the research team had lived experience of serious mental illness and contributed to
all aspects of the study.
Results
Having a care plan was associated with lower hazard for accident and emergency attendances of
26% (hazard ratio 0.74, 95% confidence interval 0.69 to 0.80), 33% for serious mental illness admission
(hazard ratio 0.67, 95% confidence interval 0.59 to 0.75) and 27% for preventable admission (hazard ratio
0.73, 95% confidence interval 0.64 to 0.83). Care plans were associated with lower overall health-care
costs (£53 per patient, on average), primary care costs (£9), hospital costs (£26) and mental health-care
costs (£12) in the current 3-month period. There was no statistically significant association of having a
care plan with re-entering specialist mental health care.
Annual reviews were associated with a reduction of 20% for accident and emergency attendances
(hazard ratio 0.80, 95% confidence interval 0.76 to 0.85), 25% for serious mental illness admission
(hazard ratio 0.75, 95% confidence interval 0.67 to 0.84) and 24% for preventable admission (hazard
ratio 0.76, 95% confidence interval 0.67 to 0.87). Annual reviews were associated with lower primary
care (£9), mental health care (£30) and total costs (£34), but not hospital costs.
High general practitioner continuity on the Continuity of Care Index (results similar for the other
indices) was associated with 11% lower hazard of accident and emergency presentation (hazard ratio
0.89, 95% confidence interval 0.83 to 0.97) and 23% lower hazard of preventable admission (hazard
ratio 0.77, 95% confidence interval 0.65 to 0.92), but not with risk of serious mental illness admission.
High continuity was associated with lower primary care costs (£3), but not with other costs.
There was no statistically significant association of continuity with re-entering specialist mental
health care.
Polypharmacy was not statistically significantly associated with the risk of accident and emergency
presentation, unplanned admission or death.
Limitations
Patients were included in our analyses on the basis of serious mental illness diagnosis codes in their
practice record. Thus, patients who were not permanently registered with a general practice or with
undetected, unrecorded or as yet undiagnosed serious mental illness, were not included. General
practitioners may also prefer to use free-text comments to record the mental health status of the
patient. Thus, the number of patients with serious mental illness in a practice may be under-reported.
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Concerns about identification of practices in the Clinical Practice Research Datalink means that there
was relatively sparse information on practice characteristics, such as staffing, location, performance on
other quality measures or patient-reported access, which may affect outcomes.
Conclusions
Our study provides the first systematic identification of indicators of quality of primary care for people
with serious mental illness. These indicators were tested for their effect on outcomes in a robust way,
using linked primary and secondary data. The results confirmed the value of processes enshrined in
current incentive schemes. Care plans and annual reviews function as good-quality indicators in the
Quality and Outcomes Framework. The results also suggest continuity of care as an important
indicator. In particular, seeing the same general practitioner over time can improve the physical health
of people with serious mental illness. Higher continuity may reduce the risk of preventable admissions
through improved management of physical health, by facilitating familiarity, communication, trust and
quality of relationship between doctor and patient.
Recommendations for research
l Better evidence is needed on the impact of primary care quality on a broader set of health
outcomes. Routine recording of measures of social functioning, health-related quality of life, patient
experience and key outcomes, such as employment and housing status, are central to the ability to
undertake research that goes beyond consideration of process measures.
l The mechanisms by which primary care quality affects utilisation of secondary care needs to be
better understood.
l Understanding variations in an individual’s capacity to benefit from specific interventions could
enable clinicians to target efforts and deliver person-centred care.
l A better evidence base is needed on what outcomes are valued by people with serious mental
illness, so that efforts can be prioritised according to what matters most to patients.
l Evidence is needed on the interfaces between health care, social care and informal care. Focusing
only on one or two parts of the system risks ignoring wider social determinants of health.
l A fuller understanding of resource implications is needed to inform resource allocation, for example
how resources ‘saved’ across sectors could be reinvested.
l Data coverage and linkage, specifically for mental health, should be improved to address further
research needs.
Funding
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Chapter 1 Background
Some of the material in this chapter is reproduced from Jacobs et al.
1 Contains information licensed
under the Non-Commercial Government Licence v2.0.
Serious mental illness
Serious mental illness (SMI) encompasses a set of chronic enduring conditions, such as schizophrenia,
bipolar disorder and other psychoses. Although some people make a full recovery, most will develop
a lifelong illness.2 Psychosis is a key symptom or feature of SMI, typically characterised by radical
changes in personality, impaired functioning and a distorted sense of objective reality, exhibited by
delusions and hallucinations. Schizophrenia is a SMI marked by severely impaired thinking, emotions
and behaviours. People with schizophrenia are typically unable to filter sensory stimuli and may have
altered perceptions of their environment, including delusions and hallucinations. If untreated, people
with schizophrenia may gradually withdraw from interactions with other people and lose their ability
to take care of their personal needs.1 Schizophrenia is a disease that usually begins in early adulthood,
and the average age at onset is 18–25 years in men and 25–35 years in women.3 Bipolar disorder
is a mood disorder that causes marked emotional changes and mood swings, whereby individuals
experience alternating episodes of mania, or hypomania, and depression. The lifetime prevalence of
schizophrenia is around 1%,4 whereas the prevalence of bipolar disorder is about 1–2% in the UK.5
The total monetary costs in England have been estimated at £11.8B for schizophrenia and psychoses in
2012,6 and £5.2B for bipolar disorder in 20077 (equivalent to £6.0B in 2012), with a large proportion
of the economic burden attributed to service costs, informal care and lost labour market output.
Therefore, SMI creates a high cost to society, as well as to the NHS.
Life expectancy for people with schizophrenia and bipolar disorder is usually around 20 years lower
than for the general population;8–12 people with SMI die prematurely, the majority from preventable
physical illnesses.13 People with SMI are at higher risk of physical ill health and, thus, hospitalisation.14
Compared with the general population, people with SMI have double the risk of diabetes, two to three
times the risk of hypertension and three times the risk of dying from coronary heart disease,15 and
experience a twofold to sixfold increase in deaths from respiratory disease.16 Owing to much higher
smoking rates than the general population, smoking-related diseases, heart disease and premature
death are more common in people with SMI.17 People with SMI are at a much higher risk of obesity,
as the atypical antipsychotic medications they take are associated with weight gain and their illness
reduces their activities and impairs their ability to exercise.18 Alcohol use disorders are common among
people with SMI and contribute to excess morbidity and mortality in this population.19
Poor compliance with medication is well recognised among people with these diagnoses and this may
lead to relapse, poorer outcomes and hospital admissions. Schizophrenia and bipolar disorder rank
among the top 10 causes of disability in developed countries worldwide.20 Despite its prevalence,
considerable disease burden, poor outcomes and costs, there has been little empirical research on the
processes of care for people with SMI. They are often disenfranchised, marginalised and experience
stigma, and thus do not receive the same priority as people with other chronic disease conditions.
In the English NHS, a number of different services provide care for people with SMI. There has been a
general trend away from long hospital stays in favour of shorter-term pharmacological stabilisation in
hospital, followed by longer multidisciplinary follow-up in the community or primary care setting. Most
people with SMI are treated in primary care by their general practitioner (GP). People with SMI consult
their GPs more frequently21 and are in contact with primary care services for a longer cumulative time
than people without mental health problems.22,23 Evidence suggests that around one-third of patients
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with SMI in the UK are treated solely by their GP or other primary care clinician.24 Primary care is
therefore central to the care of people with SMI. The GP oversees care, prescribes medication and
provides both mental and physical health services.
Primary care quality
Measuring quality
There are many different conceptions and definitions of quality. One commonly used definition in
health care is the degree to which services increase the likelihood of desired outcomes, consistent with
current professional knowledge.25 More specifically, health care can be considered to have six key aims:
(1) safety, (2) effectiveness, (3) patient-centredness, (4) timeliness, (5) efficiency and (6) equity.26 For
practical purposes of measurement, health-care quality can be further divided into three components:
(1) structures (e.g. levels of staffing), (2) processes (e.g. monitoring of cholesterol levels) and (3) outcomes
(e.g. mortality rates).27 There are multiple measures of quality, some of which are routinely recorded
by health services and government agencies, and others that are measured for specific purposes by
researchers or interest groups. These measures are often disease specific, reflecting the division of
medicine into discrete specialties.
For primary care, a disease-specific focus is problematic because most patients have a combination
of physical, psychological and social problems, and one of the core requirements of primary care
providers is to provide integrated care that accounts for this complexity.28 This approach often requires
co-ordination across different disciplines and agencies, some of which may lie outside the health-care
community. Measuring these aspects of care is challenging and they are therefore often neglected in
favour of more mechanistic measures of quality.
Primary care quality in England
The first systematic attempt to measure quality of primary care in the UK was the Collings29 study in
1950. This was damning about the quality of care provided by many general practices, describing some
as ‘bad enough to require condemnation in the public interest’.29 The outcry raised by the report
stimulated reform within the profession, leading to the establishment of the Royal College of General
Practitioners in 1952. This was followed in subsequent years by mandatory vocational training in
general practice as a specialty; incentives for physicians to work in groups; government financial
support for practice facilities, staff costs and information systems; and limited pay for performance
(P4P) (e.g. for conducting cervical screening). However, by the 1990s, quality of care was still largely
unmeasured, despite accumulating evidence of wide variations in care, and the main formal check on
substandard care was provided by the profession itself through the General Medical Council, which
dealt with reports of negligent care. A series of high-profile scandals and subsequent public inquiries in
the 1990s, including the Bristol Royal Infirmary Inquiry30 and the Shipman Inquiry,31 damaged trust in
the medical profession, which finally accepted the need for reform and for more robust methods to
monitor and improve quality of care.
From 1997 the government implemented a series of reforms aimed at improving quality of care,
supported by additional funding for the NHS. These included the creation of the:
l National Institute for Clinical Excellence [later the National Institute for Health and Care Excellence
(NICE)] to provide clinical guidelines and to conduct cost-effectiveness analysis of medical interventions
l Commission for Health Improvement (replaced by the Healthcare Commission and then the Care
Quality Commission) to regulate and inspect health and social care services
l National Service Frameworks to provide guidelines and standards of care for some common
chronic conditions.
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Against this background of quality improvement efforts, in 2003 the national contract between
the NHS and GPs was renegotiated in an effort to address an emerging recruitment and retention
crisis.32 It was recognised that existing methods of remuneration (including capitation payments, which
constituted most of practices’ income) were at best neutral towards the quality of care provided and,
in some cases, provided perverse incentives for under- or overtreatment. At that time, P4P schemes
linking remuneration directly to performance on quality indicators were emerging in the USA as a
potential method for improving quality of care and incentivising efficiency. It was therefore agreed that
funding for practices in the UK would be increased, but that this would be achieved through a national
P4P programme aimed at rewarding high-quality care.
The Quality and Outcomes Framework
In April 2004, the Quality and Outcomes Framework (QOF) was introduced as part of a new national
General Medical Services contract for primary care practices in the UK. This major P4P scheme aims to
reward higher-quality primary care by offering financial incentives to general practices. Participation is
voluntary, but due to the size of the incentives, the vast majority of practices participate.33 The QOF
includes > 100 quality targets for clinical, organisational and patient experience indicators, based on
clinical evidence and expert opinion. Under the scheme, practices earn points according to performance
between a lower target threshold (which sets the minimum level of achievement required) and an upper
threshold (which represents the maximal level of achievement expected for the average practice). The
maximum number of points and the threshold levels vary by indicator. For example, controlling blood
pressure for patients with coronary heart disease was originally worth a maximum of 19 points, with
a lower threshold of 25% (i.e. blood pressure had to be controlled for at least 25% of patients to earn
any points) and an upper threshold of 70% (i.e. any achievement > 70% earned the maximum 19 points).
Points are converted into annual payments, adjusted for relative practice size and disease prevalence.
When the QOF was introduced in 2004/5, the price per point was £75, which increased to £157 by
2013/14. By the third year of the scheme, most practices were performing above the upper thresholds
for most indicators and so attained close to the maximum 1000 points available. This translated into
payments of around £125,000 for an average-sized practice.
The mental health domain of the Quality and Outcomes Framework
One of the clinical domains of the QOF is mental health, specifically SMI, which is the focus of our
study. Indicators have been revised over time, but since 2006/7 practices have been required to record
the number of patients with SMI on their practice list, document a care plan (CP), conduct an annual
review of the patient’s physical health (AR), and monitor therapeutic levels and renal and thyroid
health for patients treated with lithium. We excluded the lithium-related indicators from our analysis
because they typically relate to patients with bipolar and mood affective disorder who are using this
mood stabiliser, a subset of all people with SMI. Our study therefore focuses on the CP and AR
indicators that are applicable to all patients on the practice SMI register. We describe these indicators
in more detail in Chapter 3, Care quality indicators.
Other measures of quality
The QOF, however, covers only some aspects of quality and may neglect other important unmeasured
dimensions.34 We therefore measured the quality of care using indicators from the QOF (the CP and
AR indicators) and non-QOF indicators (also derived from primary care patient records). These were
selected on the basis of a systematic literature review (see Chapter 2) and informed by the views and
experience of our service users on the research team and our Scientific Steering Committee (SSC).
Non-QOF indicators included antipsychotic polypharmacy and the continuity of GP consultations,
and are described in Chapter 4, Non-Quality and Outcomes Framework measures of quality: practitioner
continuity, and Chapter 5, Definition of antipsychotic polypharmacy.
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Aims and objectives
All health-care systems seek ways to improve the quality of care for their patients within the constraints
of the existing health-care budget. If successful high-quality care activities can be identified and adopted
more widely, they may generate patient benefit in the form of improved health-related quality of life and
life expectancy and wider non-health benefits (e.g. higher employment rates). Furthermore, by improving
the health of the target population, high-quality care may also prevent the need for additional health
care and lead to lower resource consumption. Such advances in care quality would therefore be of great
interest both to patients and to policy-makers looking to improve population well-being and contain
health expenditure.35
Successful quality improvement efforts targeted at primary care providers offers a critical opportunity
to reduce avoidable morbidity and upstream resource consumption. Yet, the existing evidence about
the effectiveness and cost-effectiveness of primary care activities that seek to improve quality is
relatively weak and often based on either small-scale studies with unclear generalisability, or expert
consensus in the absence of robust evidence (see Chapter 2). There is a lack of large-scale, nationally
representative studies that provide robust evidence of the association between high-quality care
activities and outcomes in a real-world setting.36,37
Our study objectives are to examine whether or not better-quality primary care for patients with SMI
can improve a broad range of outcomes [accident and emergency (A&E) attendances, emergency
admissions, mortality and costs, see Chapter 3, Outcomes for details]. The quality of care is assessed
with two sets of quality indicators derived from primary care patient records: (1) those used in the
QOF, which cover SMI-specific indicators (the CP and AR indicators) and (2) other non-QOF measures
(antipsychotic polypharmacy and the continuity of GP consultations).
Our research questions (as set out in our original research protocol) were, is better quality primary
care for people with SMI associated with:
1. lower rates of SMI hospital admissions
2. lower rates of ambulatory care sensitive condition (ACSC) emergency admissions
3. lower A&E attendances
4. reduced mortality
5. improvements in health outcomes [Health of the Nation Outcome Scales (HoNOS)]
6. reduced SMI costs in primary and secondary care?
Deviations from study protocol
When considering the potential mechanisms by which each of the four quality indicators we examine
(CP, AR, polypharmacy and continuity of care) might impact on outcomes, we recognised that some
combinations of quality indicators and outcomes are highly unlikely to arise in practice, and so decided
not to test them all explicitly. We outline our approach for which indicators are analysed against which
outcomes in Chapter 3 and the rationale for the outcomes used for the respective indicators is provided
in the empirical Chapters 4–7.
We deviated from the protocol in our analysis of the HoNOS, an outcome measure used by clinicians
in secondary mental health services (see Chapter 6). On closer examination of the potential mechanisms
through which primary care quality might impact on HoNOS outcomes within a secondary care setting,
it became apparent that the causal pathway was unclear: any effect would need to be mediated by
secondary care. We therefore changed this outcome to re-entry to mental health specialist community
care (from primary care). Our original intention was to examine the level of severity of patients
re-entering specialist mental health care using a clinician-rated outcome measure, the HoNOS. However,
we faced practical challenges in implementing this analysis. HoNOS is recorded only for individuals
treated in secondary care. Therefore, if primary care prevents relapse in people with SMI, the impact
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on HoNOS for these individuals is unknown. In addition, HoNOS is not recorded at regular intervals
for people who access secondary care services and many individuals in our data set had only one
HoNOS score. In theory, all patients have a HoNOS score completed on entry to mental health care,
or soon after, but we found this not to be the case in the data. We looked at episodes when a patient
re-entered specialist secondary mental health care after at least 12 months without secondary care
activity. A HoNOS score was documented within a month either side of that date in only 23% of such
episodes, and in only 36% of such episodes was a HoNOS score documented within 6 months either
side. Such a sample of patients would not have been selected at random, as we could not assume that
HoNOS completion was random. Rather, we suspected that those who had a HoNOS completed were
different in some unobservable but systematic way from those who did not, and that any results we
generated would not be generalisable to the wider SMI population.
We also deviated from the protocol in our analysis of costs (see Chapter 7). Initially, it was unclear that
we would be able to obtain linked data to analyse mental health community care, but this became
available during the project and we were therefore able to examine costs in primary, secondary and
community mental health care.
We also added an additional outcome to the set of health-care utilisation measures, by including all
unplanned admissions.
Patient and public involvement
Aim
It was determined from the outset that patient and public involvement (PPI) would be a key aspect
of this project. The benefits of involving experts by experience, particularly people with SMI, were
threefold: (1) it allowed us to address questions that matter to service users; (2) it enhanced the
interpretation of results, ensuring that the findings are plausible; and (3) it allowed continuing support
for the dissemination of findings of this research in a manner suitable for lay people (e.g. production of
a video showcasing the results of the study).
Methods
Two of our team members, LA and CD, have lived experience of SMI. These experts, by experience,
have actively engaged throughout the project, with LA participating in early discussions with the team
to help shape and clarify the research questions, including during the grant-writing phase. This helped
focus on quality indicators that matter to service users. LA and CD were also members of the SSC,
which provided them a further opportunity to steer the research programme.
Both experts by experience have played a pivotal role in the research team. They attended regular
research team meetings, in which research findings were discussed, allowing them the opportunity to
relay their interpretation of the results. This in turn influenced further analyses. Meeting minutes were
distributed to these individuals, alongside the rest of the team, so that they could keep up to date with
the progress of the project.
The experts, by experience, were able to liaise with and seek the expertise of various team members,
as and when needed. This enabled them to feel supported and have adequate training for the role. The
principal investigator was also available to help clarify things, when desired. Both individuals were
reimbursed, based on guidance provided by INVOLVE.38
Study results
As part of the team, LA and CD actively engaged with the literature review and contributed to the
identification of quality indicators in primary care. The involvement of these individuals, and their
unique perspective, allowed the team to keep sight of what is most important to service users.
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Both experts, by experience, have felt part of the team and have co-authored four articles during the
project, with other research papers and dissemination activities to follow.39–42
Discussion and conclusions
The insight provided by LA and CD has enhanced other team members’ understanding of SMI and the
nature of the illness, and has had a positive impact on the project. They have participated in the project
from its inception to conclusion and have felt genuinely engaged throughout.
Reflections and critical perspective
It was beneficial to have two experts by experience working on the project, as this facilitated the
engagement of at least one individual at all times, particularly during periods in which one or the other
may have been unable to attend because of illness.
BACKGROUND
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Chapter 2 Systematic literature review of
primary care quality
This chapter is based on Kronenberg et al.
39 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/. This includes minor additions and
formatting changes to the original text.
Introduction
Quality and Outcomes Framework indicators are targeted at high-priority disease areas for which
primary care has principal responsibility for ongoing care and when there is good evidence that improved
primary care will have health benefits. However, as noted in Chapter 1, Other measures of quality, the QOF
may neglect important unmeasured aspects of quality of care43 and the incentives may result in tunnel
vision44 or a focus on activities that are incentivised at the expense of other non-incentivised activities.45,46
We therefore performed a systematic review of the literature and interrogated international databases
to identify potential quality indicators that we could include in our study. We sought to include
indicators identified in the literature into our analysis as additional measures of quality of care, rather
than focusing only on QOF indicators. These additional measures could potentially supplement or even
replace indicators included in the QOF for people with SMI and could potentially be incentivised in
primary care. Identifying indicators of primary care quality for people with SMI could help shed light on
neglected areas of care, as well as providing the basis for incentive schemes aimed at improving quality.
A major focus of our analysis was the source of the data on which the indicators were based. Those
requiring primary data collection, for example via surveys of patients or health professionals, or
retrospective auditing of patient records, would be very challenging to examine in routine data. This
was an important consideration for inclusion in our analysis. Previous literature reviews on quality
indicators have focused on SMI in secondary care,47,48 whereas our review was the first to focus
specifically on people with SMI treated in primary care.
Methods
A systematic review of primary care quality indicators for people with SMI was conducted39 in
February 2015, with the aim of identifying quality indicators in addition to those already included
in the QOF.
The base search was constructed using MEDLINE and adapted to other resources. The following
databases were searched: Applied Social Sciences Index and Abstracts (ASSIA); Cochrane Central
Register of Controlled Trials (CENTRAL); Cochrane Database of Systematic Reviews; Conference
Proceedings Citation Index – Science (CPCI-S); Database of Abstracts of Reviews of Effects (DARE);
EMBASE; Ovid MEDLINE® In-Process & Other Non-Indexed Citations and Ovid MEDLINE®; PsycINFO
and MEDLINE. The full strategy for MEDLINE as a template is available in Appendix 1.
Additionally, previous reviews with overlapping aims were searched and we contacted authors to ask
for their indicators (most notably Stegbauer et al.48 and Großimlinghaus et al.49). The quality indicator
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database of the Agency for Healthcare Research and Quality50 was also searched for indicators
relevant to primary care. The final selection of indicators was informed by the views of our SSC.
Inclusion and exclusion criteria
We sought published examples of potential quality indicators that could readily be collected in primary
care with reference to routine data. Search terms were identified by an information specialist, in
conjunction with the research team. Included papers had the terms serious mental illness AND primary
care AND quality indicator, including alternative spellings and synonyms. Studies on children, and on
mental illnesses other than SMI, were excluded. All studies from January 1990 to February 2015 were
considered for inclusion. No language restrictions were applied, although all search terms were in
English, and all studies in English, German, Dutch and Afrikaans were considered due to the authors’
combined language knowledge.
Study selection
All titles were first reviewed by MG, TK, TD, RJ and Christoph Kronenberg (CK), a former member of
the research team. All studies that two members of the research team indicated as potentially relevant
were included in the abstract screening process. All abstracts were screened by LA, MG, TK, TD, RJ
and CK, and full papers were obtained if two members of the team judged the abstract potentially
relevant or in scope (i.e. covering SMI, primary care and quality indicators). Full papers were divided
into four groups and independently reviewed by MG and CD, TD and LA, TK and SG, and RJ and CK.
The focus of the selection was to identify papers that included relevant quality indicators that could be
applied in primary care. It was evident that the definition of primary care varies between different
countries, so we included indicators with elements of shared care between primary and specialist settings
(e.g. prescribing and monitoring of antipsychotic medication), while acknowledging that, in some countries,
those indicators may be more applicable to secondary care. Our search strategy complied with the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.
Data extraction and analysis
A short description of each indicator from each paper was extracted and the descriptions for similar
indicators were merged. The indicators were grouped into six relevant domains [(1) continuity of care,
(2) substance abuse, (3) access to care, (4) medication management, (5) mental health assessment and
care and (6) physical health]. The domains were selected by the research team as representing broad
areas that would encompass all the chosen indicators. Given the main focus of our study, we decided if
each indicator could, in principle, be measured from routine data or if primary data collection would
be necessary. Furthermore, we checked if the identified indicators had ever been included in the QOF.
We also assessed the quality of the evidence of the included studies using an adaptation of the Grading
of Recommendations Assessment, Development and Evaluation (GRADE) guideline,51 and rated the
quality of the evidence as high [systematic reviews or randomised controlled trials (RCTs)], moderate
(non-randomised control studies or unsystematic reviews), low (expert opinion or uncontrolled studies)
or not applicable (measure was extracted from the grey literature).
Indicator selection
We presented the final list of indicators to our SSC and discussed the list within the research team,
as well as with our PPI team members. Based on these discussions, the evidence from the literature
review and how readily the indicators could be translated into appropriate quality measures from
routine data, we decided to choose two quality indicators that were not already included in the QOF
for analysis in this study. Although some of the remaining potential indicators were, in theory, measurable
from routine data, they would be unable to be measured in the primary care data used for this study
owing to limitations of the clinical coding (e.g. quality of the data, missingness).
SYSTEMATIC LITERATURE REVIEW OF PRIMARY CARE QUALITY
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Results
In total, 1847 studies and further database sources were identified using the search. The split was ASSIA
(n= 34), CENTRAL (n= 96), Cochrane (n= 12), CPCI-S (n = 125), DARE (n= 28), EMBASE (n= 738), Ovid
MEDLINE (n = 537), PsycINFO (n = 271) and six further database sources (Agency for Healthcare Research
and Quality50, Stegbauer et al.,48 Großimlinghaus et al.,49 Parameswaran et al.52 and NICE36). After removing
duplicates using bibliographic software [EndNote X7.3 (Clarivate Analytics, Philadelphia, PA, USA) and
Zotero 4.0 (Center for History and New Media, George Mason University, Fairfax, VA, USA)], 1303 records
remained. Title screening reduced this to 356, excluding those that were not about quality indicators,
primary care, mental illness or were not included in our definition of SMI (e.g. depression or substance
abuse disorders). Abstract screening reduced the records to 113, with similar reasons for exclusion.
Finally, from those 113 records, 86 were excluded and 27 records were included in the review (Figure 1).
Out of these 27 records, a final set of 59 different indicators was extracted. The final list of indicators
are shown in Table 1.
Table 1 shows that of the 59 indicators, 52 could potentially be assessed using routine data and seven
would require primary data collection from patients or professionals. Of these 59 indicators, 17 are, or
have previously been, included in the QOF. A large proportion of the indicators relevant to primary
care are in the physical health domain. Another large subset of indicators relate to the process of
receiving care (e.g. continuity of care, access to services and frequency of contacts).
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FIGURE 1 The PRISMA flow diagram for systematic review of quality-of-care indicators for patients with SMI.
Reproduced from Kronenberg et al.39 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original text.
DOI: 10.3310/hsdr08250 Health Services and Delivery Research 2020 Vol. 8 No. 25
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Jacobs et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
9
TABLE 1 Quality-of-care indicators identified for people with SMI
Number Description Data source QOF Reference(s)
Co-ordination of care
1 Co-ordinated care: identify key worker (social worker or CPN) Routine data 53
2 Staff continuity: good communication between staff and
infrequent staff changes
Routine data 54
3 Continuity and co-ordination: CONNECT is a patient questionnaire
with 72 items, each rated on a 5-point scale, with 13 scales and
one single-item indicator (general co-ordination – ‘overall is your
mental health treatment well co-ordinated?’)
Primary care scales: ‘how often is psychiatrist in contact with your
primary care doctor?’ (never, rarely, sometimes, often, always)
Primary data 55
4 Total number of follow-up contacts during treatment episode after
initial evaluation
Routine data 56
Substance misuse
5 Patients with SMI who smoke who are offered tobacco
counselling/help to stop smoking
Routine data 36
6 Alcohol misuse screening Routine data ✓ 50
7 Screening for illicit drug use, type, quantity and frequency Routine data 50
8 Referral to substance misuse disorder specialty care, if appropriate Routine data 52
9 HIV screening with co-occurring substance misuse for SMI
service users
Routine data 57
Service provision and access to care
10 Practice can produce register of all patients with SMI Routine data ✓ 58
11 Service user registration with a primary health organisation Routine data 24
12 Markers of care recorded: contact with secondary health services,
written CPs, 6-month mental health review, identified care
co-ordinator, evidence of physical examination
Routine data ✓ 59
13 Patients who do not attend the practice for their annual review
who are identified and followed up by the practice team
Routine data ✓ 50
14 System contact: number of patients in contact with the
treatment system
Routine data 52
15 Surveillance to prevent relapse Routine data 54
16 Crisis management and out of hours services Routine data 55
17 Access to services and range of services Routine data 54
18 Family care: record of families living with person with
schizophrenia
Routine data 53
19 Duration of untreated psychosis: number of recently
diagnosed patients
Routine data 52,60
20 Waiting time between registration and start of treatment Routine data 52
Medicines management
21 All current medication clearly available at all consultations: known
drug dosages, frequencies, history of side effects, review date
Routine data 53
22 Monitor patients suffering extra pyramidal effects, check
compliance
Routine data 61
23 Assess weight gain, use of concomitant medication Routine data ✓ 62
24 Use of lithium: plasma lithium levels monitored regularly Routine data ✓ 63,64
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TABLE 1 Quality-of-care indicators identified for people with SMI (continued )
Number Description Data source QOF Reference(s)
25 Percentages of bipolar service users prescribed antidepressants
and anxiolytics
Routine data 63,64
26 Proportion of patients who are receiving depot antipsychotics who
have appropriate laboratory screening tests
Routine data 65
27 Patients have their antipsychotic medication reviewed regularly,
considering symptoms and side effects: appropriate referral
to specialist
Routine data 66
28 Polypharmacy: reduce number of patients using more than four
psychotropic drugs at the same time
Routine data 67
29 Monitoring patients with neurological, sexual, sleeping and
sedation side effects
Routine data 68
Mental health assessment and care
30 Percentage of patients given annual mental health review by a GP Routine data ✓ 69
31 Comprehensive mental status examination and history conducted
in patients with a new treatment episode
Routine data 50,53
32 Referral for specialist mental health assessment Routine data 63
33 Comprehensive assessment of comorbid psychiatric conditions and
response to treatment
Routine data 50
34 Reassess severity of symptoms Routine data ✓ 70
35 Examined for duration of untreated psychosis Routine data 60
36 Delayed diagnosis Routine data 71
37 Informal carer contacts Routine data 54
38 Information on employment status Routine data 53
Physical health assessment and care
39 Diabetes monitoring for people with diabetes and schizophrenia Routine data 50
40 Diabetes and cholesterol monitoring for people with schizophrenia
and diabetes
Routine data 50
41 Diabetes screening for people who are using antipsychotic
medications
Routine data 50
42 Blood pressure screening for patients with diabetes Routine data ✓ 50,72–75
43 Weight management/BMI monitoring Routine data ✓ 50,72–75
44 Proportion with increased BMI/abdominal waistline Routine data ✓ 50,72–75
45 Patients with diabetes who received education about diabetes,
nutrition, cooking, physical activity or exercise
Routine data 50
46 Counselling on physical activity and/or nutrition for those with
documented elevated BMI
Routine data ✓ 50
47 Retinal exam for patients with SMI who have diabetes Routine data 50
48 Foot exam for patients with SMI who have diabetes Routine data 50
49 Hypertension counselling: patients with hypertension who
received education services related to hypertension, nutrition,
cooking, physical activity or exercise
Routine data 50
50 Hypertension: recording and monitoring patients with
hypertension and high blood cholesterol (LDL)
Routine data ✓ 50,72–75
51 Breast cancer screening for women Routine data 50
52 Colorectal cancer screening Routine data 50
continued
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Table 2 shows the quality of evidence of the included studies from which the indicators were drawn.
Two studies were rated as high quality (Cochrane or systematic review, RCT), three studies as
moderate quality (non-randomised study or unsystematic review), 19 studies as low quality (expert
opinion, uncontrolled studies) and three studies were of uncertain quality, having been identified from
the ‘grey’ literature (e.g. non-government organisation documents or databases).
TABLE 1 Quality-of-care indicators identified for people with SMI (continued )
Number Description Data source QOF Reference(s)
53 Proportion of patients who have an increased blood pressure Routine data ✓ 50,72–75
54 Proportion of patients who have an increased blood glucose level Routine data ✓ 50
55 Proportion of patients who have low levels of glycosylated
haemoglobin
Routine data ✓ 50
56 Proportion of patients who have increased level of blood lipids Routine data 48
57 Comprehensive physical health assessment with appropriate
advice
Routine data ✓ 70
58 Patients with diabetes who received psychoeducation related to
weight (BMI), diabetes (blood glucose levels)
Routine data 76
59 Medical attention for nephropathy Routine data 77
BMI, body mass index; CPN, community psychiatric nurse; HIV, human immunodeficiency virus; LDL, low-density
lipoprotein.
Adapted from Kronenberg et al.39 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The table includes minor additions and formatting changes to the original table.
TABLE 2 Quality of evidence of studies identifying quality-of-care indicators for people with SMI
Study Description of study
Strength of
evidencea
Parameswaran et al.52 A total of 656 measures of quality of mental health care identified in
earlier work are rated in importance, validity and feasibility using a
modified Delphi process
3
NICE63 NICE treatment guidelines for bipolar disorder 4
NICE36 NICE treatment guidelines for schizophrenia 4
Agency for Healthcare
Research and Quality50
The Agency for Healthcare Research and Quality provides a database of
quality indicators that was used during the grey literature search
4
Lester et al.58 Focus groups with patients, GPs and nurses were conducted to explore
how to improve care in cases of acute mental health crises
3
Sweeney et al.54 Structured interviews were conducted with 167 individuals suffering from
psychoses to establish a concept of service user-defined continuity of care
3
Ware et al.55 This study reports on the field testing of an interview-based measure of
continuity of care
3
Cerimele et al.56 Narrative description of 740 bipolar primary care patients who
participated in a mental health integration programme. Quality-of-care
outcomes were derived from patient disease registry
3
Pincus et al.70 Discussion on the barriers to measuring quality of care in the mental
health arena combined with a short list of potential quality measures
3
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
TABLE 2 Quality of evidence of studies identifying quality-of-care indicators for people with SMI (continued )
Study Description of study
Strength of
evidencea
Holden53 This study audited 16 GPs on their care for 266 schizophrenia patients
and observed that the audit led to improved recording of a range of
quality indicators
3
Swartz and MacGregor57 The authors of this paper argue that in South Africa the role of mental health
nurses has been altered to focus on violence, substance abuse and HIV/AIDS
and should be refocused on psychiatry care in the primary care setting
3
Ruud60 The author summarises the literature on quality of care in mental health
services in Norway for the years 2008–9
3
Highet et al.71 Interviews with 49 bipolar patients to describe experience in primary care
in Australia. Eight themes for improvement of the primary care experience
are outlined
3
Lader61 Expert review of the standards of care in schizophrenia to reduce side
effects, while achieving best treatment outcomes
3
Haro and
Salvador-Carulla62
Observational study following 11,000 patients who were on or changing
antipsychotic medication, to determine the best course of treatment with
respect to symptoms, quality of life, social functioning and other outcomes
2
Caughey et al.64 Development, expert review and assessment of the evidence base for,
and validity of, medication-related indicators of potentially preventable
hospitalisations
3
Busch et al.65 Observational study examining trends in four measures of quality over
time in the USA
2
Young et al.66 Uncontrolled study looking at differences in quality of care as variations
from national guidelines
3
Nayrouz et al.67 Evaluation of an integrated care approach between primary care and
community care focused on people with SMI
3
McCullagh et al.59 This observational study looks at urban vs. rural differences in quality of
care for psychoses, as well as the difference in quality of care conditional
on contacts with secondary care
3
Rodgers et al.69 Audit of quality of care in 822 Scottish patients with schizophrenia 3
Osborn et al.72 Randomised trial to evaluate the impact of a nurse-led treatment to
improve screening for CVD in the SMI population
1
Yeomans et al.73 Evaluation of a computer-based physical health screening template vs.
NICE guidelines for the SMI population
3
Mitchell et al.74 A systematic review and meta-analysis of screening practices with respect
to metabolic risks for psychosis patients
1
Roberts et al.75 A retrospective view of case notes in 22 general practices to determine
whether or not patients with schizophrenia receive equitable physical
health care
3
Mainz et al.68 Description of the Danish National Indicator Project, which intends to
document and advance quality of care
3
Druss et al.77 The study compared diabetes performance measures in US Medicaid
enrolees with and without mental comorbidity
2
AIDS, acquired immunodeficiency syndrome; CVD, cardiovascular disease; HIV, human immunodeficiency virus.
a Quality of evidence51 is categorised as (1) high (Cochrane or systematic review, RCT), (2) moderate (non-randomised
control study or unsystematic review), (3) low (expert opinion, uncontrolled studies) and (4) not applicable [measure
was extracted from grey literature, e.g. (non-)government organisation documents or databases].
Adapted from Kronenberg et al.39 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The table includes minor additions and formatting changes to the original table.
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Only a very few RCTs have evaluated quality indicators. Two RCTs were reviewed in Cimo et al.,76
which produced evidence on the effectiveness of lifestyle interventions for people with type 2 diabetes
and schizophrenia or schizoaffective disorder. However, more often, indicators were based on expert
consensus or small cross-sectional studies.
Many of the indicators identified were derived from a database of indicators produced by the Agency
for Healthcare Research and Quality,50 and the strength of evidence underpinning the individual
indicators is variable.
From the large set of quality indicators reviewed, we identified two indicators that could potentially
be created and adapted from the routine data to which we had access: continuity of care (indicator 2)
and polypharmacy (indicator 28). Our SSC, our PPI team members and the literature all suggested
that these two areas were important aspects of quality of primary care for people with SMI. Although
the quality of the evidence for these indicators was rated as weak in this review, we felt that there
was sufficient interest to suggest that they would be worth exploring as important quality measures.
The two indicators we constructed are described in Chapter 3, Non-Quality and Outcomes Framework
indicators.
Discussion
Summary of findings
To our knowledge, this was the first attempt to identify potential indicators of quality of primary care
for people with SMI in a systematic way. Although we identified > 50 indicators that could potentially
be captured and monitored using routine data, crucially, we note that the quality of the available
evidence underpinning many of the indicators is relatively weak. We identified two indicators for
further analysis on their association with outcomes using routine data: (1) continuity of GP care and
(2) antipsychotic polypharmacy.
Strengths and limitations
The feasibility of collecting data for any set of quality indicators will vary across different health-care
systems. Many countries have insurance or other systems, which routinely collect activity data in
primary care. Some indicators are likely to require more effort to collect (e.g. patient questionnaires
for perceived continuity of care). Our study focused specifically on finding indicators that could be
monitored at relatively low cost to the UK health-care system.
The list of quality indicators identified here is much broader and more encompassing than the current list
of indicators contained in the QOF SMI domain. However, even if good-quality metrics were identified for
use, criticisms would remain around their adoption. These include measuring only what can be measured
(in routine data), instead of focusing on measuring what matters, and the risk of unintended consequences
arising from prioritising some activities at the expense of other non-incentivised activities. Moreover,
there are gaps in the literature and in the indicators identified, as the service user perspective is not
well represented in the literature. There is also an absence of quality indicators around aspects of the
social environment, such as the stability of housing for people with SMI. Although such factors are
important and may well influence health outcomes, the extent to which primary care could influence
these factors may be very limited and hence it may not be appropriate to hold primary care practitioners
responsible for improving quality in these domains. Finally, our search excluded non-published indicators
and those written in languages other than those listed earlier (see Inclusion and exclusion criteria).
Implications for research and practice
Donabedian’s27 conceptual framework of quality of care suggests that indicators can usually be divided
into three subcategories: (1) structure, (2) process and (3) outcome measures. As noted above, the
vast majority of indicators included in this review relate to processes of care and although aspects of
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process are highly relevant, especially to patients, it is important to establish whether or not quality
indicators also promote improved health outcomes. If so, there is a case for their inclusion in the
QOF and other initiatives aiming to improve the care of people with SMI. For physical conditions,
improvements in processes of care in primary care settings have been found to be associated with
modest improvements in intermediate outcomes (e.g. cholesterol levels78) and quality of life,79 but
associations with patient outcomes, such as emergency hospital admission, are weaker.80 For SMI, the
evidence is much more limited and suggests that higher provider performance on processes may not
be associated with better patient outcomes.43
This evidence gap is something that this research report explicitly addresses. We chose two areas in
which we could construct a range of indicators from routine data (continuity of care and polypharmacy)
and examine their respective associations with outcomes in Chapters 4–6.
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Chapter 3 Study framework
Introduction
As noted in Chapter 1, Aims and objectives, the overarching aim of this research was to examine the
relationship between four indicators of primary care quality (two indicators from the QOF and two
non-QOF indicators) and various measures of health-care utilisation, costs and outcomes.
A key contribution of this study was the use of linked routine data, which, for the first time in England,
provided linkage and coverage of the full care pathway of people with SMI. This enabled the research
team to track activity and outcomes through primary, community, hospital and A&E care settings.
This chapter describes the study design, the quality-of-care indicators, the outcomes, the data sources,
the covariates used as controls and the study samples used.
Study design
This retrospective observational study followed a cohort design, in which a group of people with a
confirmed diagnosis of SMI are followed until they experience an outcome or an event of interest
(e.g. a hospitalisation), or until the end of follow-up (end of study period or the patient moved practice).
The relationship of interest was that between the frequency or timing of these outcomes or events,
and the existing exposure to the indicators of quality of primary care. Information on patients’ socioeconomic
characteristics, medical history, the care they received, as well as their eligibility for inclusion in this
study, were taken from linked primary and secondary care administrative records (see Data sources).
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for
observational studies using a cohort design is provided in Appendix 2.
Retrospective studies based on administrative data have a number of advantages over prospective studies
that require primary data collection. These include the low cost and timeliness of data acquisition, long
follow-up over several years, wide coverage of the patient population without the step of selection into
a trial and representativeness of current clinical practice (high external validity). However, administrative
data are typically collected for other purposes than health services research (e.g. reimbursement,
documentation of patient care) and so may not contain all the information that ideally is required to fully
investigate the research question. If, for example, important confounding factors are not measured and,
therefore, cannot be controlled for in statistical analysis (i.e. omitted variables), any inference drawn from
routine administrative data may contain bias (low internal validity). Other potential biases include reverse
causation and (self-)selection into treatment.
We employed two approaches to reduce the potential for bias in our estimates. First, we used detailed
information on patients’ characteristics and health condition, as recorded by primary care professionals
(i.e. GPs, nurses, health-care assistants) to control for observed differences in health-care needs across
patients. All control variables were measured at baseline, thereby eliminating the risk that they were
contaminated by receipt of the treatment of interest. The construction of the control variables is
described in detail in Covariates. Second, when possible, we employed statistical methods that focused
on only within-subject variation in treatment exposure over time, which allowed us to control for the
influence of any time-invariant unobserved patient heterogeneity (described further in Chapter 4,
Statistical analysis).
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Statistical methodology
The longitudinal nature of the linked data used in these analyses meant that we were able to track
over time the events occurring in each patient’s health-care records. To make best use of this rich data
set, we applied survival analysis (also termed ‘time-to-event’ or ‘duration’ analysis) methodology, as this
approach captures not only the sequence of those events at the patient level, but also their timing.
This means that the analysis took into account, for example, if a quality indicator occurred before a
hospitalisation, and also how much time elapsed between the quality indicator being recorded and the
start of the hospitalisation. We hypothesised that if better-quality care improved patient health, even
when this did not result in complete prevention of outcomes like hospitalisation, it would take longer
for patients’ health to deteriorate to the point of hospitalisation. Survival analysis is able to capture
such impacts.
For some patients, we observed multiple occurrences of a particular type of event (such as A&E
department attendance). It is possible to use survival analysis methods that allow for such multiple
outcome events per person; however, for our main analyses we studied only the duration to the first
event for each person. The reason for this was that, based on clinical advice, we hypothesised that
events such as A&E department attendance, hospitalisation or re-entry to specialist care would result
in changes to the patient’s care in each of those clinical settings, which would not be observed in our
data set. By focusing on the occurrence to the first event, we avoid this source of potential omitted
variable bias.
Two different types of survival analysis are employed in this report: continuous- and discrete-time
survival analysis. The former is used in Chapter 5, when duration to event is measured in continuous
time, with day-level information on events in the analysis. The latter, used in Chapters 4 and 6, allocates
time into ‘discrete’ periods (such as quarters or years), with events known to occur between the start
and end of a given discrete time period. This approach was taken to allow us to examine a quality-of-care
indicator that is measured over discrete periods rather than on a continuous basis (as detailed in Chapter 4,
Statistical analysis). The focus in survival analysis is on the instantaneous risk, or hazard of an event taking
place (e.g. a hospitalisation). The results are interpreted in terms of the hazard ratio (HR). A HR > 1 (< 1)
indicates an increase (decrease) in the hazard of the outcome occurring at a given point in time associated
with a unit change in the explanatory variable. Alternatively, a HR > 1 (< 1) indicates a shorter (longer)
time until the event occurs. The discrete-time model in Chapter 4 can be obtained by grouping time in
the continuous-time Cox model and the results (exponentiated coefficients) can also be interpreted in
terms of HRs.81 The models we used are outlined in each chapter.
One complexity of these analyses is that the primary care quality indicators we study vary over time
for an individual patient. This necessitated the use of survival methods, which allowed for time-varying
covariates in the model. Often in survival analysis, results would be presented using graphical
representation of the survival distributions of two groups of patients (such as treatment and control).
Known as the Kaplan–Meier curves, these graphs compare groups of patients based on the level of a
covariate. However, in our studies, the groups are based on primary care quality (e.g. receipt or not of
a CP). This means that patients could switch between groups over time as their care changed. We
therefore do not present the results graphically, as such depictions would be unhelpfully complex.
For the analysis of the relationship between primary care quality and NHS costs in Chapter 7, we did
not use survival analysis. Instead, we constructed a panel data set of repeated observations on each
patient and estimated two-part models (as detailed in Chapter 7, Statistical analysis).
All analyses were performed using the suite of survival models provided in Stata® 14 (StataCorp LP,
College Station, TX, US).
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Care quality indicators
The quality of primary care was assessed using four measures derived from primary care patient
records: (1) CP, (2), AR, (3) GP continuity and (4) antipsychotic polypharmacy. The first two measures
were QOF indicators and the last two non-QOF indicators (which we constructed based on the
results of the literature review reported in Chapter 2). All indicators are described below and in
subsequent chapters.
Quality and Outcomes Framework indicators
The care plan indicator
The CP indicator requires a comprehensive CP to be agreed with individuals and their families or
carers, and documented in primary care records. It is designed to reflect good professional practice,
and should cover the patient’s current health and social care needs and how these are met. Co-ordination
arrangements with secondary care and patient preferences for contacts and treatment in the event of a
clinical relapse must also be documented. If the patient is treated under the care programme approach
(CPA), that CP, although arising from secondary care, can also be used to meet the requirements of the
QOF in primary care.82 The rationale for including this indicator in the study was that it is intended to
reflect good-quality care for people with SMI.
The annual review indicator
The AR indicator should cover use of alcohol, drugs and smoking behaviour, and offer appropriate
checks for blood pressure, cholesterol, body mass index (BMI) and diabetes. The review may also
include cervical screening attendance and medication review. The rationale for including this indicator
in the study is that patients with serious mental health problems are at increased risk of physical ill
health,83 are less likely to be offered health promotion advice,84 and are far more likely to smoke85 and
to have smoking-related diseases,86 than the general population. People with schizophrenia are also at
increased risk of impaired glucose tolerance and diabetes.87,88
Table 3 shows the development of the CP and AR indicators over time within the QOF. The CP indicator
definition remained unchanged over financial years 2006/7–2010/11, after which payment thresholds
were increased annually. The AR indicator definition also remained unchanged during 2006/7–2010/11.
From financial year 2011/12, the indicator was split into its physical care review constituent parts:
alcohol consumption, BMI, blood pressure, total cholesterol, blood glucose and cervical screening test.
The construction of these indicators is described in more detail in Chapter 4, QOF indicators of quality.
Non-Quality and Outcomes Framework indicators
Continuity of general practitioner consultations
Continuity of practitioner care is a widely accepted core principle of primary care, and denotes the
connected and coherent care that is consistent with the health needs and personal circumstances of a
patient.89 It is considered important to ensure effective and efficient health care, and is believed to
be essential for high-quality patient care. Three major types of continuity of care are commonly
distinguished, namely (1) management, (2) informational and (3) relational continuity.
The QOF indicator ‘presence of current comprehensive CP’ can be considered an informational
measure of continuity, as it captures co-ordination arrangements and information sharing with
secondary care.
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We used three well-recognised and widely applied indices measuring different dimensions of GP
continuity, which reflect management and relational continuity, but are not QOF indicators. Dispersion
across different GPs within a practice involved in the patient’s care is measured using the Continuity of
Care Index (COC), density of visits to a single GP is measured with the Usual Provider of Care Index
(UPC) and the pattern of visits across a practice is measured with the Sequential Continuity Index
(SECON). These are described in more detail in Chapter 4, Non-Quality and Outcomes Framework
measures of quality: practitioner continuity.
Inappropriate polypharmacy
Antipsychotic polypharmacy is the co-prescription of two or more different antipsychotic drugs for
an individual patient.90 It is sometimes used in clinical practice, usually for people with established
schizophrenia, when monotherapy is considered ineffectual, to improve therapeutic response. However,
there is little empirical evidence that polypharmacy is more effective than monotherapy,91 and the
equivocal evidence on the risks and benefits mean that it is not generally recommended for use in
routine clinical practice.
TABLE 3 Definition of mental health QOF indicators and payment thresholds for indicators included in this study
Indicator
Financial yeara
2006/7–
2010/11 2011/12 2012/13 2013/14
CP The percentage of patients on the
register who have a comprehensive
CP documented in the records agreed
between individuals, their family and/or
carers as appropriate
MH6
(25–50%)
MH10
(25–50%)
MH10
(30–55%)
MH002
(40–90%)
AR Review The percentage of patients with
schizophrenia, bipolar affective disorder
and other psychoses with a review
recorded in the preceding 15 months.
In the review there should be evidence
that the patient has been offered
routine health promotion and
prevention advice
MH9
(40–90%)
Review
constituents
Alcohol consumption MH11
(40–90%)
MH11
(50–90%)
MH007
(50–90%)
BMI MH12
(40–90%)
MH12
(50–90%)
MH006
(50–90%)
Blood pressure MH13
(40–90%)
MH13
(50–90%)
MH003
(50–90%)
Total cholesterol : HDL ratio MH14
(40–80%)
MH19
(45–80%)
MH004
(45–80%)
Blood glucose MH15
(40–80%)
MH20
(45–80%)
MH005
(45–80%)
Cervical screening MH16
(40–80%)
MH16
(45–80%)
MH008
(45–80%)
HDL, high-density lipoprotein.
a Payment thresholds in parentheses.
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Outcomes
We investigated the impact of primary care quality on four types of outcomes. The first type, measures
of health-care utilisation, included unplanned hospital admissions and presentations to an A&E department.
Subtypes of unplanned hospital admissions are of particular interest, including admissions for SMI,
admissions for conditions thought to be particularly amenable to primary care and ACSCs, such as
diabetes, angina, cellulitis and vaccine-preventable diseases. (The codes used to define SMI and ACSC
admissions are listed in Appendix 2.) A&E department presentations of all causes, both physical and mental
health problems, are also examined, as they are generally much higher for mental health service users
than for the general population92 and are a precursor to unplanned hospital admissions. Attendances at
emergency units have been increasing93 and evidence-based approaches to reduce emergency attendances
are urgently needed. These outcomes are analysed in Chapters 4 and 5. We acknowledge that the
context is important, and for some individual patients in specific circumstances, hospital admissions may
not necessarily be inappropriate or a signal of poor outcomes. However, in general, there is widespread
agreement that reducing this type of utilisation is beneficial to most patients.
The second outcome was mortality, which is a key outcome indicator for people with SMI and is
analysed in Chapter 5. As described above, people with SMI have 15–20 years lower life expectancy
than the general population, driven largely by premature mortality from preventable or modifiable
physical illnesses.
The third outcome was (re-)entry to specialist mental health care and is analysed in Chapter 6. This
outcome captures the situation in which patients who were not seen within specialist mental health
services for at least 1 year – suggesting that they were stable enough to be managed fully in primary
care – then re-engaged with specialist mental health services, indicating a deterioration in their
mental health, requiring specialist expertise. Again, we acknowledge that this may not in all contexts
be a negative outcome, but in general it is reasonable to assume that re-entry should be avoided,
when possible.
The fourth type of outcome measure examined in Chapter 7 was cost. Costs of health-care utilisation
were captured across the full health-care pathway for people with SMI and include costs of primary
care, drug prescriptions, A&E department presentations, inpatient admissions for both physical and
mental health problems, and specialist community mental health care.
Figure 2 summarises which measures of primary care quality and outcomes were analysed in each
chapter. The measures of care quality included were dictated by the research question and the
outcomes analysed in each specific chapter. A rationale for choice of outcomes is provided in
each chapter.
Data sources
This section describes the data sources used to compile the samples analysed in Chapters 4–7.
Clinical Practice Research Datalink
The Clinical Practice Research Datalink (CPRD) is a UK-based research service, jointly sponsored by
the Medicines and Healthcare products Regulatory Agency and the National Institute for Health
Research, as part of the Department of Health and Social Care. The CPRD collects fully coded and
deidentified patient electronic health records from a network of general practices using the Vision®
(In Practice Systems Ltd, London, UK) software system. Data for this study were extracted from the
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Outcomes examined 
QOF quality indicators Non-QOF quality indicators
AR CP Continuity of care Antipsychotic polypharmacy
Admissions for ACSCs
 See Chapter 4aAdmissions for SMI
See Chapter 5b
A&E presentations 
All unplanned admissions
Mortality
Re-entry to specialist mental
health services
See Chapter 6a
Cost See Chapter 7c
FIGURE 2 Overview of outcomes and quality indicators examined, and methods used in the report. Methods used a, discrete-time survival analysis (see Chapters 4 and 6);
b, continuous-time survival analysis (see Chapter 5); and c, a two-part model (see Chapter 7).
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CPRD GOLD database, which is drawn from practices using the Vision software system. We used the
following CPRD GOLD data files:
l patient file – basic demographics and registration details
l practice file – collection and region information
l staff file – staff role and sex
l consultation – type of consultation
l clinical – medical history events, including symptoms, signs and diagnoses
l additional clinical details – information entered in the structured data areas in the Vision software
l referral – referrals to external care centres (e.g. hospitals), including specialty and referral type
l test – qualitative and quantitative test results
l therapy – prescriptions for drugs and devices issued by the GP.
Clinical information is captured as Read codes, which are recorded by practice staff (doctors, nurses,
administrative staff, etc.) as part of routine data entry. Read codes94 are a hierarchical clinical data
coding system used in primary care in the UK that classifies diseases, patient characteristics,
procedures and tests.95
A study conducted in collaboration between the CPRD and the London School of Hygiene & Tropical
Medicine96 concluded that patients in the CPRD GOLD database are broadly representative of the
English general population, in terms of age, sex, ethnicity and BMI. This was in line with previous
research by the CPRD,98 which also demonstrated slightly lower mortality rates in younger age
groups than in national rates, and a larger median practice size than the national average.96 Owing
to the geographical distribution of Vision software use, areas in the East Midlands, Yorkshire and the
Humber and the north-east of England are under-represented relative to areas in Wales, Scotland and
Northern Ireland.
We had access to CPRD data for the period of 1 April 2000 to 31 March 2014.
Hospital Episodes Statistics
Hospital Episodes Statistics (HES) comprises detailed records for all patients who received publicly
funded care in public and private acute hospitals in England. The study data set includes HES data for
those patients who had admissions and/or A&E department presentations during the study period. The
HES data used in this study do not include hospital outpatient attendances. Admissions recorded in
HES include those for physical health problems and for mental health problems, when the patient was
admitted to an acute hospital rather than a specialist mental health inpatient facility.
Hospital admissions were classified using International Statistical Classification of Diseases and Related
Health Problems, Tenth Revision (ICD-10), codes to identify SMI and ACSC admissions. (The codes used
to classify admissions are listed in Appendix 2.)
Each linked HES record provides detailed information about the patient’s demographic characteristics,
medical condition and care pathway. Inpatient data are reported at the level of finished consultant
episodes and a new finished consultant episode is created every time a patient is discharged from the
care of one consultant to another consultant. To capture the entire care pathway and derive correct
admission numbers, we converted finished consultant episodes to continuous inpatient spells, which
cover the entire period from admission to final discharge. Continuous inpatient spells also allow for
transfers between providers of inpatient care.
We had access to HES inpatient data for the period of 1 April 2000 to 31 March 2014 and to A&E
department data for the period of 1 April 2007 to 31 March 2014.
DOI: 10.3310/hsdr08250 Health Services and Delivery Research 2020 Vol. 8 No. 25
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Jacobs et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
23
Mental Health Minimum Data Set
The Mental Health Minimum Data Set (MHMDS) (now called the Mental Health Services Data Set)
is a nationally mandated routine data collection covering adults who receive care in specialist NHS
mental health services, both inpatient- and community-based (outpatient) services. It comprises
individual-level, administrative patient data, including data on visits, hospital admissions and other
measures of service utilisation, such as contacts with health-care professionals. The study data set
includes MHMDS data for all patients who received care in specialist NHS mental health services
during the study period.
Mental Health Minimum Data Set data were used for the period of 1 April 2011 to 31 March 2014.
MHMDS data prior to this date did not include all specific dates of activity (such as outpatient visits)
required for the study.
Linked data sets
The anonymised CPRD GOLD primary care patient data can be individually linked to secondary care and
other health and area-based data sets to provide a fuller picture of the patient care record. Linkages are
available for English practices that have consented to participate in the linkage scheme, covering patients
with a valid NHS number recorded in their GP record, who have not opted out. The CPRD is expanding
its health-care data and research services to increase the number of data sets that are linked and made
available on a routine basis to the research community. This study is one of the first to use the linked
HES A&E data and the MHMDS. Approximately 75% of English practices participating in the CPRD
permit linkage of their patients’ data in this way.96 We test below whether there were systematic
differences between practices with and without linkage (see Testing for linkage bias).
In addition to HES and MHMDS linkages, for this study, the CPRD data were also linked to the Index
of Multiple Deprivation (IMD) data from 2010, for patients’ area of residence at the lower-layer super
output area (LSOA) level. This provided the ranking of the patients’ area of residence according to
twentiles of IMD data at the national level. Information was also linked at the practice level. Based on
2011 Census data,97 the practice postcodes held by the CPRD allowed practices to be classified in
rurality. They were also classified based on postcodes in terms of estimated distances to the nearest
hospital and nearest mental health inpatient facility. Exact IMD scores or distance information were
not provided to the study team to avoid disclosing location information. Finally, mortality data from
the Office for National Statistics (ONS) were also linked to the CPRD GOLD database.
To preserve anonymity, the data linkages were carried out by NHS Digital as the trusted third party of
the CPRD. To avoid the risk of reidentification, the CPRD permitted only four data sets to be linked
simultaneously. We therefore obtained the following two sets of linkages: CPRD–A&E–MHMDS–HES
and CPRD–HES–ONS–MHMDS.
Information was provided by CPRD for all patients who were eligible for linkage and had an incident or
prevalence diagnosis of SMI in their GP record on or before 31 March 2014.
We had two data use agreements with the CPRD approved by the International Scientific Advisory
Committee, one for the CPRD GOLD database linked with HES A&E data, the MHMDS, patient IMD,
distance to provider and rurality indicators (protocol number 15_213), and one for the CPRD GOLD
database linked with HES inpatient data, ONS data, distance to provider and rurality indicators (protocol
number 14_168).
Study samples
There are effectively five different samples used in the studies presented in this report, each derived
from the same set of patients present in the CPRD data. Differences arise because studies differ in the
duration over which patients were followed and due to different inclusion and exclusion criteria applied.
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The full set of patients from which the samples are derived was formed of all patients with a diagnosis
of SMI documented in primary care clinical notes or referral records on or before 31 March 2014, who
attended participating CPRD practices and whose records were eligible for data linkages (n = 34,812).
The codes used by CPRD to identify diagnoses of SMI were provided by the study team and are listed
in Appendix 2. The data set was limited to patients whose records met an acceptable standard based on
recording of registration, clinical events and demographic details, at practices deemed up to standard
according to a CPRD algorithm.96 There were 600 patients for whom IMD data could not be linked,
most likely due to their postcode being relatively new and not appearing in the LSOA lookup, so the
full combined data set comprised 34,212 patients.
The start date of observation was defined as the earliest date (after 1 April 2000) on which all of the
following conditions were met:
l Patient has a diagnosis of SMI already documented in primary care records (using Read codes).
l Patient was aged ≥ 18 years.
l Patient had been registered with a participating practice for at least 365 days. This was imposed to
allow for the observation of baseline characteristics and patterns of health-care utilisation.
The end date of the observation period for each patient was defined as the earliest of:
l the end of the patient’s registration at the practice
l 31 March 2014
l the patient’s date of death (as documented in primary care records).
The following additional conditions must be met, depending on the specific analysis.
In Chapter 4:
l The sample was limited to patients with a start date after 31 March 2007, as the CP and AR indicators
(two of the key explanatory variables) were introduced after financial year 2006/7 and data on A&E
department presentations (one of the outcomes in Chapter 4) were only available from 1 April 2007.
l The start date of observation for each patient was moved later, if necessary, so that no patients had
an A&E department presentation or a hospital admission for at least 1 year prior to the start date,
as hospital care could influence primary care activity.
In Chapter 5:
l The sample was limited to those patients for whom at least one prescription of an antipsychotic was
documented in CPRD records during the observation period.
l The start date was moved forward for patients who were hospitalised within the last 90 days, as
patients recently discharged from hospital were at higher risk of readmission. Some of these patients
had a new start date later than the last observation date and were therefore dropped from the sample.
l As A&E data were available beginning in financial year 2007/8 only, the analysis of A&E department
visits was limited to patients with an entry date after 31 March 2007. This restriction was not
imposed for the analysis of all other outcomes.
In Chapter 6:
l The sample was limited to patients with a start date after 31 March 2011 because of the use of the
MHMDS data.
l Owing to examining re-entry to specialist mental health services, represented by activity in mental
health services (such as an outpatient visit, or start of a hospital admission), we had to ensure a
period of at least 12 months with no such activity (i.e. a ‘stable’ SMI patient).
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In Chapter 7:
l Owing to the use of MHMDS data, the sample was limited to patients with a start date after
31 March 2011.
l Only patients who were observed for a full financial quarter were included.
This resulted in five samples of different sizes:
1. Chapter 4 analysis sample – 19,324 patients
2. Chapter 5 analysis sample (excluding A&E analysis sample) – 17,255 patients
3. Chapter 5 A&E analysis sample – 13,247 patients
4. Chapter 6 analysis sample – 9907 patients
5. Chapter 7 analysis sample – 16,485 patients.
Figure 3 provides an overview of how each sample was formulated.
All patients in CPRD with a diagnosis of SMI, eligible for linkage to HES data, with
active registration between 1 April 2000 and 31 March 2014, with patient and
practice data meeting quality standards
(n = 34,812)
Able to link to IMD data for the LSOA of the patient’s area of residence
(n = 34,212)
Chapter 4 Chapter 5 Chapter 6 Chapter 7
Indicators: CPs, ARs,
practitioner continuity
Outcomes: hospital
admissions, A&E
presentations
Restrict to patients
observed during 
1 April 2007 to
31 March 2014
(n = 22,079)
Restrict observation
period to at least
365 days of no
hospital use at start
of observation
(n = 19,324)
Restrict to patients
with at least one
prescription of an
antipsychotic
recorded
(n = 17,255)
Outcomes: hospital
admissions, A&E
presentations, mortality
Indicator: antipsychotic
polypharmacy
Indicators: CPs,
practitioner continuity
Indicators: CPs, ARs,
practitioner continuity
Outcomes: health-care
costs
Outcome: re-entry to
specialist mental
health-care services
Restrict to patients
observed during
1 April 2011 to
31 March 2014
(n = 17,740)
Restrict to patients
observed during 
1 April 2011 to
31 March 2014
(n = 17,740)
Restrict to patients
observed for at least
one full financial
quarter
(n = 16,485)
Restrict observation
period to at least
365 days of no
activity in specialist
mental health-care
services at start of
observation
(n = 9907)
Start of observation defined as latest of 365 days after date of registration at the
practice, 1 January of the year after the patient turned 18 years or date of SMI
diagnosis. End of observation defined as earliest of end of registration at the practice,
date of death or 31 March 2014
FIGURE 3 Sample construction for each study in the report.
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For all four analytical chapters (see Chapters 4–7), we imposed a 12-month registration period at the
practice prior to the start of the observation period, to allow us to capture medical history and
utilisation patterns, which further restricted the analysis period (see Covariates).
Testing for linkage bias
We compared the set of patients eligible for linkage to HES and MHMDS with a random sample of
3000 patients with SMI attending practices that participated in CPRD but had not permitted the
linkages, to ensure that our practice populations were not biased in observable ways. Figure 4 shows
that the linked and non-linked samples were similar in age and sex distribution.
Covariates
We measured patient and practice characteristics at or before the start of the observation period by
using data from the 12-month period of registration at the practice prior to the start of the study
observation period.
We used the same set of control variables in all analyses. This includes age, sex, age–sex interactions,
ethnicity, the number of comorbid conditions (as defined by Charlson et al.99), alcohol and smoking
status, a diagnosis of depression, the number of GP contacts (face-to-face visits and telephone calls) in
the last year and small area deprivation profile based on patients’ residence.100 We sought to make the
data as complete as possible by utilising information from different sources (e.g. cross-checking ethnicity
status from HES with that in CPRD), although any remaining missingness could be not at random.
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FIGURE 4 Clinical Practice Research Datalink samples of patients based on eligibility for linkage to other data sets.
(a) Not linked; and (b) linked.
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We approximated ability to access secondary care by the distance from the patients’ general practice
to the nearest psychiatric inpatient hospital and general hospital and by whether or not the practice is
in a rural area. Finally, we controlled for the year in which the patient entered the sample and the time
since first diagnosis.
We used Read codes recorded over the entire patient’s history and our own clinical expertise to define
three diagnostic categories: (1) schizophrenia and other psychoses, (2) bipolar disorder and affective
psychoses and (3) those who had a diagnosis from each group (codes are provided in Appendix 2).
Descriptions of covariates and their sources are described in detail in Table 4.
TABLE 4 Sources and definitions of covariates
Variable Type Details
Age Categorical
(19–35,36–45, 46–55,
56–65, > 65 years)
Based on year of event and year of birth as recorded in
primary care
Male Binary Based on sex as recorded in primary care
Ethnicity Binary (white/other) Based on HES records and CPRD Read codes
IMD (deprivation level associated
with patient’s residence area)
Categorical (quintiles) For practices that have consented to participate in the
linkage scheme, the patient postcode of residence is
mapped to LSOA using a postcode look-up file. The
LSOA of residence then allows linkage to the 2010
English IMD
Number of Charlson Comorbidity
Index comorbidities
Categorical (none,
one, two, three or
more)
CPRD Read codes recorded any time before the date of
entry to the study sample
Depression diagnosis Binary CPRD Read codes
Alcohol status/smoking status Binary Diagnostic and management codes, and additional
information entered in the structured data areas in the
Vision software
Number of GP contacts in the
preceding 12 months (face-to-face
visits and telephone calls)
Categorical (0–4, 5–9,
10–14, 15–19, ≥ 20)
From CPRD consultation file
Distance from GP to nearest
acute hospital provider/distance
from GP to nearest mental health
provider
Categorical (0–3, 3–6,
6–9, > 9 km)
We provided CPRD with a look-up table of all postcodes
in England, the estimated straight line distance from the
postcode to the nearest mental health and acute hospital
provider. CPRD carried out the linkage using contributing
practices’ postcode information. Once linked, distances
(km) were categorised into distance bands by CPRD
(e.g. 0–3, 3–6 km, etc.)
General practice in rural area Binary To construct a practice-level rurality flag we provided
CPRD with a look-up table of all LSOA levels (small
areas) in England and rurality information derived
from the RUC2011. This information was used to link
contributing practices to their corresponding rurality
flag using the practice LSOA
Calendar year Binary
Schizophrenia diagnosis/bipolar
diagnosis/both schizophrenia and
bipolar diagnosis
Binary CPRD Read codes (provided in Appendix 2)
Time since first diagnosis Categorical (1, 1–5,
> 5 years)
RUC2011, 2011 Rural–Urban Classification for Small Area Geographies.
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Chapter 4 The association between
primary care quality and hospital
care utilisation
This chapter is partly based on Ride et al.
40 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text includes minor additions and
formatting changes to the original text.
This chapter is also partly based on Ride et al.41 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original
work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text includes minor
additions and formatting changes to the original text.
Introduction
This chapter examines if three primary care activities that are framed as indicators of primary care
quality (AR of patients’ physical health, creation or maintenance of a CP and continuity of GP care)
influenced unplanned utilisation of hospital services for people with SMI. Our previous study1 using
aggregate practice-level data for the period of April 2006 to March 2010 found a positive association
between achievement rates for the QOF AR indicator and rates of SMI admission, but no association
with achievement rates for CPs43 (see Appendix 3 for an extension of this study to cover the additional
years up to 2014). However, the previous study used annual practice-level data and so could not
ascertain whether the care preceded or followed admission. Understanding the sequence and timing of
events is crucial; a prerequisite for establishing causal inference. In contrast, the current study analyses
event-level data with precise timing information for a large patient cohort. By avoiding problems
inherent in aggregation across individuals, these data allowed us to investigate more precisely the
relationship between quality of care and outcomes using survival analysis modelling techniques.
The three potential indicators of care quality analysed in this chapter were chosen because they were
either incentivised under the QOF (AR, CP) or identified as part of the literature review reported in
Chapter 2 (practitioner continuity of care). For each indicator, we expected that achievement resulted
in better information flow between patients and their GPs, and a higher likelihood that deteriorations
in patients’ mental or physical health were identified and addressed early, thus avoiding the need for
hospital care. The association between a fourth potential indicator of care quality, polypharmacy, and
hospital utilisation is considered separately in Chapter 5. This is due to the use of different inclusion
criteria for the study sample and a different analytical approach.
Methods
Sample
Patients were included in the sample if the conditions listed in Chapter 3, Study samples were met.
Continuity is measured over defined periods of time, so the observation period for each patient was
divided into periods of 3 months, dating from their first date of observation. Patients were followed
until outcome or censoring [with censoring due to the patient changing general practice, death or the
end of the study period (31 March 2014)].
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Outcome measures
We separately examined time to three types of unplanned hospital use: (1) A&E department presentations,
(2) unplanned admissions for SMI and (3) unplanned admissions for ACSC (as outlined in Chapter 3,
Outcomes). For each type of outcome, we considered only the first observed instance (presentation or
admission), as this could have influenced subsequent care quality in unobserved ways. For example,
CPs may be updated in secondary care at the end of an admission period and this may not be reflected
appropriately in the GP electronic records.
The occurrence of the outcome was measured in the 3-month period, t, and continuity of care was
measured over the 12 months prior to the outcome period, t-1 to t-4. The outcome variable was a
binary variable for each 3-month period, indicating whether or not the event occurred in that period.
Quality and Outcomes Framework indicators of quality
The analysis included time-varying care quality indicator variables for CPs and ARs. These binary
variables indicated if a CP or AR had been recorded within the 12 months prior to the current
3-month period. The choice of the 12-month window to determine expiration status was based on
the QOF guidance that a CP or AR should be undertaken and reviewed annually.
From 2006/7 to 2010/11 the QOF annual review indicator entailed the patient being given appropriate
health promotion and prevention advice. As outlined in Chapter 3, The annual review indicator and Table 3,
in 2011/12 this broad indicator was split into more specific indicators (a record of alcohol consumption,
checks of blood pressure, BMI, blood glucose or glycated haemoglobin, ratio of total to high-density
lipoprotein cholesterol and, when appropriate, cervical screening). To explore ARs for the full period of
our analysis, we formulated an aggregate indicator. This signified that the patient had at least three of
the four ‘health risk’ checks (blood pressure, BMI, cholesterol and glucose) documented within a 3-month
period.101 The date of the aggregate indicator was the date of the final check. The AR variable in the
analysis was equal to 1 for the current 3-month period if there was an AR (using the original Read
coding) or an aggregate indicator date within the 12 prior months. Appendix 3 provides an overview of
how the rates of these indicators changed over the period of analysis.
Non-Quality and Outcomes Framework measures of quality: practitioner continuity
We used three indices measuring different dimensions of GP continuity: the COC, UPC and SECON.102
The COC captures dispersion of visits across GPs as follows:
COC =
∑
J
j = 1
n2j −N
N(N−1)
, (1)
in which N is total number of visits and nj is number of visits with GP j.
The UPC is the proportion of a patient’s visits that are with the GP most frequently seen by the
patient in that year:
UPC =max
n n1
N
, . . . ,
n j
N
, . . . ,
n J
N
o
. (2)
The SECON is the proportion of consecutive pairs of visits which are to the same physician:
SECON =
∑
N− 1
i = 1
si
N
, (3)
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in which i is the visit number, N is the number of visits, N – 1 is the number of sequential pairs of visits.
si = 1 if visit i and visit i + 1 are to the same provider, and si = 0 if otherwise.
Each index ranges from 0 (lowest continuity) to 1 (perfect continuity). Illustrative examples are shown
in Table 5.
We measured continuity over 12 months (four 3-month periods), considering only face-to-face visits
with GPs. There is no standard level for ‘high’ and ‘low’ continuity, so we classified practitioner continuity
as ‘high’ if the level of continuity was above the median for the index and ‘low’ if at or below the
median level.
A minimum of two visits is required to calculate COC and SECON, but to improve index stability we
set the minimum to three visits and set continuity as ‘undefined’ below this level. We constructed a set
of categorical variables based on visit frequency and on whether continuity was low or high. This
allowed for different effects of continuity for frequent and less frequent users of family practice, as
suggested by previous research.103 Visit frequency was classified into low (zero to two visits), moderate
(three to five visits) and high (six or more visits). These categories correspond to tertiles of the full visit
distribution. Continuity indices were defined as low or high based on the median value of each index:
COC low (0–0.35) and COC high (> 0.35); UPC low (0–0.67) and UPC high (> 0.67); SECON low
(0–0.17) and SECON high (> 0.17).
Periods were then classified into five categories according to continuity level and visit frequency in the
prior 12 months: low visit frequency (with continuity undefined – the base category); moderate visit
frequency with low continuity; moderate visit frequency with high continuity; high visit frequency with
low continuity; and high visit frequency with high continuity.
Statistical analysis
The necessity of creating periods for continuity measurement led us to employ discrete-time survival
analysis to model all three care quality indicators (continuity, CP and AR) simultaneously. Although
the outcomes of interest were (effectively) continuous measures (as we had day-level data on when
the events occur), these were converted into discrete outcomes for each period, to match the
measurement of continuity. The model evaluated the association between risk of the outcome in a
particular 3-month period and each of the three care quality indicators in the prior 12 months.
TABLE 5 Examples of visit patterns and associated continuity of care indices
Scenario Visit pattern
Number
of visits
Number of
practitioners COC UPC SECON
A All visits with same GP 8 1 1 1 1
B Each visit with a different GP 8 8 0 0.13 0
C Four visits with one GP, then four visits
with another
8 2 0.43 0.50 0.86
D Five visits with one GP, then three visits
with another
8 2 0.46 0.63 0.86
E Alternating between two GPs 8 2 0.43 0.50 0
F As for scenario E but five visits with the first
GP and three visits with the second
8 2 0.46 0.63 0.29
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The hazard rate at period t is the probability of observing the outcome for individual i in period t,
conditional on the individual ‘surviving’ in the sample to period t (i.e. no censoring and the outcome
was not observed in prior periods for that individual). A complementary log–log (cloglog) model, which
is the discrete-time analogue of the continuous-time proportional hazards model, was estimated for
each outcome. This model is useful when the occurrence of the outcome is rare.
A flexible piecewise constant baseline hazard function was applied by specifying dummy variables for
each 3-month period. This assumes that the hazard function is constant within each period, but can
vary across periods and avoids imposing a more restrictive functional form on the model. The resulting
exponentiated coefficients can be interpreted as HRs, the discrete-time counterpart of the hazard from
a continuous-time proportional hazards model.81 The HR is equal to the proportional change in the
hazard of the outcome for a unit change in the variable.
The hazard rate (h) is specified as:
hit = Pr(T i = t jT i ≥ t, Xit , Zi,Dt, vi)
=1−exp½−exp(X′itβ + D′tµ + Z′iθι + vi),
(4)
in which Ti is the discrete survival time variable for individual i; t represents the time period of interest,
Xit is the vector of time-varying factors, including a constant term; Zi is a vector of time-invariant factors;
D is a series of time period dummy variables representative of the baseline hazard; and vi ∼ N(0, σ2v ) is
normally distributed individual unobserved heterogeneity.
Our main modelling approach accounted for individual unobserved heterogeneity, vi. Owing to the
incidental parameter problem104 that arises through specifying individual fixed effects to represent
such heterogeneity in non-linear models, we instead assume unobserved heterogeneity is normally
distributed and specify this as a function of the means of time-varying variables. This is often termed a
correlated random-effects model. Following Mundlak,105 we assume:
vi = a + X′iγ + Dδ + ci, (5)
in which X i is the mean of the time-varying variables, D the mean of the time dummies, a is a constant
and ci represents the remaining unobserved heterogeneity assumed to be normally distributed. The
mean variables (Xi, D) capture confounding by unobserved time-invariant patient factors (e.g. long-
standing illness, health-seeking behaviour) that drive both primary care quality and use of hospital
services. The coefficients of the period-specific levels (Xit, Dt) can be interpreted as the effect of the
quality indicator specific to that 3-month period.
To allow comparison of our results to previous studies examining the effect of continuity of care, we
also estimated models that did not specify individual heterogeneity (vi) as a function of the means of
the time-varying variables (i.e. by estimating Equation 4 directly). These models allow for normally
distributed individual heterogeneity, but it is assumed to be uncorrelated with the explanatory
variables contained in the model.
All models included observed patient characteristics as explanatory variables and adjusted standard
errors (SEs) for clustering at the practice level. We estimated separate models for each of the three
continuity indices.
Robustness checks
We tested the sensitivity of the results to the level of visit frequency at which continuity was classified
as ‘undefined’. The minimum level for measuring continuity (and corresponding categories for low vs.
moderate visit frequency) were set to two or four visits rather than three visits as in our main analysis.
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Results
Sample
The sample consisted of 19,324 patients attending 215 practices, observed for 15.8 3-month periods
on average (range 1–28 periods). Table 6 presents the characteristics of patients in the sample. Half of
the sample (50.3%) had an A&E department presentation at some point during the observation period,
13.1% had an admission for SMI and 12.8% had an ACSC admission. Using a three-visit minimum to
define continuity, median (mean) values for each continuity index were 0.35 (mean 0.46) for COC,
0.67 (mean 0.65) for UPC and 0.17 (mean 0.26) for SECON. A CP had been documented in the
previous 12 months for 40% of the patient-periods observed and an AR (or the alternate aggregate
indicator) in 69% of periods. The Spearman’s rank-order correlation between COC and UPC was 0.94
(p < 0.001), between COC and SECON it was 0.55 (p < 0.001) and between UPC and SECON it was
0.47 (p < 0.001). Mean COC in periods with a CP in the previous 12 months was 0.47, compared with
0.45 in periods without a CP in the previous 12 months (two-sample t-test of difference in means:
p < 0.001). The equivalent for UPC was 0.67, compared with 0.66 (p < 0.001), and for SECON it was
0.24 compared with 0.23 (p < 0.001).
Association between quality of care and outcomes
Table 7 presents the association between the quality measures and each outcome from the discrete-
time survival analyses, with practitioner continuity measured by the COC. The results in the second
column are HRs for the key variables of interest from our preferred specification, the correlated
random-effects model, which accounts for unobserved confounding. Results from a model that does
not account for unobserved confounding, the standard random-effects model, are presented in the
third column for comparison. Full results from the correlated random-effects models are presented
in Table 8.
TABLE 6 Sample characteristics (n = 19,324)
Characteristic n (%) Mean (SD)
Fixed at baseline
Age (years)
19–35 5328 (27.6)
36–45 4407 (22.8)
46–55 3571 (18.5)
56–65 2678 (13.9)
≥ 66 3340 (17.3)
Sex
Female 9705 (50.2)
Male 9619 (49.8)
IMD
Quintile 1 (least disadvantaged) 3113 (16.1)
Quintile 2 3546 (18.4)
Quintile 3 3605 (18.7)
Quintile 4 4484 (23.2)
Quintile 5 (most disadvantaged) 4576 (23.7)
continued
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Having a CP or AR documented in the previous 12 months was associated with lower hazard of all
three outcomes. The relative magnitude of the hazard reduction associated with CPs was 26% for A&E
department presentation [HR 0.74, 95% confidence interval (CI) 0.69 to 0.80], 33% for SMI admission
(HR 0.67, 95% CI 0.59 to 0.75) and 27% for ACSC admission (HR 0.73, 95% CI 0.64 to 0.83). The
reduction associated with ARs was 20% for A&E department presentation (HR 0.80, 95% CI 0.76 to 0.85),
25% for SMI admission (HR 0.75, 95% CI 0.67 to 0.84) and 24% for ACSC admission (HR 0.76, 95% CI
0.67 to 0.87).
TABLE 6 Sample characteristics (n = 19,324) (continued )
Characteristic n (%) Mean (SD)
Ethnicity
Black and minority ethnicities 5609 (29.0)
White 13,715 (71.0)
Diagnosis category grouping
Bipolar disorder and affective psychoses 6846 (35.4)
Schizophrenia and other psychoses 10,254 (53.1)
Both categories 2224 (11.5)
Years since diagnosis
0–1 5779 (29.9)
2–5 3953 (20.5)
> 5 9592 (49.6)
Number of Charlson Comorbidity Index comorbidities
None 13,246 (68.5)
One 4726 (24.5)
Two or more 1352 (7.0)
History of depression
No history of depression 8382 (43.4)
Comorbid depression 10,942 (56.6)
History of smoking
Non-smoker 5436 (28.1)
Current or ex-smoker 13,888 (71.9)
During the observation period
Number of 3-month periods observed 15.8 (10.0)
COC 0.46 (0.32)
UPC 0.65 (0.24)
SECON 0.26 (0.30)
CP in prior 12 months 0.40 (0.49)
Annual review in prior 12 months 0.69 (0.46)
At least one A&E department presentation 9719 (50.3)
At least one SMI admission 2525 (13.1)
At least one ACSC admission 2475 (12.8)
SD, standard deviation.
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For those with moderate visit frequency (three to five visits in the previous 12 months), higher GP
continuity was associated with 11% lower hazard of A&E department presentation (HR 0.89, 95% CI
0.83 to 0.97) and 23% lower hazard of ACSC admission (HR 0.77, 95% CI 0.65 to 0.92), but not with
hazard of SMI admission. For frequent attenders (six or more visits in the previous 12 months), higher
GP continuity was associated with 26% lower hazard of ACSC admission (HR 0.74, 95% CI 0.62 to 0.87),
but not with risk of A&E department presentation or SMI admission.
TABLE 7 Association of care quality indicators with hazard of each outcome
Indicator
Correlated random-effects
model, HR (95% CI)a
Random-effects model,
HR (95% CI)b
A&E department presentation
QOF quality indicators
CP vs. none 0.74*** (0.69 to 0.80) 0.95* (0.90 to 0.99)
AR vs. none 0.80*** (0.76 to 0.85) 0.95 (0.91 to 1.00)
Practitioner continuity
Moderate visit frequency (three to five visits): high COC vs.
low COC
0.89** (0.83 to 0.97) 0.84*** (0.77 to 0.91)
High visit frequency (six or more visits): high COC vs.
low COC
0.92 (0.84 to 1.00) 0.86*** (0.80 to 0.92)
SMI admission
QOF quality indicators
CP vs. none 0.67*** (0.59 to 0.75) 1.36*** (1.23 to 1.50)
AR vs. none 0.75*** (0.67 to 0.84) 0.97 (0.86 to 1.09)
Practitioner continuity
Moderate visit frequency (three to five visits): high COC vs.
low COC
0.99 (0.82 to 1.18) 0.98 (0.83 to 1.17)
High visit frequency (six or more visits): high COC vs.
low COC
0.91 (0.76 to 1.09) 0.94 (0.82 to 1.08)
ACSC admission
QOF quality indicators
CP vs. none 0.73*** (0.64 to 0.83) 0.98 (0.89 to 1.07)
AR vs. none 0.76*** (0.67 to 0.87) 1.03 (0.92 to 1.16)
Practitioner continuity
Moderate visit frequency (three to five visits): high COC vs.
low COC
0.77** (0.65 to 0.92) 0.74*** (0.62 to 0.88)
High visit frequency (six or more visits): high COC vs.
low COC
0.74*** (0.62 to 0.87) 0.71*** (0.61 to 0.82)
*p < 0.05, **p < 0.01,***p < 0.001.
CI, confidence interval.
a This model accounts for confounding by unobserved time-invariant individual characteristics, using the approach
following Mundlak.105
b Random-effects model assumes individual heterogeneity is uncorrelated with the explanatory variables.
Notes
Continuity: low ≤median COC, high >median COC.
Visit frequency: low = zero to two, moderate= three to five, high= six or more visits in 12 months.
HRs between two levels of continuity obtained as the ratio of exponentiated coefficients: HRhigh/low = exp(βhigh)/exp(βlow).
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TABLE 8 Full model estimates for the association between quality measures and outcomes
A&E
department
presentation SMI admission ACSC admission
HRa SEb HRa SEb HRa SEb
Time-varying variable: period level
CP 0.744*** 0.026 0.667*** 0.038 0.726*** 0.048
AR 0.805*** 0.023 0.748*** 0.044 0.763*** 0.050
Continuity/visit frequency (base: low visit frequency, continuity undefined)
Moderate frequency, low continuity 1.091* 0.042 1.217** 0.082 1.526*** 0.130
Moderate frequency, high continuity 0.976 0.041 1.200* 0.110 1.181 0.101
High frequency, low continuity 1.136* 0.058 1.628*** 0.141 2.080*** 0.213
High frequency, high continuity 1.046 0.054 1.476*** 0.149 1.531*** 0.157
Time-varying variables: mean level
CP 1.781*** 0.134 6.718*** 1.010 2.186*** 0.336
AR 1.466*** 0.092 1.812*** 0.315 2.627*** 0.475
Continuity/visit frequency (low visit frequency, continuity undefined)
Moderate frequency, low continuity 1.448*** 0.125 0.580** 0.112 1.031 0.227
Moderate frequency, high continuity 1.073 0.102 0.486** 0.118 0.747 0.170
High frequency, low continuity 2.029*** 0.169 0.598** 0.096 1.231 0.200
High frequency, high continuity 1.797*** 0.148 0.675* 0.113 1.140 0.200
Time-invariant variables (at start of observation)
Index of disadvantage (base: quintile 1, least disadvantaged)
Quintile 2 1.105* 0.047 0.987 0.081 0.933 0.064
Quintile 3 1.177*** 0.051 1.030 0.083 1.081 0.073
Quintile 4 1.244*** 0.059 1.009 0.084 1.192* 0.083
Quintile 5 (most disadvantaged) 1.409*** 0.074 1.112 0.102 1.261** 0.101
Ethnicity (base: black and minority ethnicities)
White 1.478*** 0.043 1.802*** 0.139 2.090*** 0.156
History of smoking (base: non-smoker)
Current or ex-smoker 1.067* 0.030 0.956 0.0483 1.019 0.057
Age (years) (base: 18–35 years)
36–45 0.840*** 0.026 1.000 0.0623 1.075 0.085
46–55 0.770*** 0.026 0.750*** 0.0493 1.383*** 0.117
56–65 0.819*** 0.030 0.651*** 0.0449 1.957*** 0.169
≥ 66 1.165** 0.041 0.481*** 0.0449 3.592*** 0.324
Years since SMI diagnosis (base: ≤ 1 year)
2–5 1.039 0.034 1.071 0.0740 1.158 0.091
> 5 0.943* 0.026 1.067 0.0665 1.159* 0.078
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The standard approach (random effects) to modelling continuity, which does not account for unobserved
confounding and so is not our preferred specification, produced different results (see final column of
Table 7). Compared with the correlated random-effects model, the standard approach found larger risk
reductions associated with higher GP continuity, none with annual reviews and CPs was associated
with higher (rather than lower) risk of SMI admissions.
Some patient characteristics were also associated with risk of unplanned hospital utilisation. Living in a
more deprived area was associated with a higher hazard of all three types of hospital care, as was
white ethnicity (vs. black or minority ethnicities). Age had different patterns of association with the
three types of hospital care: those in the middle range (aged 36–65 years) had lower risk of A&E
department presentation than younger or older patients, whereas younger patients (aged < 45 years)
had the highest risk of SMI admission, and the risk of ACSC admission steadily increased from the age
of 46 years. Physical comorbidities were associated with higher risk of A&E department presentation
and ACSC admissions, but lower risk of SMI admission. Those with a diagnosis grouped with bipolar
disorder (and not a diagnosis grouped with schizophrenia) were at lower risk of SMI admission.
Table 9 shows that using a different measure of GP continuity, either UPC (measuring density of visits
to a single provider) or SECON (measuring sequential continuity), produced a similar pattern of results
to those obtained using the COC (measuring dispersion), although with some differences. There was
an association between higher continuity and lower risk of SMI admission for frequent attenders
when using the UPC, and for those with moderate visit frequency using the SECON index. In addition,
there was an association between higher continuity for frequent attenders and lower risk of A&E
department presentations when using the SECON. The use of different continuity indices made no
difference to the results for CPs or ARs.
TABLE 8 Full model estimates for the association between quality measures and outcomes (continued )
A&E
department
presentation SMI admission ACSC admission
HRa SEb HRa SEb HRa SEb
Sex (base: female)
Male 1.045 0.024 1.000 0.0451 1.076 0.055
SMI diagnosis category (base: bipolar disorder, affective psychosis)
Schizophrenia or other psychosis 0.954 0.026 1.267*** 0.0672 1.058 0.058
Both categories 0.961 0.033 2.046*** 0.133 0.971 0.074
Comorbidity
Number of Charlson Comorbidity Index comorbidities 1.104*** 0.018 0.913* 0.0383 1.351*** 0.042
Comorbid depression 1.019 0.024 0.791*** 0.0383 1.047 0.054
Observations 203,534 281,017 286,940
Number of individuals 19,324 19,324 19,324
***p < 0.001, **p < 0.01, *p < 0.05.
a HR (exponentiated coefficient).
b Cluster-robust SEs.
Notes
Continuity: low ≤median COC, high >median COC.
Visit frequency: low = zero to two, moderate= three to five, high= six or more visits in 12 months.
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Robustness results
Varying the minimum number of visits deemed necessary to measure continuity, from three visits in
the main analysis to two or four visits, did not substantially change the overall findings. These results
are presented in Table 10.
Discussion
Summary of findings
The two QOF indicators, CPs and ARs, were both associated with substantial reduction in the risk of
unplanned hospitalisation for patients with SMI. Among those who had a CP documented in primary
care in the previous 12 months, the hazard of an A&E department presentation, ACSC admission or
SMI admission were 26%, 27% and 33% lower, respectively, than for patients without a recent CP.
TABLE 9 Association of GP continuity as measured by UPC or SECON with hazard of each outcome
UPC, HR (95% CI) SECON, HR (95% CI)
A&E department presentation
QOF quality indicator
CP vs. none 0.74*** (0.69 to 0.80) 0.74*** (0.69 to 0.80)
AR vs. none 0.80*** (0.76 to 0.85) 0.80*** (0.76 to 0.85)
Practitioner continuity
Moderate visit frequency (three to five visits): high continuity index
vs. low continuity index
0.90* (0.84 to 0.98) 0.84*** (0.76 to 0.91)
High visit frequency (six or more visits): high continuity index vs.
low continuity index
0.97 (0.89 to 1.05) 0.90** (0.84 to 0.97)
SMI admission
QOF quality indicator
CP vs. none 0.67*** (0.60 to 0.75) 0.67*** (0.60 to 0.75)
AR vs. none 0.75*** (0.67 to 0.84) 0.75*** (0.67 to 0.84)
Practitioner continuity
Moderate visit frequency (three to five visits): high continuity index
vs. low continuity index
0.91 (0.75 to 1.09) 0.81* (0.67 to 0.98)
High visit frequency (six or more visits): high continuity index vs. low
continuity index
0.79* (0.66 to 0.95) 0.94 (0.78 to 1.15)
ACSC admission
QOF quality indicator
CP vs. none 0.73*** (0.64 to 0.83) 0.72*** (0.64 to 0.82)
AR vs. none 0.76*** (0.67 to 0.87) 0.76*** (0.67 to 0.87)
Practitioner continuity
Moderate visit frequency (three to five visits): high continuity index
vs. low continuity index
0.83* (0.70 to 0.99) 0.83* (0.69 to 0.99)
High visit frequency (six or more visits): high continuity index vs. low
continuity index
0.79** (0.66 to 0.93) 0.83* (0.70 to 0.99)
*p < 0.05, **p < 0.01, ***p < 0.001.
Notes
Results from model that accounts for unobserved time-invariant confounding.
Continuity: low ≤median continuity, high >median continuity.
Visit frequency: low= zero to two, moderate= three to five, high= six or more visits in 12 months.
HRs between two levels of continuity obtained as the ratio of exponentiated coefficients: HRhigh/low = exp(βhigh)/exp(βlow).
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The corresponding reductions associated with ARs were 20%, 24% and 25% lower, respectively. All of
these effects were statistically significantly different from 1 when compared against a critical value of
alpha = 0.05.
The association of continuity of care and unplanned hospitalisations varied with the underlying frequency
of patients’ visits to their GP. For those with moderate visit frequency (three to five visits in the previous
12 months), higher GP continuity was associated with 11% lower hazard of A&E department presentation
and 23% lower hazard of ACSC admission, but not with risk of SMI admission. For frequent attenders
(six or more visits in the previous 12 months), higher GP continuity was associated with 26% lower hazard
of ACSC admission, but not with risk of A&E department presentation or SMI admission.
Strengths and limitations
The primary strength of this analysis was its use of detailed information on the timing of care events,
which allowed us to study the association between time-varying measures of care quality and hospital
utilisation, and to ascertain the action–outcome ordering necessary for meaningful causal inference.
Furthermore, by using statistical modelling techniques that separate within- and between-patient
variation, we controlled for time-invariant patient characteristics, when possible, and reduced the
scope for unobserved confounding. To our knowledge, this is the first time this modelling approach
has been used to analyse the effect of care quality indicators on outcomes for patients with SMI.
There are a number of limitations to our analysis. First, although we attempted to account for
time-invariant unobserved patient characteristics, we cannot rule out time-varying confounding bias
that remains uncontrolled, which may have contributed to our findings. For instance, during periods of
deterioration leading to admission, GPs may have less opportunity, or put less emphasis on, spending
time on preventative measures, such as CPs. This would induce a negative correlation between having
a current CP and risk of unplanned hospitalisation. Our results should therefore be interpreted as
showing association with many sources of confounding avoided, but not strictly causation.
Second, we restricted the sample to patients registered with the same practice for the year preceding
diagnosis, to allow us to include measures of historical health-care utilisation and medical history.
TABLE 10 Association of GP continuity with hazard of each outcome, varying the minimum number of visits required for
the measurement of COC
High COC vs. low COC Two visits, HR (95% CI) Four visits, HR (95% CI)
A&E department presentation
Moderate visit frequency 0.90** (0.84 to 0.96) 0.86** (0.78 to 0.95)
High visit frequency 0.92 (0.84 to 1.00) 0.92 (0.84 to 1.00)
SMI admission
Moderate visit frequency 0.90 (0.77 to 1.05) 0.89 (0.72 to 1.11)
High visit frequency 0.89 (0.74 to 1.07) 0.90 (0.75 to 1.07)
ACSC admission
Moderate visit frequency 0.79** (0.67 to 0.93) 0.76* (0.61 to 0.95)
High visit frequency 0.73*** (0.62 to 0.87) 0.74*** (0.62 to 0.88)
*p < 0.05, **p < 0.01, ***p < 0.001.
Notes
Results from model that accounts for unobserved time-invariant confounding.
Continuity: low ≤median COC, high >median COC.
Visit frequency: low = zero to varying minimum, moderate= varying minimum – five visits, high = six or more visits in
12 months.
HRs between two levels of continuity obtained as the ratio of exponentiated coefficients: HRhigh/low = exp(βhigh)/exp(βlow).
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However, the restriction may have excluded individuals with a more severe form of SMI if this led
them to move practice. In addition, the sample may have included some patients who were not newly
diagnosed if their diagnostic information had not been transferred to a new practice or to a new
electronic recording system.
Third, patients in England can register with only one general practice and may face greater
administrative barriers to changing practices than in other countries. This may result in less apparent
benefit of continuity of care in our results than would be observed in other health-care systems. When
patients are free to choose their provider, high practitioner continuity may reflect a strong, valued
therapeutic relationship, which may in turn improve outcomes. In England, patients may have a
constrained choice of general practice, so that higher continuity could, in principle, be less beneficial
for some individuals.
Fourth, the collection of HES A&E data commenced on an experimental basis in April 2007 and
captured 62% of national A&E department attendances in the first financial year. The experimental
label was lifted by April 2013 after capture had increased to > 80%. However, there is no reason to
consider that the capture of attendances was related to if a patient had a CP or AR, meaning that this
should not impact adversely on our comparative analysis.
Finally, the clinical outcomes we examined are important, as they represent some of the excess health
risks for people with SMI and carry substantial health-care costs. However, they are not the only
outcomes that matter. Both people with SMI and GPs value continuity of care in itself, as part of how
they experience giving and receiving care.106,107 Regular physical reviews may uncover health issues
that require treatment, but which would not necessarily have led to an ACSC admission. Broader
outcomes important to people with SMI may also be affected by the different measures of care quality,
including social functioning and health-related quality of life.108
Implications for research and practice
The association of the QOF indicators with reduced hazard of unplanned hospital use might suggest
that these activities help patients avoid hospital for conditions that can be effectively managed in
primary care. As hypothesised, proactive reviews of physical health (ARs) may lead to earlier detection
of physical health problems, whereas documentation of patients’ current health status, early warning
signs, triggers, social support needs, co-ordination arrangements with secondary care and preferred
course of action in the event of a clinical relapse (CPs) could improve the management of the patient’s
health overall. Both of these indicators could thereby prevent deterioration, reducing the need for
urgent care, with CPs also having the potential to direct patients into appropriate community-based
services during periods of deterioration, and thereby avert hospital use.
Similarly, the finding that practitioner continuity is associated with lower hazard of A&E department
presentations and ACSC admissions supports the hypothesis that seeing the same GP over time could
improve the doctor–patient relationship, facilitate communication and trust, reduce fragmentation of
care, and allow for earlier detection of problems and/or more effective and appropriate management
of problems as they arise.
The potential for better-quality care by GPs to reduce A&E department attendances and hospital
admissions suggests that improving quality may help reduce demand on secondary care services and
hence possibly reduce NHS expenditure, a question we explore in Chapter 7.
From a methodological point of view, the results presented in this analysis differed substantially from
a previous study addressing similar research questions, but using practice-level aggregate data of
hospitalisation rates and QOF achievement rates.43 Although the practice-level analysis identified a
positive association between AR and the risk of unplanned SMI hospitalisation (i.e. high-quality care
increases unplanned hospital use), the current analysis found an opposite effect. The current results
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may be more plausible given the hypothesised mechanism by which high-quality care affects patients’
health and health-care needs. Although the studies are not directly comparable – as they are based
on different samples – it is reasonable to assume that the more aggregate-level study suffers from
aggregation bias and reverse causality bias.
Our results were also informative about trends in practitioner continuity in English primary care over
time and across patient groups. We found slightly lower levels of continuity than those in an earlier
study of family physician continuity for patients with long-term mental illness in the UK,109 but much
lower than those found in studies looking only at specialist mental health care.110,111 Higher, and
rising,112 rates of consultation in family practice may contribute to these differences. Practitioner
continuity in English family practices may be affected by reductions in full-time working and increasing
practice size in future. Average UPC scores for all patients in 2011–13 were 0.61.103 Comparison with
our results suggests that this dimension of family physician continuity is not lower for patients with
SMI than for patients overall. Based on our results, we predict that further decreases in practitioner
continuity in primary care may have negative spillover effects onto the secondary care sector.
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Chapter 5 The association between
antipsychotic polypharmacy and hospital
care utilisation and mortality
This chapter is based on Kasteridis et al.
42 Reprinted with permission from Psychiatric Services
(Copyright © 2019). American Psychiatric Association. All Rights Reserved.
Introduction
Antipsychotic drugs are a common component of the therapeutic strategy for patients with SMI.
Although UK and international guidelines recommend antipsychotic monotherapy,36,113 antipsychotic
polypharmacy (hereafter polypharmacy) – defined as the concurrent use of two or more different
antipsychotic agents – is common in clinical practice.114,115
The most common rationale for polypharmacy is to improve therapeutic response when the response to
monotherapy is considered inadequate.36 However, there is little empirical evidence that polypharmacy
has higher efficacy than monotherapy. A Cochrane systematic review91 of RCTs concluded that, although
polypharmacy might be superior to monotherapy in certain clinical situations, the evidence was too
heterogeneous to derive firm conclusions. Significant risks associated with polypharmacy have been
reported, particularly excessive dosing,116 which can in turn result in adverse effects, such as metabolic
syndrome,117 cognitive impairment, extrapyramidal side effects118 and cardiovascular disorders.119
Polypharmacy efficacy and adverse effects contribute to changes in broader patient outcomes reflecting
overall polypharmacy effectiveness. Whether polypharmacy is a valid therapeutic option or a ‘dirty
little secret’,120 it remains prevalent, and empirical evidence on its effectiveness and associated outcomes
is needed.
Methods
Study design
The study employs an observational cohort design. We constructed the antipsychotic prescribing
profile of patients from primary care records, which we linked to hospital and mortality data.
The argument underpinning a cohort study design is that effectiveness is assessed under the usual
circumstances of health-care practice rather than the possibly atypical circumstances of a RCT, and in
many situations it is not possible to randomise to evaluate an intervention. As with all observational
studies, validity relies on rigorous design and adjustment of confounding factors to minimise selection
bias. Significant progress towards this direction has been made by studies from Denmark121 and
Finland,122 which focused on the effect of polypharmacy on mortality. However, studies that explore
associations between polypharmacy and inpatient hospitalisations123,124 and A&E department
attendances125 suffer from important weaknesses that stem from failure (or inability due to lack of
data) to model the timing of polypharmacy episodes and outcomes. The analysis presented in this
chapter42 improves on the fundamental issue of confoundedness, by employing a Cox survival analysis
model that analysed time to each outcome, adjusting for both time-invariant confounders and time-
dependent polypharmacy and monotherapy.126
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Sample
Patients were included in the sample if they had at least one antipsychotic drug record during the
observation period and all conditions listed in Chapter 3, Study samples, were met. For reasons
explained in Chapter 3, Study samples, we use two samples: one for the analysis of A&E department
attendances and one for the analysis of all other outcomes.
Patient outcomes
We investigated the association between polypharmacy and the occurrence of three outcomes:
(1) unplanned hospital admissions (all cause), (2) A&E department attendances and (3) mortality.
Definition of antipsychotic polypharmacy
There is no consistent definition of polypharmacy in the literature. We defined polypharmacy as the
concurrent use of two or more antipsychotic substances for at least 30 days. The overlap period
allowed for cross-tapering between substances. A longer overlap period has a higher risk of
misclassifying polypharmacy as monotherapy, whereas a shorter overlap may misclassify switching
between substances as polypharmacy.
We considered 33 antipsychotic substances covering first-generation antipsychotic drugs or typical
antipsychotics, second-generation antipsychotics or atypical antipsychotics, and depot antipsychotics127,128
(see Appendix 4 for substance product codes used).
The CPRD data provide the date a prescription was issued, but the duration of prescriptions is not
always recorded. We therefore inferred treatment duration from the total quantity (number of units)
prescribed and the numeric daily dose (ndd) (number of units per day) when duration was absent.
Furthermore, the daily dose was missing for 23% of prescriptions. For these prescriptions, we imputed
the dose using an imputation strategy explained in Appendix 4. Less than 0.02% of prescription records
were dropped from the analysis, as they had implausibly large estimated duration. From the prescription
dates and durations, we constructed the patient’s medication profile (times at which the patient was
on any antipsychotic medication and on polypharmacy).
We calculated two measures of polypharmacy prevalence. First, we calculated the annual prevalence of
polypharmacy as the number of patients with at least one polypharmacy episode in a year divided by
the total number of patients observed during that year. Second, we calculated the rate of polypharmacy,
defined as the sum of all patients’ polypharmacy days in a year over the sum of all patients’ days at
risk of polypharmacy in that year. The latter measure is an improvement over the commonly reported
point estimates of polypharmacy prevalence, which measure the proportion of eligible individuals on
polypharmacy on a given day (see Appendix 4 for a proof).
Statistical analysis
Semi-parametric Cox hazard models129 were applied to estimate the effect of polypharmacy on the
time to the first occurrence of each of the three outcomes. The model adjusts for censoring, which may
occur because (1) a patient dies, (2) registration with the practice ends or (3) the study period ends,
prior to the outcome of interest occurring. The follow-up period – time from entry to the sample
until the outcome occurs or censoring – was different from the observation period for outcomes other
than death.
An individual could have multiple polypharmacy episodes. On each day during the study period the
patient was in one of three states: (1) received no antipsychotic medication, (2) monotherapy (on one
antipsychotic or on more than one, but for < 30 days) and (3) polypharmacy. To model this, we introduced
two time-varying binary variables: (1) ‘no antipsychotic substance’, which took a value of 1 during periods
the patient was not on an antipsychotic drug and zero otherwise, and (2) ‘polypharmacy’, which took a
value of 1 during periods the patient was on two or more antipsychotic substances for > 30 days and zero
otherwise. The results were interpreted with regard to monotherapy, which was the reference category.
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Robustness checks
We performed two checks. First, to assess the impact on the results of a shorter or longer overlap
period, we estimated our models assuming overlap periods of 14, 60 and 90 days. Second, we explored
whether or not SMI admissions, which are a subset of all unplanned admissions, were affected
differently by polypharmacy.
Results
All patients were prescribed an antipsychotic substance at some point during the observation period.
Table 11 provides descriptive statistics. Unplanned admissions and mortality outcomes were studied
using the same sample of 17,255 patients from 215 practices. These patients were observed for 5.7 years,
on average, and 12.9% of them had at least one polypharmacy episode during the observation period.
The average number of polypharmacy episodes per patient on polypharmacy was 5.5 and the mean
polypharmacy episode length was 66 days (range 2–2340 days).
For the unplanned admissions analysis, the average follow-up period was shorter than the observation
period (3.6 years), with 8.8% of patients having at least one polypharmacy episode during this period.
Almost 52% of the patients (n = 8916) had an unplanned admission and, of those 52%, 7.9% had at
least one polypharmacy episode before the admission.
TABLE 11 Descriptive statistics for antipsychotic polypharmacy samples for each of three outcomes
Analysis
Unplanned admissions Death
A&E department
presentations
Full sample
Individuals, n 17,255 17,255 13,247
During observation perioda
Mean years 5.7 5.7 4.1
Patients with at least one polypharmacy episode, n 2228 2228 1548
Patients with at least one polypharmacy episode, % 12.9 12.9 11.7
Polypharmacy episodes per patient on polypharmacy 5.5 5.5 4.8
Number of switches on/off polypharmacy per year 0.96 0.97 1.15
Mean polypharmacy length (days) 66 66 69
During follow-up periodb
Mean years 3.6 5.7 2.5
Patients with at least one polypharmacy episode, n 1515 2228 1068
Patients with at least one polypharmacy episode, % 8.8 12.9 8.1
Sample of patients experiencing outcome
Individuals, n 8916 604 7523
During follow-up period
Mean years 2.6 2.8 1.8
Patients with at least one polypharmacy episode, n 704 52 511
Patients with at least one polypharmacy episode, % 7.9 8.6 6.8
a Observation period: from entry to the sample until the earliest of death, end of registration with practice or
31 March 2014.
b Follow-up period: from entry to the sample until outcome occurs or censoring (end of observation period).
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For the mortality analysis, the average time to death or censoring was 5.7 years. Among the 604
patients who died (3.5%), 52 (8.6%) had received polypharmacy.
The smaller sample for A&E department attendances consists of 13,247 patients from 215 practices.
Of the 7523 patients with an A&E department attendance, 511 (6.8%) had received polypharmacy.
Figure 5 shows that the annual prevalence of polypharmacy fluctuated between 5% and 6%, whereas
the polypharmacy rate was around 2%. Polypharmacy rate estimates were lower than the annual
polypharmacy prevalence because the former reflected both if a patient was on polypharmacy during
the year and the total duration of polypharmacy episodes. Figures of the annual prevalence of
(antipsychotic) polypharmacy (APP) and the polypharmacy rate for different overlap periods are
provided in Appendix 4.
Summary statistics for the explanatory variables are presented in Table 12. Approximately 35% of
patients had at least one of the Charlson Comorbidity Index morbidities and 13% were diagnosed with
both schizophrenia and bipolar disorder during the observation period.
Table 13 presents the survival analysis estimates for the two time-varying variables for our main
specification, assuming an overlap period of 30 days. Being on polypharmacy (relative to monotherapy)
was not statistically significantly associated with the risk of unplanned admission, death or A&E
department presentation. Not being prescribed any antipsychotic substance increased the hazard
(relative to monotherapy) of an unplanned admission to hospital by 8.2% (95% CI 3% to 13.6%) and
1
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7
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
APP annual prevalence
APP rate
FIGURE 5 Polypharmacy prevalence. Kasteridis et al.42 Reprinted with permission from Psychiatric Services (Copyright ©
2019). American Psychiatric Association. All Rights Reserved.
TABLE 12 Descriptive statistics for the explanatory variables in the polypharmacy analysis
Variable Patients, n %
Age at entry date (years)
19–35 4484 26
36–45 3718 22
46–55 3017 17
56–65 2341 14
> 65 3695 21
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TABLE 12 Descriptive statistics for the explanatory variables in the polypharmacy analysis (continued )
Variable Patients, n %
IMD
Quintile 1 2618 15
Quintile 2 3093 18
Quintile 3 3238 19
Quintile 4 4064 24
Quintile 5 4242 25
Male 8171 47
White 12,521 73
General practice in rural area 1921 11
Number of primary care contacts in year preceding entry into the sample
0–4 3798 22
5–9 4496 26
10–14 3271 19
15–19 2158 13
≥ 20 3532 20
Distance from GP to nearest acute provider (km)
0–3 7489 43
3–6 4925 29
6–9 2160 13
> 9 2681 16
Distance from GP to nearest mental health provider (km)
0–3 3441 20
3–6 4330 25
6–9 3178 18
> 9 6306 37
Number of Charlson Comorbidity Index comorbidities at entry into the sample
None 11,273 65
One 4441 26
Two 1079 6
Three or more 462 3
History of depression at entry into the sample 9746 56
Schizophrenia 9653 56
Bipolar 5342 31
Both schizophrenia and bipolar 2260 13
Reproduced from Kasteridis et al.42 Reprinted with permission from Psychiatric Services (Copyright © 2019). American
Psychiatric Association. All Rights Reserved.
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the hazard of an A&E department presentation by 18.6% (95% CI 13.5% to 23.9%), but had no effect
on mortality risk. For estimates of the impact of other explanatory variables on outcomes, see Appendix 4.
Having both diagnoses of schizophrenia and bipolar disorder increased the hazard of an unplanned
admission by 20% (HR 1.20, 95% CI 1.12 to 1.29). Living in a more deprived area was associated with a
higher hazard of unplanned admissions and A&E department attendances, but not mortality, as was white
ethnicity compared with black or minority ethnicities.
Robustness check results
Table 14 shows the results of sensitivity analyses that explored the impact of changing the length of
overlap in the definition of polypharmacy. The estimated relationships were generally insensitive to the
length of overlap. The only exception is unplanned admissions: when the lower boundary of the overlap
duration was reduced to 14 days, polypharmacy was associated with an increased hazard of unplanned
admission of about 21%.
The results for SMI admissions are reported in Appendix 4. The results show no association between
SMI admissions and polypharmacy.
Discussion
Summary of findings
The principal findings of the study are threefold. Annual polypharmacy prevalence fluctuates over time
by between 5% and 6%. Relative to those on monotherapy, patients who are not on antipsychotic
medication have an 8.2% (18.6%) higher hazard of an unplanned hospital admission (A&E department
presentation). Relative to monotherapy, polypharmacy is not significantly associated with mortality,
unplanned hospital admissions or A&E department presentations.
TABLE 14 Association of polypharmacy with outcomes under different assumptions about the minimum length of
medication overlap
Days
Unplanned admissions Death A&E presentations
HR 95% CI HR 95% CI HR 95% CI
14 1.21** 1.08 to 1.37 1.11 0.87 to 1.40 0.94 0.80 to 1.11
30 1.14 0.98 to 1.32 1.02 0.76 to 1.37 0.95 0.80 to 1.14
60 1.08 0.90 to 1.30 0.90 0.63 to 1.28 0.98 0.79 to 1.21
90 1.02 0.80 to 1.29 0.83 0.54 to 1.28 0.80 0.62 to 1.03
**p < 0.01.
Reproduced from Kasteridis et al.42 Reprinted with permission from Psychiatric Services (Copyright © 2019). American
Psychiatric Association. All Rights Reserved.
TABLE 13 Association of polypharmacy with outcomes: base-case analysis
Unplanned admissions Death A&E department presentations
HR 95% CI HR 95% CI HR 95% CI
Polypharmacy 1.14 0.98 to 1.32 1.02 0.76 to 1.37 0.95 0.80 to 1.14
No antipsychotic substance 1.08** 1.03 to 1.14 1.02 0.94 to 1.10 1.19*** 1.14 to 1.24
**p < 0.01, ***p < 0.001.
Reproduced from Kasteridis et al.42 Reprinted with permission from Psychiatric Services (Copyright © 2019). American
Psychiatric Association. All Rights Reserved.
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Strengths and limitations
This study is a step forward towards understanding the links between polypharmacy and health-care
utilisation and mortality. As with all observational studies, validity relies on rigorous design and
adjustment of confounding factors to minimise selection bias. We addressed this fundamental issue
employing a three-step strategy.
First, we constructed the antipsychotic prescribing profile of patients from primary care records. In the
UK, family practices provide the majority of care for patients with SMI,24 including the management of
long-term prescribing. Therefore, unlike previous studies that used solely hospital data to investigate
polypharmacy,130 we defined polypharmacy and monotherapy from primary care data. Second, we
linked primary care data with hospital and mortality data at patient level, to determine the sequence of
polypharmacy episodes, hospital utilisation and mortality. Third, we employed a Cox survival analysis model
that analysed time to each outcome, adjusting for both time-invariant confounders and time-dependent
polypharmacy and monotherapy.126 By specifying polypharmacy as a time-dependent variable, we addressed
the statistical challenge arising in cases in which the exposure is not present throughout the entire
time of observation. The use of a large, linked data set, coupled with a suitable survival analysis model,
provided more robust estimates of the effects of polypharmacy on outcomes than would be possible
with aggregate data or a cross-sectional design.
There are three main limitations to the study. First, the measures of health status and health-care
utilisation prior to diagnosis of SMI may not fully depict the complexities of health status, including
severity of the condition. Second, imputing the treatment duration for a number of prescriptions may
introduce measurement error in the calculation of polypharmacy. Last, we explored the effect of
polypharmacy on broadly defined outcomes. Future research could investigate whether effects vary by
reason for admission or for particular combinations of antipsychotic medication.
UK guidelines36 recommend against combining antipsychotic drugs, except as a last resort. These
recommendations are based on limited supportive evidence for superior efficacy of polypharmacy over
monotherapy, as well as concerns that combined antipsychotics are associated with an increased risk
of side effects. Our study cannot draw conclusions on the polypharmacy effect in terms of efficacy and
tolerability and, bearing in mind the limitations of an observational study (despite its advanced design),
cannot substitute for RCTs. Its contribution lies in providing real-world evidence on the effectiveness
of polypharmacy.
Implications for research and practice
Our study examined the overall effectiveness of polypharmacy relative to monotherapy by investigating
associations between polypharmacy and three patient outcomes. We found no evidence of a positive or
negative effect of polypharmacy on mortality, inpatient hospitalisations or A&E department presentations.
At a policy level, these findings do not rule out polypharmacy options, but highlight the need for further
research on the appropriateness of polypharmacy.
Current UK guidance36 recommends antipsychotic monotherapy as a treatment option, and our results
provide further supportive evidence by establishing a negative association between antipsychotic
monotherapy and hospitalisations. This may be because drug therapy helps to stabilise the patients’
condition and allows better management of their physical health. Being prescribed an antipsychotic
may be associated with closer or more regular clinical monitoring in the primary care setting, as set out
in the guidelines, which recommend that prescription of an antipsychotic should be considered as ‘an
explicit individual therapeutic trial’,117 accompanied by detailed requirements for monitoring. The latter
may facilitate timely diagnosis and treatment of health problems, avoiding the need for hospital care.
The lack of significant association between polypharmacy and any of the three outcomes provides
some reassurance that the safety profile of polypharmacy may be comparable to that of monotherapy.
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For a shorter overlap period (14 days or longer), which captured more cross-tapering in the definition
of polypharmacy, we observed an increase in the risk of unplanned admission. One explanation is that
patients who changed drugs might have had more unstable disease profiles and/or that changing drugs
further destabilised their condition. This suggests a need for close monitoring in the first few weeks of
cross-tapering, when the risk of unplanned hospitalisation is higher.
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Chapter 6 The association between
primary care quality and (re-)entry to
specialist mental health-care services
Introduction
This chapter examines the association between the quality of primary care and the time to (re-)entry
into secondary specialist mental health-care services for people with SMI.
We examined the effects of two care quality indicators on time to re-entry to secondary care mental
health care: one QOF indicator (CPs developed in primary care) and one non-QOF indicator (the
continuity of primary care, which included the number of GP visits within the previous 12 months).
Details of these two measures are provided in Chapter 3, The care plan indicator, and Chapter 3, The annual
review indicator. The reason for choosing these two quality indicators was that they have potential to
prevent, or delay the onset of, acute episodes of SMI by regular reviews of medication and other types of
care, and by offering ongoing primary care support. We also considered polypharmacy and ARs as potential
indicators of care quality, but rejected these in the context of re-entry to specialist mental health care. The
focus of ARs is on patients’ physical health, rather than their mental health, and avoidance of polypharmacy
would not be expected to reduce the need for specialist mental health care.
If patients are not currently being treated in secondary care and receive most of their care from their
general practice, it is plausible that the quality of that care could affect the time to (re)-entry to
secondary care. For example, if a patient’s mental health is deteriorating – and their risk of re-entry to
secondary mental health care increases – then the GP could see the patient more frequently and/or
ensure that they see the patient themselves each time (i.e. increase the continuity of care) to help
stabilise them and so prevent a re-entry.
Methods
Study design
We restricted our sample to individuals whose mental health had been managed fully within primary
care for at least 12 months (described as ‘stable’) (see Chapter 3, Study samples). This observational
cohort analysis used discrete-time survival analysis to explore the effect of primary care quality on the
risk that a ‘stable’ patient with SMI would re-enter specialist mental health care. The outcome was
measured in 3-month periods and the primary care quality indicators were measured over the prior
12 months.
Sample
We limited the sample to people who had not been treated in specialist mental health care for at
least 12 months prior to the current quarter, as captured in the MHMDS, to try to isolate the effect
of primary care quality. The MHMDS includes specialist inpatient and community care. We hypothesised
that if the patient was seeing both specialist mental health services and their GP within a 12-month
period, the specialist care would be more influential on their subsequent mental health and use of
specialist services.
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Care quality indicators
The two primary care quality indicators examined in this analysis were CPs and GP continuity, as outlined
in Chapter 3, The care plan indicator, for CPs and Chapter 3, Continuity of general practitioner consultations,
and Chapter 4, Non-Quality and Outcomes Framework measures of quality: practitioner continuity, for GP
continuity. These were hypothesised to influence patient mental health and the probability that a patient
would remain stable in the care of the GP rather than requiring specialist care. This analysis uses the UPC
to measure GP continuity, as re-entry to specialist mental health-care services reflects deterioration of
mental health and being seen by the same GP who knows the patient could help stabilise the patient and
prevent re-entry. As in Chapter 4, periods were classified according to both number of visits in primary
care and level of GP continuity in the 12 months prior to the start of the period. The classifications were
low visit frequency (with continuity undefined – the base category); moderate visit frequency with low
continuity; moderate visit frequency with high continuity; high visit frequency with low continuity; and
high visit frequency with high continuity (as outlined in Chapter 4, Non-Quality and Outcomes Framework
measures of quality: practitioner continuity).
Outcomes
Re-entry to specialist care, although a measure of health-care utilisation rather than health itself, was
used as a potential proxy for deterioration in the patient’s mental health. We did not examine first
entry to specialist care, as most patients are treated in a specialist context when first diagnosed with
SMI. Based on clinical advice, we based our approach on the assumption that only patients whose SMI
was stable and well managed would be discharged from specialist services back to the care of their GP
for ongoing management. If a patient then re-entered specialist mental health care, this was considered
likely to indicate a deterioration in their mental health and a need for escalated care beyond that
provided by the GP.
The outcome variable was a binary variable, indicating that within a 3-month period, the patient had
some recorded activity in either inpatient- or community-based specialist services, having had no
secondary care activity recorded in the previous 12 months. The MHMDS classifies periods of patient
engagement with services into cluster episodes (CEs), intended to depict the dates during which the
patient receives treatment while allocated to a particular category of mental health problem or needs
(termed a ‘cluster’). However, we found that it was common for activities recorded in MHMDS to be
outside the bounds of CEs, suggesting recording of errors either of the CE dates or of activities that
did not actually occur. We assumed that the former was more likely and based our classification of
periods of specialist mental health care on the dates of activity, rather than CE dates.
Statistical analysis
The analysis applied discrete-time survival analysis, with 3-month periods as the unit of time, following
essentially the same approach as that outlined in Chapter 4, but with a different outcome variable
(see Chapter 4, Statistical analysis for additional detail on this method). Note that, as the outcome indicator
is re-entry to secondary care, a HR < 1.0 on a quality measure implies that the measure is associated with
a better outcome (a reduced probability of re-entry to secondary care). This approach accounted for the
different timing of entry and exit to the observation period for individuals in the sample, and different
timing of the outcome. It captured the sequence of events (primary care quality preceding re-entry to
specialist care), as well as the duration of time spent in each state. We used a panel-complementary
log–log (cloglog) model with a correlated random-effects specification (Mundlak correction),105 to account
for unobserved patient-specific effects.
The hazard of re-entering specialist care in a 3-month period – either in the community or as an
inpatient – was defined as a function of primary care quality in the previous 12 months, and of patient
and practice characteristics as common to all the analyses presented in this report. SEs were adjusted
to account for clustering of multiple patients within each practice.
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Results
The resulting sample consisted of 70,774 quarterly observations on 9907 patients treated at 214
primary care practices in England.
Table 15 outlines the characteristics of the sample. Most of those who re-entered specialist care during
the period of observation (702 individuals, 7.09% of the sample) did so by re-entering community-based
mental health care (695 individuals), rather than entering inpatient mental health care directly (seven
individuals). The median (mean) value for the UPC in the observed periods was 0.67 (mean 0.66), with
34.8% of periods classified as ‘high’ continuity. A CP had been documented in the previous 12 months
for 24% of the patient-periods observed. Mean UPC in periods with a CP in the previous 12 months
was 0.68 with 43% of periods classified as ‘high UPC’, compared with a mean of 0.65 and 32% of periods
classified as ‘high UPC’ in periods without a CP, in the previous 12 months.
TABLE 15 Sample characteristics (n= 9907)
Characteristic n (%) Mean (SD)
Fixed at baseline
Age (years)
19–35 1766 (17.8)
36–45 1898 (19.2)
46–55 1975 (19.9)
56–65 1711 (17.3)
≥ 66 2557 (25.8)
Sex
Female 5161 (52.1)
Male 4746 (47.9)
IMD
Quintile 1 (least disadvantaged) 1715 (17.3)
Quintile 2 1931 (19.5)
Quintile 3 1907 (19.2)
Quintile 4 2214 (22.3)
Quintile 5 (most disadvantaged) 2140 (21.6)
Ethnicity
Black and minority ethnicities 3118 (31.5)
White 6789 (68.5)
Diagnosis category grouping
Bipolar disorder and affective psychoses 4000 (40.4)
Schizophrenia and other psychoses 4893 (49.4)
Both categories 1014 (10.2)
Years since diagnosis
0–1 1409 (14.2)
2–5 2044 (20.6)
> 5 6454 (65.1)
continued
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As Table 16 shows, for periods preceding re-entry to specialist care, on average, in the previous
12 months, patients had more visits to their GP, were more likely to have a CP and had higher GP visit
continuity than in the 12 months preceding periods in which they did not re-enter specialist care.
The coefficients from the regression model of the discrete-time survival analysis are presented in
Table 17. In these results, each level of GP visit continuity is compared with the base category
(i.e. two or fewer visits in the prior 12 months). A more informative comparison is that between high
and low continuity, which was obtained by taking the ratio of exponentiated coefficients, presented
in Table 18. For example, for patients with moderate visit frequency (three to five visits in the prior
12 months), the coefficients on the high and low UPC were exponentiated, with the ratio of these
two scores taken to obtain the association of high continuity with the hazard of the outcome
compared with low continuity, for that visit level. These results showed that there was no statistically
significant association between level of GP visit continuity or the presence of CPs and the hazard of
re-entering specialist mental health care.
Factors associated with a higher hazard of re-entering specialist care were greater socioeconomic
disadvantage, white ethnicity (vs. black or minority ethnicities) and having diagnoses from both
schizophrenia- and bipolar-type classifications (vs. bipolar-type classification alone). Factors associated
with a lower hazard of re-entering specialist care were middle age (46–65 years vs. 18–35 years),
longer time since diagnosis of SMI (> 2 years vs. 0–1 years) and number of physical comorbidities.
TABLE 15 Sample characteristics (n = 9907) (continued )
Characteristic n (%) Mean (SD)
Number of Charlson Comorbidity Index comorbidities
None 6759 (68.2)
One 2401 (24.2)
Two or more 747 (7.5)
History of depression
No history of depression 4151 (41.9)
Comorbid depression 5756 (58.1)
During the observation period
Number of 3-month periods observed 9.7 (3.2)
UPC 0.66 (0.24)
CP in prior 12 months 0.24 (0.43)
Re-entered secondary mental health care 702 (7.1)
SD, standard deviation.
TABLE 16 Comparison of quality indicators between those who do or do not re-enter mental health care
Re-entry
In the current period In the prior 12 months
% of
periods
% of
patients
Mean (median)
number of GP visits % with CP
% with UPC
above median
Re-enters mental health care 3.8 27.2 5.51 (4) 27.9 38.2
Does not re-enter mental health care 96.2 72.8 4.17 (3) 23.4 34.7
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TABLE 17 Results from discrete-time survival analysis of re-entry to secondary mental health services
HR SE
Time-varying variables: period level
Continuity/visit frequency (base: low visit frequency, continuity undefined)
Moderate frequency, low continuity 1.353** 0.129
Moderate frequency, high continuity 1.210* 0.095
High frequency, low continuity 1.695*** 0.186
High frequency, high continuity 1.558*** 0.165
CP 1.079 0.073
Time-varying variables: mean level
Continuity/visit frequency (base: low visit frequency, continuity undefined)
Moderate frequency, low continuity 0.733 0.150
Moderate frequency, high continuity 1.420* 0.192
High frequency, low continuity 1.219 0.169
High frequency, high continuity 1.133 0.151
CP 1.100 0.140
Time-invariant variables (at start of observation)
IMD (base: quintile 1, least disadvantaged)
Quintile 2 1.161 0.102
Quintile 3 1.270* 0.122
Quintile 4 1.556*** 0.153
Quintile 5 (most disadvantaged) 1.599*** 0.165
Ethnicity (base: black and minority ethnicities)
White 1.296*** 0.072
Age (years) (base: 18–35)
36–45 0.979 0.075
46–55 0.857* 0.066
56–65 0.777** 0.072
≥ 66 0.894 0.071
Years since SMI diagnosis (base: ≤ 1 year)
2–5 0.782** 0.057
> 5 0.724*** 0.059
Sex (base: female)
Male 1.037 0.052
SMI diagnosis category (base: bipolar disorder, affective psychosis)
Schizophrenia or other psychosis 1.044 0.057
Both categories 1.404*** 0.100
continued
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Discussion
Summary of findings
We explored whether or not better quality of primary care was associated with reduced risk of
re-entering specialist mental health-care services, either in the community or as an inpatient. Our
results indicate no statistically significant associations between either of the two primary care quality
measures and the risk of re-entry to specialist care. This suggests that neither the continuity of GP
visits to the same doctor nor the presence of a CP in the previous 12 months reduced the chance of
deterioration of mental health status, implied by the need for re-entry to specialist care.
However, a lower risk of re-entry was significantly associated with other explanatory variables: being
aged between 45 and 65 years (compared with a younger age group), having had a SMI diagnosis for
> 2 years and having two or more physical comorbidities. It is possible that individuals who have had
a diagnosis for a longer period may potentially have a more stabilised condition than newly diagnosed
patients, which may reduce their risk of re-entry to services. Those with a larger number of physical
comorbidities may have been at lower risk if management of physical health took precedence over
referral to secondary mental health services for the patient’s mental health condition.
A higher risk of re-entry was associated with greater socioeconomic deprivation, being white and
having a diagnosis that included schizophrenia-type classifications, in addition to bipolar-type
classifications. The latter may suggest that patients with more complex mental health conditions are
TABLE 17 Results from discrete-time survival analysis of re-entry to secondary mental health services (continued )
HR SE
Number of Charlson Comorbidity Index comorbidities (base: none)
One 1.041 0.057
Two or more 0.732** 0.073
Comorbid depression 1.012 0.052
Constant 0.022*** 0.007
*p < 0.05, **p < 0.01, ***p < 0.001.
Notes
Continuity: low ≤median UPC, high >median UPC.
Visit frequency: low= zero to two, moderate= three to five, high= six or more visits in 12 months.
TABLE 18 Association of GP visit continuity and CPs with hazard of re-entering specialist mental health care
HR (95% CI)
CP vs. none 1.08 (0.93 to 1.22)
GP visit continuity
Moderate visit frequency (three to five visits): high UPC vs. low UPC 0.89 (0.76 to 1.06)
High visit frequency (six or more visits): high UPC vs. low UPC 0.92 (0.78 to 1.09)
*p < 0.05, **p < 0.01, ***p < 0.001.
Notes
Continuity: low ≤median UPC, high >median UPC.
Visit frequency: low= zero to two, moderate= three to five, high= six or more visits in 12 months.
HRs between two levels of continuity obtained as the ratio of exponentiated coefficients: HRhigh/low = exp(βhigh)/exp(βlow).
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more at risk of re-entry and the link with deprivation may reflect the commonly observed greater
utilisation of many types of health-care services by socially disadvantaged populations experiencing
higher levels of need.131
Overall, only 7% of the sample categorised as being ‘stable’ re-entered specialist secondary care
services over a 12-month period, with very few of these patients re-entering inpatient care directly
(seven patients). Despite the lack of association with the indicators of primary care quality, re-entry is
therefore an uncommon occurrence and suggests that the management of stable patients in primary
care is, by and large, successful.
Strengths and limitations
The main strengths of the analysis relate to the longitudinal nature of the data and the methods employed,
which improve on standard cross-sectional analyses based on aggregate data. First, by linking primary care
and secondary care data together at the patient level we can observe the timing and sequence of events.
This allowed us to identify a sample of patients who were categorised as having been ‘stable’ for a period
of time and then observe their utilisation of specialised secondary care from that time onwards. As with
the other analyses presented in this report, the use of survival analysis techniques allowed us to exploit
fully this data linkage to investigate the relationship between primary care quality and utilisation of
secondary care. Owing to the rarity of such data linkages, there has been very little previous research
on this topic that uses the richness of individual-level data available to this study.
One of the main limitations of the analysis relates to our inability to use the HoNOS scores as a measure
of severity of mental health condition, as originally planned (as described in Chapter 1, Deviations from
study protocol). This also means that our results may be confounded, given that severity is likely to
be an important factor in determining the degree to which the condition can be controlled solely in
primary care. Some patients who were deteriorating (and, therefore, went on to appropriately re-enter
secondary care) may have been offered more continuity of care and care planning as a priority by their
GPs (indicating good-quality care), rather than re-entry indicating a failure of primary care quality.
Re-entry to specialised services may not be a reliable indicator of deterioration of SMI condition,
as we do not know from these routine data the reason for and circumstances leading to re-entry. Most
patients re-entering the secondary care sector in our sample entered community care services rather
than going directly into inpatient care. Depending on the nature of the community services received,
they may not be targeted at addressing deterioration, but more at enhancing the quality of general
support received. Again, it is feasible that re-entry into secondary care is not always a negative outcome
that signals poor management. Last, we had limited measures of primary care quality and it is feasible
that there were other aspects of that care that influenced the risk of deterioration of condition, as well
as re-entry into secondary care.
Implications for research and practice
The absence of a statistically significant positive association between aspects of quality of primary care
and re-entry to specialist secondary care services suggests that prevention of a deterioration of SMI is
not solely within the control of GPs. This is not surprising, given the complexity of SMI conditions and
the range of services and settings appropriate to meet these needs. The main implication for research
arises from the challenges arising from the HoNOS data, which are detailed in Chapter 1, Deviations
from study protocol. Good measures of health outcome for people with SMI are central to the ability
to undertake research that goes beyond consideration of process measures. Improved recording of
HoNOS scores in secondary care would facilitate this and further allow more generalisable conclusions
to be drawn from research. Further research to investigate the underlying reasons for re-entry to specialist
secondary care services would provide greater insight into the role of primary care in supporting patients
to avoid deterioration of SMI conditions.
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Chapter 7 The association between
primary care quality and multisector costs
This chapter is partly based on Ride et al.
132 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text includes minor additions
and formatting changes to the original text.
Introduction
We found CPs and ARs for patients with SMI to be associated with lower risk of hospital SMI-related
admissions, ACSC admissions and reduced A&E department attendances. In addition, higher GP continuity
was associated with lower risk of hospital ACSC admissions and A&E department attendances. It might
therefore be expected that CPs, ARs and GP continuity were successful at reducing health-care costs.
There is an absence of evidence on primary care quality and subsequent SMI expenditures. In part, this
is due to the inherent complexity of estimating health-care costs for people with SMI, as services are
accessed through a number of routes (primary care, secondary care, A&E department and community
mental health services). This makes the tracking of costs for people with SMI difficult and requires
access to multiple sources of administrative data. However, the question of if and, if so, to what extent,
better-quality primary care impacts on health-care costs for people with SMI is important. It is known
that patients with SMI have high levels of utilisation of health services and often have comorbidities
that require further appropriate and timely treatment (as outlined in Chapter 1, Serious mental illness).
Better management in primary care may have cost implications across a number of service settings.
This chapter seeks to address this gap in the literature by directly examining the relationship between
primary care quality and health-care expenditure for people with SMI.
In this chapter, we examine the association of CPs, ARs and GP continuity with health service costs
for patients with SMI. Previous chapters showed these quality measures to be associated with use of
hospital care, but their cost implications are unclear. We did not investigate the association between
NHS costs and our fourth measure of quality – polypharmacy – because of the greater difficulty in
measuring it and because we found no association of polypharmacy with unplanned hospital admissions,
A&E department attendance or mortality.
Methods
Study design
Quarterly costs of health-care utilisation for primary care, inpatient admission, A&E department
attendances and community mental health services were estimated using a bottom-up costing approach
for 3 financial years (12 quarters), from 1 April to 31 June 2011 (quarter 1 of 2011/12) through to
1 January to 31 March 2014 (quarter 4 of 2013/14), applying unit costs for the 2013/14 financial year.132
We examined the association of costs in a financial quarter with primary care quality in the previous
12 months, accounting for a range of individual and practice characteristics, and unobserved
time-invariant heterogeneity.
DOI: 10.3310/hsdr08250 Health Services and Delivery Research 2020 Vol. 8 No. 25
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Jacobs et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
59
Sample
The sample consisted of 150,748 quarter observations across 16,485 adults with SMI for the financial
years 2011/12 to 2013/14, as outlined in Chapter 3, Study samples.
Table 19 shows the distribution of characteristics across the sample. Just over half of the patients in
the sample (56%) were observed for all 12 quarters. The mean age in the sample was 52 (median 50)
years. The majority (71%) of patients were white. Around one-third of patients had at least one
physical comorbidity and two-thirds had comorbid depression. Three-quarters of patients were current
or ex-smokers and 20% had been recently diagnosed with SMI. People in the sample were more likely
to live in urban areas than rural areas and in more deprived areas.
TABLE 19 Characteristics of patients included in the multisector cost analysis (n= 16,485)
Characteristic n %
Age (years)
18–35 3410 20.7
36–45 3390 20.6
46–55 3397 20.6
56–65 2616 15.9
> 65 3672 22.3
Sex
Female 8313 50.4
Male 8172 49.6
IMD
Quintile 1 (least deprived) 2630 16.0
Quintile 2 3033 18.4
Quintile 3 3038 18.4
Quintile 4 3825 23.2
Quintile 5 (most deprived) 3959 24.0
Ethnicity
Black, minority ethnicities 4690 28.5
White 11,795 71.5
Rurality of general practice
Urban area 14,592 88.5
Rural area 1893 11.5
Distance from general practice to nearest general hospital (km)
0–3 7227 43.8
> 3–6 4607 27.9
> 6–9 2085 12.6
> 9 2566 15.6
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TABLE 19 Characteristics of patients included in the multisector cost analysis (n = 16,485) (continued )
Characteristic n %
Distance from general practice to nearest inpatient mental health service (km)
0–3 3246 19.7
> 3–6 4228 25.6
> 6–9 3007 18.2
> 9 6004 36.4
Diagnostic grouping
Bipolar disorder and affective psychosis 6076 36.9
Schizophrenia and other psychoses 8575 52.0
Both categories 1834 11.1
Number of Charlson Comorbidity Index comorbidities
None 10,523 63.8
One 4413 26.8
Two 1108 6.7
Three or more 441 2.7
Comorbid depression
No history of depression 6347 38.5
History of depression 10,138 61.5
History of smoking
Non-smoker 3818 23.2
Current or ex-smoker 12,667 76.8
Years since diagnosis
0–1 3228 19.6
2–5 3148 19.1
> 5 10,109 61.3
Number of quarters observed
1 896 5.4
2 829 5.0
3 756 4.6
4 672 4.1
5 623 3.8
6 622 3.8
7 602 3.6
8 573 3.5
9 574 3.5
10 516 3.1
11 597 3.6
12 9225 56.0
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Care quality indicators
As noted in the Introduction, we focus in this chapter on the two QOF indicators (described in Chapter 3,
Quality and Outcomes Framework indicators) as measures of primary care quality, as practices were
financially incentivised on these measures. We also include GP visit continuity (described in Chapter 3,
Continuity of general practitioner consultations).
Costing methods for primary care data
Table 20 provides an overview of all the sources of utilisation data and unit costs (not just primary
care). Primary care utilisation data were extracted from CPRD records based on Read codes recorded
by practice staff, as part of routine data entry. Three types of primary care activity were included in the
analysis: (1) consultations, (2) drugs prescribed and (3) diagnostic tests.
Unit costs for consultations were obtained from national estimates of the cost per minute of staff time
for GPs and practice nurses for 2014.133 We used individual visit duration data to calculate visit costs
rather than a standard unit cost because of evidence suggesting that consultations for patients with
mental health problems are likely to be longer than average consultations.137–140 We considered
multiple visits in a day for a patient to a single staff member as duplicates, but included visits to
different staff members on the same day.
The CPRD visit duration variable was based on the time that a patient’s electronic record was open for
use by a member of practice staff, and our use of this variable assumed that GPs and nurses would open
the electronic file when they were about to see the patient and close it at the end of the consultation.
However, files may also be opened for review or other purposes at times that do not correlate to
patient care, or may not be closed at the end of a consultation. We therefore applied restrictions when
visit duration was recorded as zero minutes or > 120 minutes. A recording of zero minutes indicates
that the file was opened for < 1 minute. The CPRD data set included two date variables: (1) the date of
TABLE 20 Overview of measures of utilisation and unit costs
Unit of utilisation Source of utilisation data Source of unit cost
Primary care
GP consultations: per minute of face-to-face contact CPRD Curtis133
Practice nurse consultations: per minute of face-to-face contact CPRD Curtis133
Drug prescriptions: per prescription CPRD therapy section,
BNF codes
Prescribing and
Medicines Team134
Diagnostic tests: per test CPRD test section,
Read terms
DHSC135
Hospital
A&E department presentations: per presentation HES DHSC135
Inpatient admissions: episode of care HES DHSC135
Community mental health services
Consultations: per minute of contact MHMDS Curtis133
ECT: per episode MHMDS Greenhalgh et al.136
CP approach reviews: per review MHMDS Curtis133
Day attendances: per day MHMDS Curtis133
Mental health admissions: per day MHMDS DHSC135
BNF, British National Formulary; DHSC, Department of Health and Social Care; ECT, electroconvulsive therapy.
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data entry and (2) the date associated with the consultation, as entered by the practice staff member.
If the duration was zero minutes and if the date of data entry was later than the visit date, we
assumed that this reflected retrospective recording of a visit that should be costed and applied the
sample median duration for that type of visit (see Table 20). Otherwise, we assumed that the entry
did not reflect an episode of patient care and dropped these observations from the data. We capped
the maximum duration at 120 minutes, assuming that this reflected a file being left open but without
ongoing patient care.
A cost of £3.60 per minute of patient contact for GPs included travel and qualification costs, but
excluded nursing care staff costs, as we were accounting for these by counting nurse visits separately.
A cost of £0.88 per minute of patient contact for practice nurses included qualification costs.
Table 21 outlines the average visit duration for different types of primary care visits observed in
the sample.
The costs of drug prescriptions were derived from the prescription costs analysis for 2014,134 which
applied the British National Formulary (BNF) edition 66141 classification system. This provided the net
ingredient cost per item according to the drug tariff. It did not include any discounts, dispensing fees
or adjustment for income, and was based on the usual quantity dispensed for that drug. Numbers of
drug prescriptions were taken from the therapy section of the CPRD data set. We used data at the
BNF subparagraph level when available or otherwise at the most specific BNF level available (from
paragraph, section or chapter level). This approach did not account for other items listed in CPRD as
‘therapy’ that were not included in the BNF, such as dressings or glucose test strips.
National average unit costs for diagnostic tests were taken from the NHS reference costs for the financial
year 2013/14,135 covering diagnostic imaging, diagnostic services, pathology services and outpatient
procedures. The reference costs listed the average cost across the NHS of providing a particular health-care
service. Utilisation volume of each test was taken from Read terms (descriptive terms attached to Read
codes) recorded in the test section of the CPRD data set. These were classified, following clinicians’ advice,
into groups that corresponded to the NHS reference cost categories. For example, Read terms for blood
tests recorded in CPRD data included ‘liver function test’, and ‘serum creatinine’, which were both classified
as ‘clinical biochemistry’ and allocated to that unit cost from the reference costs. A supplementary file is
available online and lists the Read terms included in the CPRD data and how they were classified into
reference cost categories (see Report Supplementary Material 1).
TABLE 21 Visit duration (minutes) in primary care and mental health services
Visit Mean (minutes) Median (minutes)
Primary care
GP: face to face, clinic 10.8 9
GP: telephone 6.4 4
GP: face to face, home visit, other 11.8 5
Nurse: face to face, clinic 11.4 9
Nurse: telephone 5.8 4
Nurse: face to face, home visit, other 7.1 4
Community mental health services
Doctor 53.5 30
Nurse 49.1 35
Other health-care professional 55.3 50
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Costing methods for community mental health care
We used a subset of the activity recorded in MHMDS as measures of utilisation of community mental
health services. Specifically, we counted health-care professional contacts (consultations), CPA reviews,
electroconvulsive therapy (ECT) sessions and day attendances, and assigned units costs reported
by the Personal Social Services Research Unit (PSSRU)133 and the Electronic Staff Record (ESR).142
The cost of consultations was dependent on the staff type and the duration of the contact.
We used staff groups defined in the PSSRU unit costs 2014,133 namely hospital-based scientific and
professional staff, nurses and doctors. Each of these groups was divided into subcategories (called bands)
with different costs per hour. Other types of staff (ambulance staff, administration and estates staff,
health-care science, general payments) had cost equal to zero. When the occupation code was not
recorded in MHMDS, we used the job role to assign a consultation to one of the three staff groups.
The PSSRU unit costs reported costs per hour for these groups and bands, which included not only the
staff members’ salary but also cost of training and overheads, and were therefore a measure of the total
cost of 1 hour of work by the different staff groups.
However, the occupation codes available in MHMDS identified the three staff groups defined in the
PSSRU unit costs 2014,133 but not the bands within them. So, we needed a way to calculate an average
cost for each of the three staff groups, which we could then match to MHMDS.
We used the ESR to allocate each staff type to a staff group and a band, and then calculated the
(weighted) average cost of each staff group (which took into account the composition, in terms of
bands, within the staff group).
The ESR had two parts, one containing information regarding the number of workers of different types
(measured as full-time equivalents, rather than as head counts) and one containing information regarding
the salary for those types of staff. The data for staff numbers were available for each month, so we
calculated the average over the financial year (1 April–31 March). The salary data were available by
financial year. We used data for 2013/14. ESR contained information for different types of organisations;
we focused only on providers that have submitted data to MHMDS (mental health trusts). We used the
occupation code and the salary to allocate each staff type to a staff group and a band (the occupation
code identified the staff group and the salary was used to identify the band). We then attached the PSSRU
unit cost for each staff group and band, and calculated the average cost per hour for the three staff
groups (hospital-based scientific and professional staff, nurses and doctors) as a weighted average of the
different types of staff in the mental health trusts (i.e. the average cost per hour of, for example, a nurse
reflected the number of nurses in the different bands across all mental health trusts). We also calculated
an overall average (including staff groups with zero cost), which we used as a cost for consultations in
MHMDS without staff type.
As the duration of the contact was an important part of the calculation of the cost of a consultation,
we needed to make sure that there were no observations with zero or missing duration. If the duration
was zero, we used the information regarding attendance to adjust this: if the patient had attended we
initially recoded the duration to missing (which we later replaced) and if the patient had not attended
(or the information regarding attendance was missing) we recoded the duration to 1, a minimum
amount of staff time that would be required to record that the patient did not attend. When the
duration was missing, we replaced it with the average for those from the same staff group for that
consultation medium.
Table 21 shows the mean duration of outpatient mental health visits observed in the data. We matched
the occupation code of each consultation to the staff groups in PSSRU and assigned to them the cost
calculated using ESR and PSSRU. For observations without staff type, we used the overall average cost
per hour.
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We restricted the number of consultations per day to a maximum of two for each type of staff member.
Regarding CPA reviews, MHMDS provided the date only and not the staff involved or duration.We
assumed, following clinical advice, that reviews (which were supposed to be multidisciplinary) involved a
psychiatrist and a nurse and lasted 30 minutes, a lower-bound estimate. Cost per ECT session was based
on past costings136 updated to 2013/14 values using the hospital and community health services pay and
price inflation series.143 Day attendance cost was based on the cost of day care provided by local authority
social services for people with mental health problems.133
Costing methods for hospital data
Admissions to specialist mental health inpatient facilities were recorded in MHMDS and admissions to
general hospitals (including admissions to non-specialist mental health providers) were recorded in
HES. We costed these separately.
Admissions to specialist mental health inpatient facilities
The cost of mental health admissions depended on the duration of the admission (days) and the category
of mental health problem or needs (termed the ‘cluster’) to which the patient was assigned (the hospital-
reported reference costs of admitted days varied by mental health cluster).135 The admitted periods (called
ward stays in MHMDS) did not record the cluster, so we needed to get this information from either a CE
or a mental health clustering tool (MHCT), as both these types of activities recorded a cluster. A CE
identified a continuous period in which the patient was receiving care under the banner of a particular
cluster. The MHCT is an algorithm used by a treating clinician or team to allocate patients to a particular
cluster based on the patient’s symptoms and functioning. We merged these data to the admitted periods
(all fields taken from MHMDS) and compared the start date of the admitted period with the start date of
the CEs, and to the dates of MHCTs in the same spell. This allowed us to identify the closest, in absolute
value (i.e. before or after the start of the admitted period), start of a CE and the closest MHCT. If the CE
start was closest to the start of the admitted period, we used the cluster recorded in the CE as the cluster
of the admitted period. If the MHCTwas closest, we used that cluster, and if both the start of the CE and
the MHCTwere equally close to the start of the admitted period, we used the cluster recorded in the CE.
This is because the MHCT can be overridden by clinicians.We excluded admissions with the same start
and end dates, and for the 14% of admissions without an assigned cluster we used a weighted average
cost across all clusters.
General hospital costs
We identified inpatient hospital admissions and A&E department presentations from HES records.
The classification system for hospital activity in England is Healthcare Resource Groups (HRGs), which
are similar to Diagnosis-Related Groups used in other health-care systems. Inpatient episodes of care
and A&E department attendances were grouped into HRGs, reflecting type of activity (inpatient or
A&E department HRGs), additional high cost inpatient procedures and long inpatient stays. Costs for
these activities were taken from the hospital-reported reference costs.
First, all episodes of care were assigned to one of more than 2000 core HRGs based on the clinical and
demographic information of the patient. Second, separate unbundled HRGs were assigned to episodes
with high-cost elements of treatment, such as high-cost procedures, chemotherapy, diagnostic imaging
and high-cost drugs. Third, HRGs may have contained episodes with much higher length of stay than
the average episode in the group. To deal with these long-stay outliers, an upper trimming point was
calculated by adding 1.5 times the interquartile range to the third quartile. For admissions exceeding
the upper trim point, days above that point are reimbursed at the excess bed-day rate.
Accident and emergency activity was grouped similarly, with the exception that treatment and
investigation codes were used to capture clinical information instead of procedure and diagnosis codes.
All NHS hospitals reported reference costs for each HRG, broken down by setting (e.g. general surgery)
and type of activity (e.g. day case, elective, non-elective). As our research did not relate to the variation
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in costs across hospitals or settings, we assigned reference costs by HRGs and type of activity only
(unbundled costs were aggregated on the HRG level only).
The allocation of episodes to HRGs was carried out using the costing grouper software available on
the NHS Digital website.144 Data were cleaned and prepared according to the grouper guidance. We
grouped all the activity using the 2012/13 version of the HRGs design and the corresponding 2012/13
reference costs to obtain costs for each activity, then used the Hospital and Community Health Services
Pay and Price Inflation index143 to express costs in 2013/14 prices. For episodes with missing or invalid
essential data fields, the grouper returned an error HRG code. After minor adjustments and imputation
of some non-essential fields, the error rate for our sample was reduced to about 7% for inpatient
episodes and 10% for A&E department presentations. Although HES includes admissions to specialist
mental health facilities, these were not costed, because these were captured through MHMDS, but
mental health conditions treated by non-specialist mental health providers (HRGs starting with ‘WD’)
were included in general hospital costs. Using the inpatient episode start and end dates, costs were
apportioned into the financial years 2011/12–2013/14. When an episode of care extended over two
quarters, we attributed costs to each quarter based on the proportion of episode days in each of the
two quarters.
Statistical analysis
We calculated costs for each patient for each quarter for each sector – primary care, general hospital
costs, specialist mental health care (including inpatient- and community-based care) – and for total costs
(as the sum of the three sector costs). To provide some indication of the proportion of health-care costs
that are related to mental health as distinct from physical health for this population, we identified a
subset of costs that could be clearly labelled as mental health ‘related’, comprising all specialist mental
health-care costs (inpatient and outpatient), and mental health drug costs in primary care.
The aim of the empirical analysis was to relate the quality of care for a patient to the costs the patient
incurs in primary and secondary care. Individual patient health-care cost data are usually highly skewed,
with a long right tail. They are also usually characterised by a large mass at zero (patients who do not
incur health-care costs in a particular period). These features need to be accounted for in the empirical
modelling. This was undertaken by the use of two-part models.145 The first part used a probit model to
estimate the probability of incurring a positive cost. The second part used a generalised linear model
(GLM)146 to estimate the level of cost for those patients who incurred a positive cost. The GLM allowed
for flexible forms for the distribution of costs to take into account its skewed nature. Based on the
results of the modified Park’s test147 and the Pregibon link test,148 we selected a gamma distribution
and log-link function for the second part of the model.
The probit model to estimate the probability of incurring costs can be written as:
Pr(y it > 0jXit) =Φ(θqQualitq + βX it + δZi + ci). (6)
The GLM to estimate the level of costs for individuals who incur costs can be represented as:
E½y itjxit, y it > 0 = exp(αqQualitq + γX it + λZi +mi). (7)
For both Equations 6 and 7, yit was the cost for individual i in quarter t (and follows a gamma
distribution in Equation 7), Qualitq are the three quality indicators (CP, AR and GP visit continuity), Xit is
a vector of observed time-varying explanatory variables and Zi is a vector of observed time-invariant
explanatory variables. ci and mi represent unobserved individual-specific random effects. In Equation 6,
Φ() is the standard normal cumulative density function required to estimate a Probit model.
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Equations 6 and 7 are non-linear models, which do not allow for the unobserved individual-specific
effects to be specified as fixed effects via the use of a set of dummy variables to represent individuals
(often referred to as the incidental parameter problem). Instead, we accounted for the individual-
specific effects, ci and mi, using the Mundlak approach105 (as outlined in Chapter 4, Statistical analysis),
by modelling these as functions of the within-individual means of the observed time-varying variables,
as follows:
ci = ψ + ξXi + αi, (8)
in which X is the mean of Xit for each individual and ai is a random error term assumed to be normally
distributed and uncorrelated with Xi. We adopted an equivalent specification for mi in Equation 7.
Marginal effects of each explanatory variable on overall estimated cost were calculated by obtaining
predictions from the first and second parts of the model for each individual at the base level of the
variable and at an alternative level, and then taking the mean of these effects over all individuals.
For example, for a binary variable, such as a CP, the predicted probability [Pi] of non-zero costs for
individual i was obtained from the first part of the model with the CP variable set at zero and at 1
(P^i0 and P^i1), with all other variables at their observed levels. The equivalent predictions of the level of
cost with CP set at zero and 1 were obtained from the second part of the model (y^ i0 and y^ i1). The point
estimate of the average marginal effect of a CP on overall cost was then estimated as:
AME = ½∑
i
(p^i1y^ i1− p^i0y^ i0)÷ n. (9)
Standard errors were calculated by accounting for clustering of patients within practices. For the
average marginal effects SEs (seAME─ ) were obtained by bootstrapping using 1000 replications,
149
for which:
seAME =
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
R−1
∑R
r=1
(AMEr −AME
─
)
2
,
r
(10)
and R is the number of replications, AMEr is the estimated marginal effect in replication r and is the
mean of the bootstrapped estimates.
Robustness check
As an alternative to using the consultation duration data in CPRD and MHMDS, we estimated costs
using the average duration for different types of consultations derived from the 2006/07 General
Practice Workforce Survey150 that were applied by Curtis.133
Results
Resource use and costs
The mean quarterly health-care cost per patient was £1309.96, with £653.38 (50%) identifiable as
related to SMI. Figure 6 shows that total costs decreased with age until middle age and then increased
for patients aged > 65 years, whereas the proportion of costs related to SMI steadily decreased with
age. For patients aged 19–35 years, 64% of total costs were related to SMI, whereas for patients
aged > 65 years the proportion was 34%, reflecting a greater emphasis on management of physical
comorbidities.
Table 22 shows that primary care costs (£235) made up approximately 18% of total mean quarterly
costs, general hospital costs (£481) constituted 37% and specialist mental health-care costs (£594)
accounted for around 45%.
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FIGURE 6 Costs per quarter for people with SMI by age group: total and SMI related.
TABLE 22 Quarterly health-care cost by sector and total, over patient characteristics
Total cost (£)
Primary care
cost (£)
General
hospital cost (£)
Mental health
service cost (£)
Mean SD Mean SD Mean SD Mean SD
Overall cost 1310 4721 235 369 481 2325 594 3248
Age (years)
19–35 1444 5491 140 265 423 2102 882 4123
36–45 1198 4650 197 336 354 1907 647 3365
46–55 1199 4366 245 380 377 1940 577 3072
56–65 1201 4149 275 419 491 2384 435 2595
≥ 66 1504 4865 306 395 747 3037 450 2928
Sex
Female 1297 4409 275 410 492 2184 530 2979
Male 1323 5024 194 315 470 2462 660 3505
Ethnicity
Black, minority ethnicities 865 4071 165 264 286 2146 414 2749
White 1491 4950 264 400 561 2389 667 3428
Diagnostic grouping
Bipolar disorder and affective psychosis 1099 3958 250 354 447 2130 402 2539
Schizophrenia and other psychoses 1363 4982 215 362 493 2477 654 3480
Both categories 1722 5590 275 429 532 2222 915 4012
Years since diagnosis
0–1 1558 5305 224 360 566 2513 768 3652
2–5 1249 4570 226 375 448 2171 574 3205
> 5 1276 4632 240 369 473 2327 563 3168
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TABLE 22 Quarterly health-care cost by sector and total, over patient characteristics (continued )
Total cost (£)
Primary care
cost (£)
General
hospital cost (£)
Mental health
service cost (£)
Mean SD Mean SD Mean SD Mean SD
IMD
Quintile 1 (least deprived) 1130 4306 220 343 430 2206 481 2890
Quintile 2 1195 4348 227 339 459 2197 510 2935
Quintile 3 1388 4967 238 375 526 2394 625 3492
Quintile 4 1345 4741 244 379 476 2267 625 3280
Quintile 5 (most deprived) 1425 5038 241 391 504 2495 680 3473
Number of Charlson Comorbidity Index comorbidities
None 1198 4654 183 299 390 2015 625 3340
One 1407 4718 290 410 549 2474 568 3128
Two 1813 5332 442 557 887 3600 483 3007
Three or more 1944 4694 495 530 1132 3599 316 2553
Comorbid depression
No history of depression 1319 4955 184 297 483 2525 651 3464
History of depression 1304 4572 266 403 480 2194 558 3109
History of smoking
Non-smoker 1235 4747 193 275 468 2446 574 3221
Current or ex-smoker 1332 4713 247 391 485 2288 600 3356
Rurality of general practice
Urban area 1336 4808 231 360 490 2370 615 3310
Rural area 1107 3983 264 427 413 1941 430 2721
Distance from general practice to nearest acute hospital (km)
0–3 1369 4948 232 374 516 2486 621 3329
3–6 1270 4563 221 321 458 2168 592 3194
6–9 1244 4550 258 408 460 2256 526 3172
> 9 1268 4471 252 396 441 2177 575 3174
Distance from general practice to nearest inpatient mental health service (km)
0–3 1385 5037 228 349 515 2464 643 3400
3–6 1341 4774 230 355 520 2587 590 3233
6–9 1384 4993 221 335 503 2378 659 3440
> 9 1211 4353 249 402 425 2004 537 3071
Per cent observations with zero cost 8.4 12.0 85.5 62.8
SD, standard deviation.
Note
Mean and SD for all patients, including those with zero cost.
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Table 22 also provides mean cost per quarter for subgroups of patients. The mean total costs increased
with age, level of deprivation and number of comorbidities and were higher for white patients (vs.
black or minority ethnicities) and for patients diagnosed with SMI more recently. Patients with both
schizophrenia- and bipolar-type disorders had higher costs than those with schizophrenia-type disorders
alone, with bipolar-type disorders associated with the lowest costs.
Of the quarterly observations, 8.4% had zero total cost, 12.0% had zero primary care cost, 62.8% had
zero community mental health cost and 85.5% had zero hospital cost. Approximately one-third (33.3%)
of the quarterly observations had no CP or AR recorded in the prior 12 months, 5.4% had a CP but no
AR recorded, 40.3% had an AR but no CP recorded and 20.9% had both recorded. Overall, just over
one-quarter of observations (26.3%) had a CP recorded in the prior 12 months and nearly two-thirds
(61.3%) had an AR recorded.
Table 23 outlines the mean and median quarterly utilisation of the different types of service making up
these costs across all individuals in the sample.
Regression results
The average marginal effects of quality on cost estimated from the two-part models are presented in
Table 24. CPs in the 12 months prior to the start of the current 3-month period were associated with
lower health-care costs in the current 3-month period, in terms of overall costs and in primary care
and hospital costs, but not mental health-care costs. ARs were associated with lower primary care,
mental health care and total costs, but not with hospital costs. High GP visit continuity in the prior
12 months was associated with lower primary care costs in the current 3-month period, but not with
total costs or any of the other sectors of costs.
TABLE 23 Resource utilisation within each sector per quarter
Sector Resource unit
Quarterly
utilisation
Mean quarterly cost (£)Mean Median
Primary care GP: face-to-face clinic visit 1.2 1 58.99 (all primary care visits)
GP: telephone visit 0.2 0
GP: face-to-face home visit, other 0.06 0
Nurse: face-to-face clinic visit 0.4 0
Nurse: telephone visit 0.02 0
Nurse: face-to-face home visit, other 0.01 0
Tests (pathology, radiology, etc.) 2.1 0 13.09
Drug prescriptions 16.0 8 162.99
Specialist mental health Visits 3.4 0 183.73 (outpatient care)
Day attendances 0.1 0
ECT sessions 0.005 0
Reviews 0.2 0
Mental health inpatient bed-days 1.2 0 409.95
General hospital Inpatient bed-days in general hospital 1.9 0 481.20
A&E department presentations 0.1 0 16.66
Note
Data for all patients, including those with no utilisation.
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TABLE 24 Average marginal effects from two-part models of costs, for total costs and by sector
Total costs (£), ME (95% CI) Primary care (£), ME (95% CI) Hospital (£), ME (95% CI) Mental health (£), ME (95% CI)
Primary care quality indicators in 12 months prior
CP –53.40*** (–66.51 to –40.29) –9.47*** (–11.56 to –7.37) –25.53*** (–39.83 to –11.24) –12.50*** (–17.91 to –7.08)
AR –33.32*** (–46.92 to –19.73) –9.21*** (–11.44 to –6.99) –6.44 (–19.00 to 6.11) –14.97*** (–21.17 to –8.76)
High UPC (GP visit continuity) –1.46 (–12.77 to 9.85) –2.81** (–4.67 to –0.95) 1.52 (–10.40 to 13.43) 3.42 (–1.37 to 8.21)
Patient characteristics (at start of observation)
Index of disadvantage of patient’s neighbourhood (base: quintile 1, least disadvantaged)
Quintile 2 24.27 (–1.85 to 50.39) 1.75 (–4.16 to 7.66) 17.70 (–1.25 to 36.65) 14.50 (–0.20 to 29.20)
Quintile 3 96.02*** (43.82 to 148.23) 5.63 (–5.04 to 16.30) 82.53*** (42.80 to 122.25) 31.58* (4.00 to 59.16)
Quintile 4 207.90*** (122.89 to 292.91) 18.85* (2.96 to 34.75) 155.83*** (85.52 to 226.15) 61.41** (18.34 to 104.48)
Quintile 5 (most disadvantaged) 399.19*** (259.83 to 538.55) 39.40** (16.67 to 62.14) 249.84*** (137.30 to 362.37) 123.58*** (56.00 to 191.16)
Ethnicity (base: black and minority ethnicities)
White 288.90*** (272.78 to 305.02) 43.49*** (39.50 to 47.48) 175.86*** (166.06 to 185.66) 84.97*** (76.15 to 93.78)
Age (years) (base: 18–35 years)
36–45 –21.24 (–47.56 to 5.09) 27.57*** (22.46 to 32.67) –6.39 (–20.48 to 7.69) –34.54*** (–52.44 to –16.63)
46–55 –8.67 (–56.42 to 39.08) 82.68*** (71.45 to 93.90) 6.73 (–20.26 to 33.73) –72.18*** (–99.08 to –45.27)
56–65 30.09 (–42.88 to 103.05) 183.32*** (159.58 to 207.06) 79.16** (24.35 to 133.98) –124.36*** (–151.17 to –97.55)
≥ 66 147.31* (–32.06 to 262.57) 352.02*** (303.52 to 400.52) 324.15*** (177.41 to 470.90) –158.90*** (–179.39 to –138.41)
Years since SMI diagnosis (base: ≤ 1 year)
2–5 –73.62*** (–108.60 to –38.64) –5.92 (–12.70 to 0.87) –12.54 (–37.08 to 12.01) –44.84*** (–62.80 to –26.87)
> 5 –168.22*** (–220.89 to –115.54) –17.05** (–28.20 to –5.90) –43.52* (–82.01 to –5.03) –93.39*** (–118.08 to –68.69)
Sex (base: female)
Male –50.66*** (–68.62 to –32.69) –33.88*** (–37.82 to –29.94) –31.85*** (–43.26 to –20.45) 4.45 (–5.13 to 14.03)
continued
D
O
I:
1
0
.3
3
1
0
/h
sd
r0
8
2
5
0
H
e
a
lth
S
e
rv
ice
s
a
n
d
D
e
liv
e
ry
R
e
se
a
rch
2
0
2
0
V
o
l.
8
N
o
.
2
5
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
2
0
.T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
Ja
co
b
s
et
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
a
n
d
S
o
cia
l
C
a
re
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riv
a
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
x
tra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
v
id
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
v
e
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
L
ib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
v
a
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
iv
e
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
7
1
TABLE 24 Average marginal effects from two-part models of costs, for total costs and by sector (continued )
Total costs (£), ME (95% CI) Primary care (£), ME (95% CI) Hospital (£), ME (95% CI) Mental health (£), ME (95% CI)
SMI diagnosis category (base: bipolar disorder, affective psychosis)
Schizophrenia or other psychosis 66.64*** (48.64 to 84.64) –15.67*** (–19.83 to –11.51) 4.23 (–7.26 to 15.71) 60.72*** (51.95 to 69.48)
Both categories 335.36*** (278.60 to 392.12) –15.76*** (–23.92 to –7.60) 81.74*** (48.74 to 114.73) 339.61*** (289.28 to 389.94)
Number of Charlson Comorbidity Index comorbidities (base: none)
One 152.69*** (131.96 to 173.42) 62.19*** (57.71 to 66.68) 60.71*** (45.94 to 75.49) 7.46 (–3.63 to 18.56)
Two 535.88*** (458.49 to 613.26) 239.33*** (222.23 to 258.43) 267.40*** (208.86 to 325.95) –13.88 (–36.38 to 8.62)
Three or more 1362.61*** (1210.37 to 1604.84) 667.03*** (595.50 to 738.56) 719.38*** (540.28 to 898.48) –65.18*** (–88.15 to –42.20)
Depression (base: no history of depression)
Comorbid depression –0.32 (–19.54 to 18.90) 32.96*** (29.23 to 36.68) 2.56 (–10.62 to 15.73) –25.30*** (–35.97 to –14.63)
Smoking (base: no history of smoking)
Current or ex-smoker 40.76*** (20.96 to 60.56) 17.32*** (13.10 to 21.53) 4.40 (–10.60 to 19.41) 11.83* (1.34 to 22.33)
Practice characteristics (time invariant)
Rurality (base: urban area)
Rural area –16.34 (–45.15 to 12.47) 10.47** (3.63 to 17.31) –5.32 (–25.78 to 15.13) –36.30*** (–49.50 to –23.09)
Distance (km) from GP to nearest acute provider (base: 0–3 km)
3–6 –18.21 (–39.33 to –2.90) –5.80* (–10.23 to –1.38) –27.17*** (–41.22 to –13.12) –5.41 (–17.13 to 6.31)
6–9 –52.52** (–91.95 to –13.10) 1.23 (–7.63 to 10.09) –48.03*** (–73.73 to –22.33) –45.85*** (–63.65 to –28.05)
> 9 –35.15 (–94.73 to 24.44) 3.82 (–9.49 to 17.13) –55.06** (–91.25 to –18.88) –33.05* (–60.78 to –5.31)
Distance (km) from GP to nearest mental health provider (base: 0–3 km)
3–6 6.78 (–20.37 to 33.93) 5.27 (–0.62 to 11.16) 2.68 (–16.41 to 21.77) –10.37 (–24.30 to 3.56)
6–9 –1.07 (–50.63 to 48.50) 1.57 (–9.12 to 12.25) –6.39 (–43.99 to 31.22) –1.38 (–27.74 to 24.98)
> 9 –29.75 (–97.17 to 37.67) 12.33 (–3.51 to 28.18) –39.93 (–88.92 to 9.06) –15.99 (–49.80 to 17.83)
*p < 0.05, **p < 0.01, ***p < 0.001.
ME, marginal effect.
Note
SEs and 95% CIs obtained by bootstrapping with 1000 replications.
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Other factors were also associated with costs. Greater socioeconomic disadvantage was associated
with higher costs across sectors, as were white ethnicity (vs. black or minority ethnicities) and physical
comorbidities. Older age was associated with higher primary care and hospital costs, but with lower
mental health-care costs. Patients whose general practice was further from the nearest acute facility
had lower hospital costs. Men had lower costs overall and in primary and hospital care. Smoking was
associated with higher costs overall and in primary care. SMI diagnosis of a bipolar-type disorder was
associated with lower costs than diagnosis of a schizophrenia-type disorder or both categories, and
longer duration of SMI was associated with lower costs also.
Table 25 shows how the two parts of the model contributed to the estimated marginal effects for total
costs. It reports the coefficients from the estimated models for having positive cost (see Equation 6)
and for costs given that they were positive (see Equation 7). In the first part of the model, a negative
coefficient implied that the probability of incurring any cost is reduced. In the second part of the
model, the coefficients were the proportional change in cost (β = (∂y/∂x)/y). CPs were associated both
with a higher probability of having positive costs and with a lower level of cost if a cost was incurred,
whereas ARs showed no statistically significant association with the probability of having non-zero costs,
but were associated with a lower level of cost if a cost was incurred. Overall, both CPs and ARs were
associated with lower costs (as shown in Table 24). High GP visit continuity was associated only with a
lower probability that a non-zero cost would be incurred, but overall is not associated with a statistically
significant difference in cost.
TABLE 25 Results from first and second part of the two-part model for total costs per quarter
First part, β (SE) Second part, β (SE)
Period-specific quality indicators
CP –0.078* (0.032) –0.101*** (0.014)
AR –0.001 (0.025) –0.062*** (0.013)
High UPC (GP visit continuity) –0.048* (0.019) –0.002 (0.011)
Mean of quality indicators
CP 1.641*** (0.129) 0.638*** (0.062)
AR 2.058*** (0.084) 0.282*** (0.045)
High UPC (practitioner continuity) 0.245** (0.083) –0.284*** (0.040)
Patient characteristics (at start of observation)
Index of disadvantage of patient’s neighbourhood (base: quintile 1, least disadvantaged)
Quintile 2 –0.021 (0.077) 0.052 (0.042)
Quintile 3 0.014 (0.085) 0.138** (0.043)
Quintile 4 0.078 (0.082) 0.182*** (0.040)
Quintile 5 (most disadvantaged) 0.243** (0.089) 0.247*** (0.040)
Ethnicity (base: black and minority ethnicities)
White 0.497*** (0.042) 0.633*** (0.031)
Age (years) (base: 18–35 years)
36–45 0.141** (0.052) –0.048 (0.038)
46–55 0.316*** (0.068) –0.019 (0.036)
56–65 0.508*** (0.072) 0.070 (0.037)
≥ 66 1.068*** (0.075) 0.199*** (0.038)
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Older age was associated with a higher probability of incurring non-zero costs and age > 65 years was
associated with a higher cost, if a cost was incurred. White ethnicity was associated with both a higher
probability of incurring cost and with a higher level of cost if any cost was incurred, and the same
pattern was seen for physical comorbidities. The reverse pattern (lower probability and lower cost)
was observed for men.
Robustness check
The robustness check supports the findings from the core analyses, assuming the average duration for
each type of consultation, as applied in Curtis133 (instead of using the CPRD duration data), did not
make a substantial difference to the estimated marginal effects of the quality indicators, as shown in
Table 26 (compare with the results in Table 24).
TABLE 25 Results from first and second part of the two-part model for total costs per quarter (continued )
First part, β (SE) Second part, β (SE)
Years since SMI diagnosis (base: ≤ 1 year)
2–5 –0.205** (0.068) –0.124** (0.039)
> 5 –0.221** (0.064) –0.187*** (0.037)
Sex (base: female)
Male –0.477*** (0.043) –0.085*** (0.022)
SMI diagnosis category (base: bipolar disorder, affective psychosis)
Schizophrenia or other psychosis –0.059 (0.044) 0.135*** (0.025)
Both categories 0.292*** (0.072) 0.402*** (0.039)
Number of Charlson Comorbidity Index comorbidities (base: none)
One 0.452*** (0.048) 0.281*** (0.027)
Two 1.259*** (0.141) 0.482*** (0.040)
Three or more 1.711*** (0.295) 0.607*** (0.064)
Depression (base: no history of depression)
Comorbid depression 0.202*** (0.047) –0.005 (0.024)
Smoking (base: no history of smoking)
Current or ex-smoker 0.197*** (0.046) 0.074* (0.031)
Practice characteristics (time invariant)
Rurality (base: urban area)
Rural area 0.113 (0.095) –0.028 (0.050)
Distance (km) from GP to nearest acute provider (base: 0–3 km)
3–6 0.106 (0.081) –0.037 (0.035)
6–9 0.023 (0.115) –0.069 (0.062)
> 9 0.198* (0.092) 0.032 (0.048)
Distance (km) from GP to nearest mental health provider (base: 0–3 km)
3–6 0.016 (0.110) 0.012 (0.045)
6–9 –0.088 (0.121 –0.012 (0.052)
> 9 0.099 (0.105) –0.057 (0.052)
Observations, n 150,748 138,091
Individuals, n 16,485 16,139
*p < 0.05, **p < 0.01, ***p < 0.001.
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Discussion
Summary of findings
We calculated the costs of health-care utilisation in each quarter for people with SMI using a bottom-up
costing approach for 16,485 patients and a total of 150,748 patient-quarter observations. Using 2013/14
unit costs, the mean quarterly health-care cost per patient was £1309.96, with £653.38 (50%) identifiable
as related to SMI (rather than to physical health). Converted to 2018 terms (using the health domain of
the Consumer Price Index151), mean quarterly health-care cost per patient was £1432.81, with £714.65
related to SMI. Total costs decreased with age until middle age, and then increased for patients aged
> 65 years, whereas the proportion of costs related to SMI steadily decreased with age. For patients
aged 19–35 years, 64% of total costs were related to SMI, whereas for patients aged > 65 years the
proportion was 33%, reflecting a greater emphasis on management of physical comorbidities. Primary
care costs (£235) made up approximately 18% of total mean quarterly costs, general hospital costs (£481)
constituted 37% and specialist mental health-care costs (£594) accounted for around 45%.
We estimated two-part models of costs, examining the effect of patient characteristics and quality of
care on (1) the probability that they had any (i.e. non-zero) NHS cost in a quarter and (2) the level of
cost for those with positive cost. We estimated that having a CP in the previous 12 months was associated
with lower health-care costs in the current quarter. On average, the overall cost per quarter per patient
was reduced by £53.40, primary care cost by £9.47, hospital costs (excluding those due to SMI) by £25.53
and specialist mental health costs (including inpatient care) by £12.50. Having an AR in the previous
12 months was associated with lower primary care costs (£9.21), mental health-care costs (£14.97) and
total costs (£33.32), but not with hospital costs in the current quarter. High practitioner continuity in
the prior 12 months was associated with lower primary care costs (£2.81) in the current 3-month period,
but not with total costs or with hospital or mental health service costs.
Cost implications
We found in previous chapters that CPs and ARs for people with SMI were associated with reduced
risk of hospital SMI-related admissions, ACSC admissions and A&E department attendances, and that
greater continuity reduced the risk of hospital ACSC admissions and A&E department attendances.
It was therefore to be expected that CPs, ARs and greater GP continuity were associated with reduced
hospital costs.
General practices were financially incentivised via the QOF to provide CPs and ARs to people with SMI
and these payments had an opportunity cost in terms of forgone care elsewhere in the NHS. It was
beyond the scope of our study to attempt a comparison of the value of the gains to people with SMI
from CPs and ARs with the opportunity costs of providing them. However, we could compare the QOF
payments to practices for providing CPs and ARs with the reductions in costs for people with SMI.
TABLE 26 Results of robustness checks for care quality indicators
Primary care quality indicators in
12 months prior
Main analysis (from Table 24),
ME (£) (95% CI)
Average duration for primary
care visits, ME (£) (95% CI)
CP –53.40*** (–66.51 to –40.29) –52.90*** (–66.24 to –39.57)
AR –33.32*** (–46.92 to –19.73) –31.67*** (–45.39 to –17.96)
High UPC (GP visit continuity) –1.46 (–12.77 to 9.85) –0.54 (–12.07 to 11.00)
*p < 0.05, **p < 0.01, ***p < 0.001.
ME, marginal effect.
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Having a CP in the previous year reduced total costs in a quarter for a person with SMI by £53.40, or
£213.60 per year (Table 27). There were 353,695 CPs in all practices in England in 2012/13, so that if
the cost saving estimates were valid for all 8020 practices in England taking part in the QOF, and not
just those in our sample, the total annual cost saving from CPs for patients with SMI would be £75.5M.
Practices were awarded 47,965 points under QOF indicator MH10 for achievement of CPs and, at a
national average price per point of £133.76, the total QOF payment for CPs was £6.4M. The total
reduction in costs for people with SMI was thus around 11 times as large as the total QOF payments
to practices for CPs and the net saving of NHS expenditure was £69.1M. As the other columns in
Table 27 suggest, the reductions in NHS costs for people with SMI in each of the three sectors were
considerably smaller than the total QOF payments for CPs.
We can make similar calculations for ARs, although because of the change in the definition of ARs
from 2011/12, we used data on QOF payments for the AR indicator MH9 in 2011/12, rather than in
2012/13. As ARs were associated with smaller reductions in total costs for people with SMI, the net
cost implications were less dramatic and were, indeed, only positive in relation to total costs.
TABLE 27 Cost savings and QOF expenditure for CPs and ARs
Sector
Mental healthTotal
Primary
care
Hospital
(not SMI related)
CPs
Cost saving per quarter per patient per CP (£) 53.40 9.47 25.53 12.50
Effect per year (£) 213.60 37.88 102.12 50.00
CPs England 2012/13, n 353,695 353,695 353,695 353,695
Cost saving (England) (£) 75,549,252 13,397,967 36,119,333 17,684,750
Total points for MH10 2012/13 47,965 47,965 47,965 47,965
Price per point (£) 133.76 133.76 133.76 133.76
Total QOF payment for MH10 (£) 6,415,798 6,415,798 6,415,798 6,415,798
Net cost saving (£) 69,133,454 6,982,168 29,703,535 11,268,952
Cost saving per QOF payment 10.77 1.09 4.63 1.76
ARs
Effect per quarter per AR (£) 33.32 9.21 6.44 14.97
Effect per year per AR (£) 133.28 36.84 25.76 59.88
ARs in England 2010/11, n 336,988 336,988 336,988 336,988
Cost saving (England) (£) 44,913,761 12,414,638 8,680,811 20,178,841
Total points for MH9 2012/13 183,748 183,748 183,748 183,748
Price per point (£) 125 125 125 125
Total QOF payment for MH9 (£) 22,968,500 22,968,500 22,968,500 22,968,500
Net cost saving (£) 21,945,261 –10,553,862 –14,287,689 –2,789,659
Cost saving per QOF payment 0.95 –0.54 –0.38 –0.12
Notes
Figures in italics are based on coefficients that were not statistically significant at 5%.
Net cost saving is calculated on the extreme assumption that if there were no QOF payments, CPs and ARs would not
be provided by practices.
Represents 2012/13 prices.
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Although the calculations in Table 27 suggested that the cost savings for people with SMI across all
three sectors for CPs and ARs were much greater than the corresponding QOF payments to practices,
this does not imply that withdrawing these payments would have increased total costs for people with
SMI, as we did not attempt to estimate the effects of the payments on the number of CPs. However,
the magnitude of the cost saving associated with CPs suggests that even a small reduction in CPs, due
to removal or reduction in the QOF incentive payment, would have had an opportunity cost in terms of
care forgone in other parts of the NHS. Alternatively, to deliver the same level of care overall, the
budget would have needed to increase.
Strengths and limitations
Tracking health-care resource use of people with SMI is particularly problematic because they receive
NHS care in primary, secondary and community care. To assess accurately the implications of better
quality of primary care on health-care expenditure, detailed information at an individual level is required
over a substantial period of time. A strength of this study is in exploiting data linked across a number of
administrative sources at an individual patient level. Successful linkage and management of such data is
non-trivial and requires both substantial expertise and computational resources. The ability to observe
health-care use in continuous time over a 3-year period provided a richness of data of sufficient detail
to allow us to link resource use to practice quality accurately and robustly. Costing health-care services,
particularly primary care consultations, was not straightforward and required a number of assumptions
to be made, for example about the duration of a consultation when these were recorded in the data
set as zero or > 2 hours. Although we believe that our assumptions were reasonable, better-quality
recording in primary care would make cost estimates more reliable. However, complex data derived
from different administrative systems will always require some assumptions to be applied when data
are imputed and cleaned to prepare for analysis. Health-care cost data are typically highly skewed
with long right-hand-side tails in their distribution, and often contain a large mass point at zero. These
features were observed in our data and required non-standard regression models to estimate the link
between costs and covariates. With a large mass point at zero, the two-part model applied here was the
appropriate way to derive marginal effects of the impact of quality on costs.
Implications for research and practice
We found that younger patients with a SMI had a high level of need and generated additional costs
for the NHS, mainly in specialist mental health care. There was also considerable variation between
patients: most did not generate any hospital costs in a given year, but those who did were more likely
to be admitted to general rather than mental health wards and may have had long and costly admissions.
Further research to identify characteristics of patients who are more likely to develop comorbidities
and to require admission may help to identify interventions that could improve outcomes for people
with SMI and reduce secondary care costs. A better understanding of the characteristics of patients
who attend general rather than mental health hospitals and variations in admission patterns may also
help identify ways to manage costly resources more efficiently.
We found that the greatest volume of care for people with SMI was provided by specialist services,
with patients having three times as many contacts as with primary care. As we used primary care
records in this research, we had limited information on the quality of specialist services, and this
warrants further investigation. In terms of quality of primary care, only one-fifth of patients received
both a CP and an AR, and one-third received neither, despite the existence of financial incentives for
practices to provide them. These low rates may have had serious implications for patient health and
NHS resources: patients who were in receipt of a CP had fewer emergency contacts and generated
lower primary and secondary care costs than those without, and patients who were reviewed annually
generated lower primary and mental health-care costs. These interventions require further exploration,
as the pathways to improved outcomes remain unclear (e.g. ARs were not, as might be expected,
associated with reduced secondary care costs, but with reduced mental health-care costs).
DOI: 10.3310/hsdr08250 Health Services and Delivery Research 2020 Vol. 8 No. 25
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Jacobs et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
77
According to the national QOF results,152 7832 patients nationally (12.7% of registered people with SMI)
were ‘exception reported’ for the CP indicator in 2017/18, with wide geographical variation (from 6.6%
in London North East and Central to 18.6% in Midlands Central). Another 41,784 patients (9.1%) did
not receive a CP, despite not having a reason for exclusion recorded. There may therefore be potential
to improve outcomes and substantially reduce costs for people with SMI by moving towards full
implementation of CPs and ARs. Although most patients receive the recommended care in the context
of the financial and reputational incentives offered by QOF, variation in achievement rates between
regions and practices suggests that higher rates are achievable. Further research into the reasons why
patients do not receive CPs and ARs could suggest potential solutions to this problem, and address the
geographical variations in quality and costs of care.
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Chapter 8 Conclusions and recommendations
Summary of findings
This study undertook two substantive analyses. The first was a systematic review (see Chapter 2) to
identify primary care quality indicators for patients with SMI that could be assessed using routine data. In
total, 1847 studies and database sources were identified using the search. A final set of 27 records were
examined, which generated a set of 59 different quality indicators. Of these, 17 had already been included
in the QOF. The quality of the evidence underpinning most of the indicators was relatively weak. However,
we decided to construct two quality indicators identified in the review process and by PPI members as
being important (continuity of GP care and polypharmacy), to enhance our subsequent analyses.
The second substantive component of analysis was applying a retrospective observational study using
linked administrative data from primary care practices in England. Practices were those contributing to
the CPRD GOLD database, with linkages made to hospital records in HES, A&E department attendances,
mortality and community mental health service records in MHMDS. We tracked a cohort of people with
SMI in primary care until they experienced an outcome or an event, using survival analysis and four
different samples, depending on the outcomes examined and the inclusion and exclusion criteria.
In Chapter 4, the sample consisted of 19,324 patients attending 215 practices. Half of the sample
(50.3%) had an A&E department presentation at some point during the observation period, 13.1% had
an admission for SMI and 12.8% had an ACSC admission. A CP had been documented in the previous
12 months for 40% of the patient-periods observed and an AR in 69% of periods.
Having a CP documented in the previous 12 months was associated with a lower hazard of 26% for A&E
department attendances (HR 0.74, 95% CI 0.69 to 0.80), 33% for SMI admissions (HR 0.67, 95% CI 0.59
to 0.75) and 27% for ACSC admissions (HR 0.73, 95% CI 0.64 to 0.83). The reduction associated with
AR was 20% for A&E department presentation (HR 0.80, 95% CI 0.76 to 0.85), 25% for SMI admission
(HR 0.75, 95% CI 0.67 to 0.84) and 24% for ACSC admission (HR 0.76, 95% CI 0.67 to 0.87).
An alternative way to express this is the absolute risk of each outcome with and without each care
quality indicator, obtained by using the model results to predict the probability of each outcome for
the individuals in the sample under two scenarios, that: (1) no-one has the indicator and (2) everyone
has the indicator. Using this approach, the model estimated that the hazard of A&E department
attendance was 5.4% without a CP and 4.1% with a CP, hazard of SMI admission was 0.9% without a
CP and 0.6% with a CP, and hazard of ACSC admission was 0.7% without a CP and 0.5% with a CP, per
3-month period. Equally, the hazard for an A&E department attendance was 4.7% without an AR and
3.8% with an AR, for SMI admissions it was 0.8% without an AR and 0.6% with an AR, and for ACSC
admissions it was 0.7% without an AR and 0.5% with an AR, per 3-month period.
For those with moderate visit frequency (three to five visits in the previous 12 months), higher GP
continuity was associated with 11% lower hazard of A&E department presentation (HR 0.89, 95% CI
0.83 to 0.97) and 23% lower hazard of ACSC admission (HR 0.77, 95% CI 0.65 to 0.92), but not with
risk of SMI admission. For frequent attenders (six or more visits in the previous 12 months), higher GP
continuity was associated with 26% lower hazard of ACSC admission (HR 0.74, 95% CI 0.62 to 0.87),
but not with risk of A&E department presentation or SMI admission.
Expressed as absolute risk, for those with moderate visit frequency, the hazard for A&E department
attendances was 4.0% with low continuity and 3.6% with high continuity, whereas the hazard for ACSC
admissions was 0.6% with low continuity and 0.4% with high continuity, per 3-month period.
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In Chapter 5, the sample consisted of 17,255 patients for the analysis of unplanned admissions and
mortality (and 13,247 for A&E department attendances) from 215 practices. On average, 12.9% of
patients had at least one episode of polypharmacy during the observation period. The average number
of polypharmacy episodes per patient on polypharmacy was 5.5 and the mean polypharmacy episode
length was 66 days (range 2–2340 days). Annual prevalence of polypharmacy fluctuated between
5% and 6%.
Relative to monotherapy, polypharmacy was not significantly associated with higher mortality, unplanned
hospital admissions or A&E department attendances. Not being prescribed any antipsychotic substance
increased the hazard (relative to monotherapy) of an unplanned admission to hospital by 8.2% (95% CI
3% to 13.6%) and the hazard of an A&E department presentation by 18.6% (95% CI 13.5% to 23.9%),
but had no effect on mortality risk.
In Chapter 6, the sample consisted of 70,774 quarterly observations on 9907 patients treated at 214
practices. Most of those who re-entered specialist care during the period of observation (702 individuals,
7.09% of the sample) did so by re-entering community-based mental health care (695 individuals),
rather than direct into inpatient mental health care (seven individuals). For periods preceding re-entry
to specialist care, on average, in the previous 12 months patients had more visits to their GP, were more
likely to have a CP and had higher practitioner continuity than in the 45 months preceding periods in
which they did not re-enter specialist care.
Results from the discrete-time survival analysis showed there was no statistically significant association
between level of practitioner continuity or CP and hazard of re-entering specialist mental health care.
Factors associated with a higher hazard of re-entering specialist care were greater socioeconomic
disadvantage, white ethnicity (vs. black or minority ethnicities), and having diagnoses from both
schizophrenia- and bipolar-type classifications (vs. bipolar-type classification alone). Factors associated
with a lower hazard of re-entering specialist care were middle-age (aged 46–65 years vs. aged 18–35
years), longer time since diagnosis of SMI (> 2 years vs. 0–1 years) and number of physical comorbidities.
In Chapter 7, quarterly costs of health-care utilisation were estimated using a bottom-up costing
approach and the sample consisted of a total of 150,748 quarter observations across 16,485 patients.
The mean quarterly health-care cost per patient (at 2012/13 costs) was £1310, with £653 (50%)
identifiable as related to SMI (rather than physical health). Total costs decreased with age until middle
age and then increased for patients aged > 65 years, whereas the proportion of costs related to SMI
steadily decreased with age. For patients aged 19–35 years, 64% of total costs were related to SMI,
whereas for patients aged > 65 years the proportion was 34%, reflecting a greater emphasis on
management of physical comorbidities. Primary care costs (£235) made up approximately 18% of total
mean quarterly costs, general hospital costs (£481) constituted 37% and specialist mental health-care
costs (£594) accounted for around 45%.
Marginal effects estimated from the two-part models suggest that CPs in the 12 months prior to the
start of the current 3-month period were associated with lower health-care costs in that period, in
terms of overall costs (£53 per patient), primary care costs (£9), hospital costs (£26) and mental health-
care costs (£12). ARs were associated with lower primary care costs (£9), mental health-care costs
(£15) and total costs (£33), but not with lower hospital costs. High practitioner continuity in the prior
12 months was associated with lower primary care costs (£3) in the current 3-month period, but not
with lower mental health-care costs, hospital costs or total costs.
In terms of the cost implications of our analysis, we compared the reductions in costs for people with
SMI with the costs of QOF payments to practices for providing CPs and ARs. We estimated that the
annual savings from CPs across all sectors was £75.5M in 2012/13 relative to the total QOF payments
for CPs of £6.4M, suggesting a net saving of NHS expenditure of £69.1M. The net savings in NHS costs
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for people with SMI was positive across all three sectors for CPs. The equivalent net saving figure for
ARs in 2011/12 was smaller at £21.9M and was only positive in relation to total costs (not across any
of the sectors).
Table 28 summarises the results for each indicator by each outcome.
Comparison with other research
Previous research into the relationship between primary care quality and unplanned hospital utilisation
has often relied on aggregate-level data, such as the study by Baker et al.,153 which found that higher
performance on the QOF overall was not a predictor of area-level A&E department attendances. Other
studies have shown an association between subjective assessment of higher primary care quality and
lower utilisation of A&E.154,155 Our previous study (Gutacker et al.43) found that higher achievement on
the AR indicator was associated with a higher rate of SMI admissions. Our new analysis, which was
able to determine the sequence of events and found the reverse association, supports the hypothesis
that the previous study’s findings may have been driven by QOF indicators being documented after a
hospital admission. A study by Harrison et al.156 found that the introduction of the QOF was associated
with a decrease in unplanned admissions for incentivised ACSCs, consistent with our finding that CPs
were associated with a reduced risk of ACSC admissions.
TABLE 28 Summary of results for each indicator against outcomes
Quality
indicator
SMI
admissions
ACSC
admissions
All
unplanned
admissions
A&E
department
attendances Mortality
Re-entry to
specialist
mental health
services Cost
QOF indicators
CPs Lower
hazard
Lower
hazard
Lower
hazard
Not significant Lower total
costs, primary
care costs,
hospital costs,
mental health
costs
ARs Lower
hazard
Lower
hazard
Lower
hazard
Lower total
costs, primary
care costs,
mental health
costs, but not
hospital costs
Non-QOF indicators
Continuity of
care
Not
significant
Lower
hazard
Lower
hazard
(moderate
visits); not
significant
(high visits)
Not significant Lower primary
care costs, but
not other
costs
Polypharmacy Not
significant
Not
significant
Not
significant
Note
Shading indicates outcomes not assessed.
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The estimated annual antipsychotic polypharmacy prevalence in our study is not directly comparable
with other studies owing to diversity in the definition of polypharmacy, and differences in the sample
characteristics and methodology. A large international study estimated a global median of 20%,157 but
there is considerable variation between and within geographic locations.157,158 Higher rates of polypharmacy
have been estimated for the UK, but the patients included in those studies were prescribed at least one
antipsychotic at the date of data collection and polypharmacy was defined as the concurrent use of more
than one antipsychotic on that single date159,160 (a definition that is likely to overestimate polypharmacy).
A more comparable approach by Kadra et al.,130 using a 6-week overlap to define polypharmacy, estimated
prevalence to be 11.5%. The lower estimate of polypharmacy prevalence in our study is because, although
some patients are at risk of polypharmacy for the entire calendar year, others are present for only a few
days and, therefore, are less likely to be on polypharmacy for that year. In Kadra et al.130 patients were at
risk for the entire study period.
It is widely believed that polypharmacy increases the risk of mortality and hospitalisations, but there is
a lack of methodologically sound studies to support this assumption. To our knowledge, the only previous
study using data drawn at a national level of medication prescriptions and appropriate methods to adjust
for confounding factors was conducted by Tiihonen et al.122 Tiihonen et al.122 investigated the impact of
polypharmacy on mortality using a cohort of 2588 patients from Finnish hospital data and concluded
that polypharmacy was not associated with increased mortality. This conclusion is reinforced by our study
using a significantly larger cohort of 17,255 patients with a record of SMI diagnosis in primary care.
Our study further concludes no association between polypharmacy, inpatient hospitalisations123,124 and
A&E department attendances, in contrast with the positive correlations found in previous studies.123–125
There is a dearth of evidence on the cost implications of primary care quality for people with SMI.
Previous studies have focused mostly on the costs of SMI, both direct costs to the health-care system,
often emphasising hospital costs, and sometimes the wider indirect costs to society.161–168 A systematic
review169 examining the association between mental health-care hospital costs and patient characteristics
identified the presence of psychotic or affective symptoms as key cost drivers of hospital costs. Other
studies have used a micro-costing approach to examine differences in characteristics between high-cost
users (the top decile) and the rest of the cost distribution,170,171 and show that a small proportion of mental
health-care users can account for a disproportionately large share of health-care costs, the majority of
those being patients with SMI.
Strengths and limitations
The primary strength of the research presented in this report was the access to detailed linked
primary, secondary and community care records, covering the full patient population with a confirmed
diagnosis of SMI from a representative sample of general practices in England. These linkages allowed,
for the first time, analysis of the entire patient pathway from routine care provided by GPs, over acute
services delivered in hospitals’ A&E departments and wards, to long-term inpatient care provided in
specialised mental health hospitals and in the community. This is especially relevant in the case of
chronic conditions, such as SMI, for which secondary care is not limited to acute hospitals and for
which widely available data sets, such as HES in England, provide only a partial picture of the quality
and quantity of care received.
In addition, the study benefited from event-level data, which allowed the chronological order of
exposure to treatment (e.g. receipt of a CP) and subsequent outcome (e.g. hospitalisation) to be
determined. This is a necessary condition for establishing causality. Previous studies of the effect of
high-quality primary care on unnecessary hospitalisations, as incentivised in the QOF, were limited
to aggregate data at the practice-year level,43,156 and, therefore, could not ascertain which patients
received care or experienced outcomes, or in which order.
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The use of these large linked longitudinal data sets provide more robust estimates than would be
possible with smaller sample sizes in a cross-sectional design or with aggregate data. Our sample sizes
are an improvement on much of the previous literature in this area, which has suffered from small
sample sizes.
Another strength of this study was the use of advanced statistical methods that allowed controlling
for time-invariant unobserved patient heterogeneity. Failure to observe, and thus control for, time-
invariant differences across patients may lead to biased estimates of the relationships of interest
if time-invariant patient characteristics correlate with outcomes. Examples of unobserved patient
characteristics that can be assumed to be stable – at least over short time periods – include severity,
family history and health-care-seeking behaviour.
We were able to construct measures of primary care quality in areas of importance to patients who
went beyond those currently included in the QOF. As well as enriching our analysis, this is also
informative for the future development of the QOF for SMI.
A significant strength of this study was costing health-care services across a number of administrative
sources at an individual patient level, which required significant expertise as well as extensive
computational resource. To the best of our knowledge, a bottom-up costing of the full patient care
pathway has not been undertaken previously. This enabled us to determine in which health sectors
savings might fall as a result of improvements in quality of primary care. It also allowed us to compare
the cost of QOF indicators with the savings that are generated from use of these indicators, which
enables a better understanding of relative resource use.
The main limitation of this research derives from the observational nature of the data and the
consequential inability to control for confounding due to non-random allocation to treatment and
reverse causality bias. For example, patients who are at low risk of complications may be less likely to
have a CP written for them if health-care professionals perceive the benefit of such a CP to be low.
This would result in an upwards biased estimate of the effectiveness of CPs in an unselected population.
Conversely, during periods of deterioration leading to admission, GPs may have less opportunity to,
or put less emphasis on, spending time on preventative measures, such as CPs. This would induce a
negative correlation between having a current CP and risk of unplanned hospitalisation. The direction
of bias is undetermined and our results should be interpreted as showing association, not causation,
while keeping in mind that these analyses are an advance on previous studies that used aggregate rather
than individual-level data, and cross-sectional rather than longitudinal data.
A further limitation of our study is the focus on newly diagnosed patients and their care patterns. It is
conceivable that patients who had been diagnosed with SMI more recently would have received more
attention from their GP than those who had already been living with their condition for a long time
and were stable. It is therefore unclear whether or not the estimated associations would also apply to
subpopulations of people with SMI that were not included in our study.
Another limitation is that we have assumed that some aspects of health-care utilisation, such as
an admission or re-entry to secondary mental health services, are poor outcomes. However, it is
conceivable that some of these events, including an emergency admission, may be entirely appropriate
and may not always be a negative outcome that signals poor management. We are unable to tell from
routine data whether or not this is the case. Equally, our definition of polypharmacy will include some
patients for whom this is an appropriate management strategy and within prescribing guidelines, and
does not represent a negative outcome, although polypharmacy is a well-used, macro-level indicator of
poor prescribing practice.
Finally, the clinical outcomes we examined are important as they represent some of the excess health
risks for people with SMI and carry substantial health-care costs. However, they are not the only
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outcomes that matter. For example, both people with SMI and GPs value continuity of care in itself as
part of how they experience receiving and giving care.106,107 Regular physical reviews may uncover
health issues that require treatment, but which would not necessarily have led to a hospital admission.
Broader outcomes, which are important to people with SMI, may also be affected by the different
measures of care quality, including social functioning and health-related quality of life.108 Patient-
reported outcome measures and patient-reported experience measures would provide a way to
capture broader measures of outcome and quality, but are not routinely collected and reported in
primary care or hospital care.
Generalisability
All samples analysed in Chapters 4–7 used CPRD GOLD primary care data to identify patients with
a diagnosis of SMI. A study conducted in collaboration between CPRD and the London School of
Hygiene & Tropical Medicine96 concluded that patients in the CPRD GOLD database are broadly
representative of the UK general population in terms of age, sex, ethnicity and BMI. This was in line
with previous research by CPRD,98 which also demonstrated slightly lower mortality rates in younger
age groups than national rates, and a larger median practice size than the national average. Owing to
the geographical distribution of Vision software use, areas in the East Midlands, Yorkshire and The
Humber, and the north-east of England are under-represented relative to areas in Wales, Scotland and
Northern Ireland.
All samples were also restricted to those patients eligible for linkage to other data sources, including HES,
which relies, in part, on the general practice providing consent. Previous research172 has shown that
patient characteristics are similar between those eligible for linkage and those who were not, including
in terms of age, BMI, duration of follow-up, medication use and medical history. However, there were
small variations in practice consent by geographical region, with practices in London being less likely,
and practices in the south-west of England being more likely, to take part in the linkage scheme.
Patients were included in the studies based on SMI diagnosis codes being recorded in their primary
care record. This means that patients who were not permanently registered with a general practice
would not have been included. Additionally, patients with SMI but unknown to the GP (e.g. not yet
presented to a GP, or fully managed within secondary or specialist care) would not have been included.
Additionally, GPs may choose not to use specific codes to record that a patient had SMI when the
diagnosis was less certain, or if they preferred to use free-text comments to record the mental health
status of the patient. However, it should be noted that GPs are typically closely involved in the care
of patients with SMI and, hence, the reliance of this study on primary care records to identify such
patients is not a major limitation.
This study used only CPRD GOLD primary care data, which led to a lack of geographical
representativeness of England as a whole. Future studies should consider combining CPRD GOLD data
with the newly available CPRD Aurum data, collected from practices using the EMIS (EMIS Health,
Leeds, UK) software system, to improve representativeness.
Patient and public involvement
An integral aspect of this research project was the involvement of experts by experience. Both CD and LA
have lived experience of SMI and their contributions to this project were invaluable. Key contributions
were (1) assessing the degree to which the outcomes and quality measures we discussed throughout the
project (not just those we analysed) were important and valid for service users; (2) drawing on their own
experience of the entire care pathway to advise us on the interpretation of results; and (3) acting as a sense
check about a whole range of aspects of the project, allowing us to stand back from the technicalities of the
modelling and think about what we were really trying to do.
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Both individuals formed part of the research team, which involved attending regular team meetings
and contributing to discussions of the analytical approach and interpretation of the results, as well as
participating on the SSC and guiding the research programme. Having two individuals involved in the
PPI aspect of this project throughout allowed insights from more than one perspective. It also meant
that when an individual was unable to attend meetings, the other individual was still able to contribute.
The experts by experience had the support of other research team members, as and when needed.
The involvement of people with lived experience allowed the team to focus on key elements important
to people who use health-care services for their mental health. CD and LA assisted with many aspects
of the project: from the start in developing the research proposal, to interpreting the results, to finally
disseminating the findings in a manner suitable for laypeople (e.g. supporting deriving the key messages
for production of a video). Both individuals have co-authored publications, and LA is now actively
engaged in research, and reports that her involvement in the project has enhanced her skills in research.
A workshop for primary care practitioners on ‘improving the quality of primary care for people with
serious mental illness’ was held to gather the perspective of GPs and other health-care professionals
on the practical aspects of primary care quality for people with SMI. At this workshop, we asked
participants for feedback on issues relating to the care of people with SMI, including writing of CPs,
liaison with specialist mental health care, management of physical compared with mental health,
challenges of providing care for the patient population and system constraints. The feedback helped
guide the research team’s thinking around the variation in delivery, adherence, content and quality of
CPs and ARs.
Conclusions
The provision of both CPs and ARs represent indicators of good-quality primary care, in that they are
associated with a lower risk of SMI admissions, ACSC admissions and A&E department attendances,
and thus reductions in more expensive secondary care utilisation. Both of these quality indicators are
also associated with reduced total costs across the health-care sector, although the distribution of the
cost reductions varies across indicators. CPs are associated with lower primary care and hospital costs,
whereas ARs are associated with lower primary care and mental health-care costs. It would therefore
seem reasonable to continue to incentivise both these indicators in the QOF, and encourage their use
and uptake in clinical practice.
We provided important new evidence on two additional non-QOF indicators, as we found the evidence
base for many quality indicators for people with SMI in primary care lacking. The non-QOF indicators
we identified also hold promise as quality indicators. High continuity of care was associated with a
lower risk of ACSC admissions and A&E department attendances. It also served to reduce primary care
costs, although only by a small amount. Continuity of care is, however, difficult to operationalise as a
QOF indicator for two reasons: First, there are many definitions of continuity of care and there is no
consensus on what constitutes the most appropriate definition. Second, a continuity of care indicator
could potentially be ‘gamed’ by practitioners (e.g. by changing coding practices without a corresponding
change in clinical practice). In contrast, an indicator for (absence of) polypharmacy could be operationalised
for the purposes of the QOF, but polypharmacy showed no significant associations with any of the
outcomes we examined. Although it would not necessarily be a good indicator to include as a metric
into a P4P scheme, in the absence of clinical benefit, the analysis nevertheless provided important new
evidence that when the use of polypharmacy may be deemed clinically necessary, it does not appear to
increase risks of mortality or higher utilisation. Our findings give support to current guidelines encouraging
antipsychotic monotherapy, rather than polypharmacy, in routine clinical practice.
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Although it may not be appropriate to incentivise the two non-QOF indicators as metrics in a P4P
scheme, the indicators nevertheless provide important information about primary care quality and do
support the evidence base on what would constitute good-quality care for this particular patient group.
Implications for practice
Many of the indicators identified in our systematic review relate to aspects of physical care. Many
people with SMI have significant needs for physical health care that may be missed or undertreated,
leading to avoidable morbidity and disability, and premature mortality.173 Consideration should
therefore be given to the development of a broader set of quality indicators, including those focusing
on physical care. Given the increased risks of diabetes, cardiovascular disease and respiratory disease
in this population, ongoing primary care for people with SMI could improve health outcomes by
focusing on disease prevention through tackling obesity and smoking.174,175
Similarly, several quality indicators from our systematic review relate to the processes of care,
including continuity of care and ongoing contact with relevant services. Targeting comprehensive
primary care to people with SMI could promote their engagement with appropriate specialised mental
and physical health-care services, helping them to reach their full potential.
Our results suggest that seeing the same family physician over time can improve the physical health of
people with SMI. These findings are similar to those in previous studies.103,176 Higher continuity of GP
care may reduce the risk of ACSC admissions through improved management of physical health, by
facilitating familiarity, communication, trust and quality of relationship between doctor and patient.177
Our results also showed that better continuity of care reduced primary care costs.
Current changes in UK general practice mean continuity is likely to decrease rather than improve
(particularly with practice closures, recruitment and retention problems, increasing use of locums and
formation of practice networks). This suggests that practices should prioritise continuity of care in this
patient group, despite the challenges in doing so.
We found that having a CP or AR documented in the previous 12 months was associated with a lower
risk of A&E department presentations and SMI and ACSC admissions (by around one-third). Given
that there is considerable scope for improvement in completion rates, support for increasing timely
completion of CPs and ARs could help to improve achievement rates and reduce variation between
regions and practices. Taken together with our findings that these activities are associated with lower
health-care costs, this strategy could be a promising approach to reducing health-care costs.
Our finding that, relative to monotherapy, polypharmacy is not significantly associated with higher
mortality or unplanned hospital admissions and A&E department presentations, and the relatively low
levels of polypharmacy (prevalence rate of 2%), perhaps suggests that, in clinical practice in the UK
(outside inpatient and acute care), polypharmacy may not be as large an issue as previously reported.178
Our results also provide support for the role of antipsychotic therapy in reducing unplanned admissions
and A&E department presentations, which may be markers of mental illness relapse. For a shorter overlap
period (≥ 14 days), which captured more cross-tapering in the definition of polypharmacy, we observed an
increase in the risk of unplanned admission. This could be because patients who changed drugs might have
had more unstable disease profiles and suggests a need for close monitoring in the first few weeks of
cross-tapering, when the risk of unplanned hospitalisation is higher.
Although the emphasis has in part been moving away from QOF towards local enhanced services,179
the requirement for evidence on quality indicators in primary care remains undiminished, and will be
needed to develop future guidance and incentives under local improvement schemes and will inform
proposed reviews of QOF in mental health.180 Any changes in incentive structures for quality indicators
to bring about improved outcomes needs to be evidence based.
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Recommendations for research (in order of priority)
Better evidence is needed on the impact of primary care quality on a broader set of health
outcomes for people with serious mental illness
Most indicators included in our systematic review (see Chapter 2) relate to processes of care, and
although highly relevant, especially to patients, it is important to establish whether or not they lead
to improved health outcomes. With the exception of mortality (which we examined only in relation to
polypharmacy), all our study outcome measures were based on health-care utilisation. We had planned to
examine effects on the severity of SMI using the clinician-rated HoNOS outcome measure (see Chapter 6);
however, HoNOS is not recorded in primary care and the quality of reporting in secondary care is patchy.
We therefore used another measure of health-care utilisation instead: re-entry to secondary care.
Although these outcomes are likely to impact on health status and are also important in terms of their
implications for the efficient use of NHS resources, they are indirect measures of health outcomes.
To be included in the QOF, quality indicators must be supported by NICE evidence-based clinical
guideline recommendations or evidence from systematic reviews. This is why the large majority of
indicators we identified are not currently part of the QOF. Better measures of health outcome are
essential to determine the effectiveness of current and potential QOF indicators.
Good measures of health outcome for people with SMI are central to the ability to undertake research
that goes beyond consideration of process measures, for example measures of social functioning, patient
experience and health-related quality of life. Routine recording of quality-of-life measures would enable
the cost-effectiveness of incentive policies and other measures of primary care quality to be determined.
Looking beyond direct health outcomes to the impact of high-quality care on wider aspects of mental
health and well-being would mean including data on other non-health outcomes, such as employment and
housing status.
The mechanisms by which primary care affects utilisation of hospital care need
to be understood
Although not all hospital care can, or should, be avoided for people with SMI, the prevention of acute
episodes of the condition is a key objective of good primary care. Our study assesses ‘real-world’
primary care quality, rather than care provided in accordance with strict protocols in a clinical trial
context. Our study data are therefore likely to encompass wide variations in the content and delivery
of primary care (e.g. an AR). A better understanding of the nature and quality of CPs and ARs, which
might be best gained through qualitative research rather than using observational data, would help
understand who receives CPs and ARs, why some patients do not receive incentivised care and how
that may affect their utilisation of secondary care. It is unclear which components, or combination
of components, of care are most effective in preventing avoidable hospital care. The timing and setting
for providing care also needs to be understood. For example, further research to investigate the
underlying reasons for re-entry to specialist secondary care services would provide greater insight into
the role of primary care in supporting patients to avoid the deterioration of SMI conditions.
A clear conceptual framework would be an essential first step, identifying the potential mechanisms
by which aspects of primary care quality impact secondary care use among this specific patient group.
Interface issues with care provided in other settings, such as informal care provided by families or friends,
or social care, could also be identified within the framework. Hypotheses could then be drawn and tested
empirically. If suitable data do not exist – which is highly probable – primary studies may be needed.
Understanding variations in capacity to benefit could help to deliver person-centred care
Our study found that CPs and ARs were associated with significantly lower hazards of A&E
department attendances and emergency admissions and, in some cases, with lower costs. However,
these are average effects and mask a range of effects at individual level. A better understanding of the
variations in outcomes could enable clinicians to target efforts accordingly. For example, capacity to
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benefit may vary according to each individual’s clinical and sociodemographic characteristics. Equally,
certain subgroups may be underserved or face greater barriers to accessing care; evidence on supply
side facilitators could be used to improve the delivery of person-centred care.
A better evidence base is needed on what outcome measures and quality indicators are
most highly valued by people with serious mental illness, so that efforts can be prioritised
according to what matters most to patients
There is a growing literature on what matters to people with SMI and how to better incorporate
patient perspectives into outcome measurement in mental health, including the development and
application of patient-reported outcome measures and experience measures. However, we need to
know which outcome measures and quality indicators matter most to people with SMI, so that efforts
to measure these in routine data can be prioritised. Focus groups with service users could provide
views on what outcomes matter and various elicitation methods, including qualitative research and
discrete choice experiments, can be used to prioritise outcome and quality measures using patient
preferences. However, any new indicators should be properly consulted on before implementation. An
evidence base on how patients prioritise outcome and quality measures could help to focus resources
and efforts towards areas that matter most to patients, for example if people with SMI value having a
CP renewed when nothing has changed over time, or whether they care about continuity with the
same GP or would more highly value ease of seeing any GP urgently. These preference sets may also
vary by different groups (e.g. age, sex or ethnicity) and it would be important to understand better this
variation to facilitate a targeted approach to service delivery.
Evidence is needed on how patient outcomes are influenced by the interfaces between
health care, social care and informal care
Serious mental illness is a complex set of diseases that typically affects individuals across the life
course and in all areas of their lives. Focusing on only one or two parts of the health-care system when
examining patient outcomes risks ignoring wider social determinants of health and well-being and
increases the chances of drawing spurious inferences about cause and effect.
To the best of our knowledge, our study was the first to cover the full patient care pathway for people with
SMI, and this was facilitated by the use of MHMDS, the collection of which is a welcome effort to improve
the coverage and quality of data on people with mental health problems. However, details on the type of
care provided by different health and social care professionals are sketchy and are reported inconsistently.
There is almost no information on informal social support networks (friends and family). Many of these
types of care may be substitutes or complements. The inter-relationships between these types of care need
to be clarified through further research, so that care can be integrated around the individual. This is likely
to require the collection of primary data, as such factors are not recorded in routine care data.
A fuller understanding of resource implications is needed to inform resource allocation
This study has indicated the potential for better-quality primary care to reduce costs in secondary
care. However, a more detailed research agenda investigating the mechanisms for identifying, releasing
or transferring and reinvesting resources ‘saved’, particularly across sectors, would be welcome. This
would provide valuable evidence on which to base decisions about the allocation of resources, as well
as informing the integration of care, which is often hampered by financial barriers.
Data coverage and linkage, specifically for mental health data, should be improved to
address further research questions
Throughout this report, we have commented on some of the limitations of our analyses that arise from
constraints in the nature of the data to which we had access. Improving the scope of routine outcome
measurement in mental health services and facilitating linkages from diverse data sources would enhance
the ability to address further important research questions. Facilitating researcher access to relevant
data sets in a timely way is also a key aspect of enhancing both the quantity and quality of mental
health research undertaken.
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Appendix 1 Systematic literature review
of primary care quality
BOX 1 Annotated search strategy: MEDLINE via OVID SP
Searched: February 2015
Date range: January 1990 to February 2015
1. serious mental illness*.tw. (2037)
2. serious mental disorder*.tw. (260)
3. serious psychiatric illness*.tw. (61)
4. serious psychiatric ill-health*.tw. (0)
5. serious mental ill-health*.tw. (0)
6. serious psychiatric disorder*.tw. (130)
7. severe mental illness*.tw. (2679)
8. severe mental disorder*.tw. (720)
9. severe mental ill-health*.tw. (2)
10. severe psychiatric illness*.tw. (128)
11. severe psychiatric disorder*.tw. (379)
12. severe psychiatric ill-health*.tw. (0)
13. major mental disorder*.tw. (288)
14. major mental illness*.tw. (350)
15. major psychiatric illness*.tw. (151)
16. major psychiatric ill-health*.tw. (0)
17. major psychiatric disorder*.tw. (730)
18. major mental ill-health*.tw. (0)
19. schizophrenia/or schizophrenia, catatonic/or schizophrenia, disorganized/or schizophrenia, paranoid/or
shared paranoid disorder/ (86,432)
20. (Schizophrenia* or schizophrenic or dementia praecox).tw. (90,771)
21. Schizotypal Personality Disorder/ (2217)
22. (disorder* adj2 schizotypal).tw. (702)
23. (disorder* adj1 delusional).tw. (703)
24. Psychotic Disorders/ (32,708)
25. ((psychotic adj2 disorder*) or (schizoaffective adj2 disorder*) or psychoses or psychosis or
schizophreniform).tw. (38,127)
26. bipolar disorder/or cyclothymic disorder/ (32,171)
27. (Bipolar adj2 (disorder* or depression or depressive or psychosis or psychoses)).tw. (22,038)
28. (Manic state* or mania).tw. (8053)
29. (Manic adj2 (disorder* or depression or depressive or psychosis or psychoses)).tw. (4445)
30. (cyclothymic disorder* or cyclothymic personalities or cyclothymic personality).tw. (95)
31. or/1-30 (179,930)
Line 31 captures terms for serious mental illness.
32. exp Primary Healthcare/ (82,203)
33. general practitioners/or physicians, family/or physicians, primary care/ (18,403)
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34. general practice/or family practice/ (64,455)
35. (family adj2 pract*).tw. (11,764)
36. (primary adj2 care).tw. (89,376)
37. (general adj2 pract*).tw. (69,034)
38. (family adj2 physician*).tw. (12,969)
39. Ambulatory Care/ (36,401)
40. or/32-39 (268,786)
Line 40 captures terms for primary care.
41. Quality Indicators, Healthcare/ (10,737)
42. (quality adj2 indicat*).tw. (6747)
43. (quality adj2 measure*).tw. (12,491)
44. (quality adj2 criteria).tw. (3829)
45. (performance adj2 indicat*).tw. (4837)
46. (performance adj2 measure*).tw. (14,194)
47. (performance adj2 criteria).tw. (1367)
48. (incentive* adj3 scheme*).tw. (207)
49. (incentive* adj3 assess*).tw. (96)
50. (incentive* adj3 measure*).tw. (152)
51. (incentive* adj3 outcome*).tw. (96)
52. “Standard of Care”/ (1049)
53. (standard* adj2 care).tw. (25,676)
54. (standard* adj2 healthcare).tw. (400)
55. “Quality of Healthcare”/ (58,460)
56. (quality adj2 (healthcare or care)).tw. (39,007)
57. patient outcome assessment/ (934)
58. (patient adj2 outcome assessment*).tw. (70)
59. (patient adj2 outcome measure*).tw. (2492)
60. proms.tw. (263)
61. patient satisfaction/or patient preference/ (63,756)
62. (patient* adj2 satisfaction).tw. (26,024)
63. (patient* adj2 experience*).tw. (59,692)
64. (patient* adj2 preference*).tw. (8103)
65. quality.tw. (594,390)
66. or/41-65 (782,974)
Line 66 captures terms for quality indicators.
67. 31 and 40 and 66 (551)
Line 67 identifies records that contain at least one term for serious mental illness, and at least one term for
primary care and at least one term for quality indicators.
68. limit 67 to yr=‘1990 -Current’ (537)
Line 68 applies the date limit.
BOX 1 Annotated search strategy: MEDLINE via OVID SP (continued)
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Appendix 2 Study framework
TABLE 29 Read codes used to identify diagnostic categories of SMI
Category Read codes used to identify diagnostic category
Schizophrenia and other psychoses E100.00 E100.11 E100000 E100100 E100200 E100300 E100400
E100500 E100z00 E101.00 E101000 E101400 E101500 E101z00
E102.00 E102000 E102100 E102500 E102z00 E103.00 E103000
E103200 E103300 E103400 E103500 E103z00 E104.00 E105.00
E105000 E105200 E105500 E105z00 E106.00 E107.00 E107.11
E107000 E107100 E107200 E107300 E107400 E107500 E107z00
E10y.00 E10y.11 E10y000 E10y100 E10yz00 E10z.00 E120.00
E121.00 E122.00 E123.00 E123.11 E12y.00 E12y000 E12yz00
E12z.00 E13..00 E13..11 E131.00 E132.00 E133.00 E133.11
E134.00 E13y.00 E13y100 E13yz00 E13z.00 E13z.11 E1z..00
E212200 Eu20.00 Eu20000 Eu20011 Eu20100 Eu20111 Eu20200
Eu20211 Eu20212 Eu20213 Eu20214 Eu20300 Eu20311 Eu20400
Eu20500 Eu20511 Eu20600 Eu20y00 Eu20y12 Eu20y13 Eu20z00
Eu21.00 Eu21.11 Eu21.12 Eu21.13 Eu21.14 Eu21.15 Eu21.16
Eu21.17 Eu21.18 Eu22.00 Eu22000 Eu22011 Eu22012 Eu22013
Eu22014 Eu22015 Eu22100 Eu22111 Eu22200 Eu22300 Eu22y00
Eu22y11 Eu22y12 Eu22y13 Eu22z00 Eu23.00 Eu23000 Eu23011
Eu23012 Eu23100 Eu23112 Eu23200 Eu23211 Eu23212 Eu23214
Eu23300 Eu23312 Eu23y00 Eu23z00 Eu23z11 Eu23z12 Eu24.00
Eu24.12 Eu24.13 Eu25.00 Eu25000 Eu25011 Eu25012 Eu25100
Eu25111 Eu25112 Eu25200 Eu25212 Eu25y00 Eu25z00 Eu25z11
Eu26.00 Eu2y.00 Eu2y.11 Eu2z.00 Eu2z.11 Eu44.14
Bipolar disorder and affective psychoses E11..00 E11..12 E110.00 E110.11 E110000 E110100 E110200
E110300 E110400 E110600 E110z00 E111.00 E111000 E111100
E111200 E111300 E111400 E111500 E111600 E111z00 E112400
E113400 E114.00 E114.11 E114000 E114100 E114200 E114300
E114400 E114500 E114600 E114z00 E115.00 E115.11 E115000
E115100 E115200 E115300 E115400 E115500 E115600 E115z00
E116.00 E116000 E116100 E116200 E116300 E116400 E116500
E116600 E116z00 E117.00 E117000 E117100 E117200 E117300
E117400 E117500 E117600 E117z00 E11y.00 E11y000 E11y100
E11y300 E11yz00 E11z.00 E11z000 E11zz00 E130.00 E130.11
E13y000 Eu30.00 Eu30.11 Eu30000 Eu30100 Eu30200 Eu30211
Eu30212 Eu30y00 Eu30z00 Eu30z11 Eu31.00 Eu31.11 Eu31.12
Eu31.13 Eu31000 Eu31100 Eu31200 Eu31300 Eu31400 Eu31500
Eu31600 Eu31700 Eu31800 Eu31900 Eu31911 Eu31y00 Eu31y11
Eu31y12 Eu31z00 Eu32300 Eu32311 Eu32312 Eu32313 Eu32314
Eu32800 Eu33213 Eu33300 Eu33311 Eu33312 Eu33313 Eu33314
Eu33315 Eu33316 Eu3z.11
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TABLE 30 Conditions classified as SMI or ambulatory care sensitive admissionsa
Condition ICD-10 code(s) used to identify the conditionb
SMI admission codes
SMI F20 F21 F22 F23 F24 F25 F26 F27 F28 F29 F30 F31
ACSC admission codes
Angina I10 I24.0 I24.8 I24.9
Asthma J45 J46
Chronic obstructive pulmonary disease J41 J42 J43 J44 J47
First diagnosis J20 + second diagnosis, one of J41 J42 J43 J44 J47
Congestive heart failure I50 I11.0 J81
Diabetes (in any diagnosis field) E10.0 E10.1 E10.2 E10.3 E10.4 E10.5 E10.6 E10.7 E10.8 E11.0
E10.1 E11.2 E10.3 E11.4 E10.5 E11.6 E10.7 E11.8 E12.0 E10.1
E12.2 E10.3 E12.4 E10.5 E12.6 E10.7 E12.8 E13.0 E10.1 E13.2
E10.3 E13.4 E10.5 E13.6 E10.7 E13.8 E14.0 E10.1 E14.2 E10.3
E14.4 E10.5 E14.6 E10.7 E14.8
Epilepsy G40 G41 O15 R56
Hypertension I10 I11.9
Anaemia D50.0 D50.8 D50.9
Cellulitis L03 L04 L08 L88 L98.0 L98.3
Dehydration E86
Dental A69.0 K02 K03 K04 K05 K06 K08 K09.8 K09.9 K12 K13
Ear, nose and throat infections H66 H67 J02 J03 J06 J31.2
Gangrene (in any diagnosis field) R02
Gastroenteritis K52.2 K52.8 K52.9
Nutritional deficiencies E40 E41 E42 E43 E55 E64.3
Perforated or bleeding ulcer K25.0 K25.1 K25.2 K25.4 K25.5 K25.6 K26.0 K26.1 K26.2 K26.4
K26.5 K26.6 K27.0 K27.1 K27.2 K27.4 K27.5 K27.6 K28.0 K28.1
K28.2 K28.4 K28.5 K28.6
Urinary tract infection or pyelonephritis N10 N11 N12 N13.6 N39.0
Influenza (in any diagnosis field, exclude
secondary diagnosis of D57)
J10 J11
Pneumonia (in any diagnosis field, exclude
secondary diagnosis of D57)
J13 J14 J15.3 J15.4 J15.7 J15.9 J16.8 J18.1 J18.8
Tuberculosis A15 A16 A19
Other vaccine-preventable diseases
(in any diagnosis field)
A35 A36 A37 A80 B05 B06 B16.1 B16.9 B18.0 B18.1 B26 G00.0
M01.4
a Based on Bardsley et al.181
b Based on the first diagnosis field in HES data unless otherwise specified.
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TABLE 31 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: checklist of items
that should be included in reports of cohort studies
Item Item number Recommendation Page number
Title and abstract 1 (a) Indicate the study’s design with a commonly used term
in the title or the abstract
v
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found
xxiii–xxvii
Introduction
Background/rationale 2 Explain the scientific background and rationale for the
investigation being reported
1–3
Objectives 3 State specific objectives, including any prespecified
hypotheses
4
Methods
Study design 4 Present key elements of study design early in the paper 17
Setting 5 Describe the setting, locations and relevant dates, including
periods of recruitment, exposure, follow-up and data
collection
24–27
Participants 6 (a) Give the eligibility criteria and the sources and methods
of selection of participants. Describe methods of follow-up
24–27
(b) For matched studies, give matching criteria and number
of exposed and unexposed
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders and effect modifiers. Give diagnostic criteria,
if applicable
19–21, 27–28
Data sources/
measurement
8a For each variable of interest, give sources of data and
details of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than
one group
21–24
Bias 9 Describe any efforts to address potential sources of bias 17
Study size 10 Explain how the study size was arrived at 26
Quantitative variables 11 Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why
28
Statistical methods 12 (a) Describe all statistical methods, including those used to
control for confounding
18, 31–32, 44,
52, 66–67
(b) Describe any methods used to examine subgroups and
interactions
27
(c) Explain how missing data were addressed 27, 44, 64–66,
121
(d) If applicable, explain how loss to follow-up was
addressed
(e) Describe any sensitivity analyses 32, 45, 67
continued
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TABLE 31 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: checklist of items
that should be included in reports of cohort studies (continued )
Item Item number Recommendation Page number
Results
Participants 13a (a) Report numbers of individuals at each stage of study
(e.g. numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow-up and analysed)
26
(b) Give reasons for non-participation at each stage 26
(c) Consider use of a flow diagram 26
Descriptive data 14a (a) Give characteristics of study participants (e.g. demographic,
clinical, social) and information on exposures and potential
confounders
33, 34, 45, 53,
54, 60, 61
(b) Indicate number of participants with missing data for
each variable of interest
(c) Summarise follow-up time (e.g. average and total
amount)
33, 34, 45, 53,
54
Outcome data 15a Report numbers of outcome events or summary measures
over time
33, 45, 53, 54,
67–69
Main results 16 (a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision
(e.g. 95% CI). Make clear which confounders were
adjusted for and why they were included
35, 46, 47, 54,
70–72
(b) Report category boundaries when continuous variables
were categorised
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period
79
Other analyses 17 Report other analyses done (e.g. analyses of subgroups and
interactions, and sensitivity analyses)
39, 48, 75
Discussion
Key results 18 Summarise key results with reference to study objectives 79–81
Limitations 19 Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias
82–84
Interpretation 20 Give a cautious overall interpretation of results, considering
objectives, limitations, multiplicity of analyses, results from
similar studies and other relevant evidence
85, 86
Generalisability 21 Discuss the generalisability (external validity) of the study
results
84
Other information
Funding 22 Give the source of funding and the role of the funders for
the present study and, if applicable, for the original study
on which the present article is based
iii
a Give information separately for exposed and unexposed groups.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
Appendix 3 The association between
primary care quality and hospital
care utilisation
Practice-level analysis
Overview
The practice-level analysis investigated whether or not better quality of primary care is associated with
unplanned hospital admissions. It was an extension of our previous project1 and a precursor of the
patient-level analysis in the current project.
Quality of primary care was captured by the practice performance on the CP and AR indicators discussed
in Chapter 3, Quality and Outcomes Framework indicators. Although the patient-level analysis utilised
patient-level information on the two indicators, in the practice-level analysis CPs and ARs were analysed at
the practice level using two measures of achievement on these indicators: (1) the population achievement
rate and (2) the reported achievement rate, which we define in the next subsection. Our two research
questions were formulated as follows:
1. What is the association between the CP population and reported achievement rates with
emergency hospital admissions for SMI?
The analysis was carried out for the period 2006/7–2013/14.
2. What is the association between the AR reported achievement and emergency hospital admissions
for ACSCs?
The analysis was performed for the period 2011/12–2013/14. The impact of the AR indicator on all
physical hospital admissions during the period 2006/7–2010/11 was assessed in our previous SMI
project. For reasons explained in the next subsection, the population achievement rate was not analysed.
In a previous study,1 we conducted a practice-level analysis to investigate the association between
achievement rates on the CP and AR indicators and hospital admissions for SMI and physical
conditions for the period of 2006/7 to 2010/11. The current practice-level analysis differs in two ways:
first, we analysed ACSCs instead of all physical conditions; second, we extended the study period to
include 3 more years (2011/12–2013/14).
We combined patient- and general practice-level data for the study period of April 2006 to March 2014.
Specifically, we merged QOF data from around 8500 general practices in England with admissions
data from HES (aggregated to practice level) for the study period of April 2006 to March 2014, using
a unique general practice identifier. We linked these data to publicly available information on general
practice characteristics, characteristics of their patient population, such as disease prevalence, and
population characteristics, such as deprivation and other potential confounders recorded at small area
level. We also controlled for measures of access to care.
Practice performance
The ‘population achievement’ rate is defined as the percentage of patients in the relevant (CP or AR)
register for which the indicator was achieved. Practices can ‘exception report’ patients from the
indicators according to valid exception reporting criteria, such as the patient is deemed unsuitable for
treatment, is newly registered with the practice or newly diagnosed, or that the patient exercises
informed dissent. The ‘reported achievement’ rate removes exception-reported patients from the
achievement calculation. In this study, both measures were used to ascertain whether or not results
are sensitive to the choice of achievement measure.
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As explained in Chapter 3, The annual review indicator, the AR indicator was split into six subdomains
after 2010/11. For each year in the period of 2011/12 to 2013/14, we calculated the AR achievement
rate by weighting the achievement rate on each of the six subdomains by the associated QOF points.
For instance, the AR achievement rate for 2011/12 is given by:
AR =
(MH11) × 4 + (MH12) × 4 + (MH13) × 4 + (MH14) × 5 + (MH15) × 5 + (MH16) × 5
27
, (11)
in which MH11–MH16 denote the achievement rates on the subdomains, the maximum of points a
practice receives on an indicator is 4 or 5 and the total maximum points that can be received is 27.
For each general practice, we obtained information on the population and reported achievement rates
from the QOF data set.
As shown in Figure 7, the average annual achievement rates for the CP indicator initially increased over
time, but reached a plateau in 2009/10. The average population(-reported) achievement rate increased
from 64% (76%) in 2006/7 to about 81% (89%) in 2009/10 and remained at about the same level until
2012/13. The drop in population achievement in 2013/14 was due to changes in the definition of
excepted reported patients. Owing to this inconsistency in definition, we restricted our analysis to the
2006/7–2012/13 period, with respect to population achievement.
The average reported achievement rate for the AR indicator was flat through our study period
(2011/12–2013/14). We did not consider the AR population achievement rate in the analysis, as
the definition of exception-reported patients changed in year 2012/13, making the AR population
achievement rate inconsistent across years.
Sample and outcomes
We extracted information on all NHS-funded inpatient activity for people aged ≥ 18 years who were
diagnosed with SMI. To identify people who had been diagnosed with SMI, we searched all primary and
secondary diagnosis fields in HES since April 2001 for the following ICD-10 diagnosis codes: F20–F25,
F28 and F29, covering schizophrenia, schizotypal and delusional disorders, and F30 and F31, covering
bipolar and mood affective disorders.
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To capture all relevant activity, we linked patient records across time and identified all secondary care
provided to the patient from April 2006 onwards. SMI admissions were defined as when the patient
had a primary diagnosis of SMI (see ICD-10 codes above) in the first episode of the inpatient spell.
Admissions for ACSC conditions were defined by specific ICD-10 codes.181
Covariates
We controlled for a number of GP and practice characteristics, local population characteristics and
measures of access to secondary care. To reflect differences between practices and regions in terms
of supply and access to care, we recorded the catchment population prevalence of NHS community
psychiatric residential beds and the catchment population providing informal care.
Finally, we used primary care trust-level fixed effects to capture all time-invariant differences between
primary care trusts in terms of their resource capabilities, including the availability of crisis resolution
and home treatment teams that provide alternative home care in an emergency and play a ‘gatekeeping’
role in admissions to hospital.
Table 32 summarises all dependent and independent variables in the SMI and ACSC samples. Further
details about the covariates used can be found in our previous project.1
TABLE 32 Study variables
Variable description Source
SMI sample
(2006/7–2013/14)
ACSC sample
(2011/12–2013/14)
n Mean n Mean
Number of SMI admissions within a year HES 62,882 3.63
Population achievement (CP)a QOF 55,200 77.41
Reported achievement (CP) QOF 62,882 86.21
Number of ACSC admissions within a year HES 23,111 0.56
Population achievement (AR) QOF 23,111 74.83
Reported achievement (AR) QOF 23,111 88.35
Proportion of male GPs in general practice GMS 62,882 0.59 23,111 0.56
Proportion of foreign GPs in general practice GMS 62,882 0.32 23,111 0.32
Mean age (years) of GPs in general practice GMS 62,882 47.81 23,111 47.55
General practice is contracted under PMS GMS 62,882 0.42 23,111 0.41
General practice is alternative provider of medical services GMS 62,882 0.01 23,111 0.02
Practice list size ADS 62,882 6878 23,111 7135
Patient population: average age (years) ADS 62,882 39.96 23,111 40.26
Patient population: proportion of male patients ADS 62,882 0.50 23,111 0.5
IMD, income domain, 2010 ONS 62,882 0.16 23,111 0.16
Proportion of non-white, PCA ONS 62,882 0.11 23,111 0.11
NHS psychiatric residents/1000, PCA ONS 62,882 0.21 23,111 0.21
Proportion living in urban setting, PCA ONS 62,882 0.82 23,111 0.82
Proportion providing informal care, PCA ONS 62,882 0.10 23,111 0.1
Distance (miles) to closest acute hospital HES 62,882 4.89 23,111 4.89
Distance (miles) to closest mental health hospital HES 62,882 9.65 23,111 9.65
ADS, attribution data set; GMS, General Medical Services; PCA, practice catchment area; PMS, Personal Medical Services.
a As CP population achievement in 2013 is not considered, descriptive statistics are based on fewer observations.
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Model specification
We estimated panel data models to assess the impact of primary care quality on hospital admissions.
As the response variable – number of admissions to hospital per practice per year – is a non-negative
integer, we employed count data models. Specifically, we estimated both fixed- and random-effects
Poisson models.
As the number of patients at risk of admission differed across practices, a crucial part of the model
specification is to define the proper exposure variable (i.e. the pool of practice patients at risk of
hospital admission). This is defined as the CP register (or the AR register) and enters the set of
explanatory variables logarithmically.
We calculated robust SEs for the fixed-effects model and bootstrapped SEs for the random-effects
model. Statistical significance was always assessed at the 5%, 1% and 0.1% levels. All models are
estimated using the xtpoisson and poisson commands in Stata.
Results
We analysed the association between CPs and emergency SMI admissions and the association between
ARs and emergency ACSC admissions using two separate samples. The two samples differ in the
number of participating practices because practices were excluded from the samples if the number of
patients on the register was below five, and these numbers are different for the CP and AR register.
The SMI sample consists of 8250 general practices that have reported treating patients with SMI during
the 8-year study period. The panel is unbalanced, with only 7267 (88%) of the practices contributing
observations every year. The reason for the unbalance is that for some years, some practices (1) do not
report or participate in the QOF, (2) have fewer than five patients with SMI on their patient register,
(3) their overall list size is < 1000 patients, or (4) are yet to be established or have ceased to exist. In
total, there are 62,882 practice-year observations. The ACSC sample consists of 7856 general practices
during the 3-year study period and about 96% of them contribute observations every year. In total,
there were 23,111 practice-year observations.
Figure 8 shows the average annual admission rates for the SMI and ACSC samples. Despite a slight
increase in the average number of SMI admissions per general practice per year (from 3.41 to 3.50)
during the period 2006–13, the SMI admission rates exhibited a negative trend, falling from 8.18% in
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2006 to 6.51% in 2013. The reason is that the CP register – the denominator in the admission rate –
increased over the same period from 44 to 55 patients. During the period 2011–13, the ACSC
admission rates exhibit a positive trend, increasing from 0.89% in 2011 to 1.07% in 2013.
Table 33 presents the effects of a 10 percentage point change in the QOF achievement rates on
(1) the number of hospital admissions (see Table 33, column 4) and (2) the percentage change in
admissions (see Table 33, column 6).
The association between CP achievement and SMI emergency admissions is statistically significant when
only population achievement is considered. Even then, it is positive and small. The random-effects model
estimates that a 10 percentage point increase in the CP population achievement rate is associated with
an increase of 0.025 SMI admissions by general practice (0.72%). The fixed-effects model estimates a
slightly larger increase of 0.037 admissions by general practice (1.02%).
We found no association between the AR reported achievement rate and ACSC admissions.
Discussion
Our results showed a small positive association between CP achievement and emergency SMI
admissions. This finding is consistent with the results from our previous SMI project.1 A 10 percentage
point change in the CP population achievement rate increases SMI admissions by 1.08% according to
the previous study1 and by 0.72% according to the current study. The small difference is due to the
extension of the study period by 2 years (2006/7–2010/11 vs. 2006/7–2012/13). The effects of ARs
are not comparable between the two studies, as the previous study focused on all physical admissions,
whereas the current focuses on ACSC admissions.
However, the practice-level analysis is subject to serious limitations. First, we cannot be sure if the
specific individuals who were admitted had received QOF checks. It is possible that those who were
admitted as emergencies had not received an annual QOF review. It is also possible that individuals
admitted as emergencies did receive QOF reviews, but only after discharge from hospital, rather than
prior to admission, which could also explain the positive association.
TABLE 33 Effect of a 10 percentage point increase in QOF achievement on hospital admissions
Effect Model n
Absolute change
(number of
admissions) 95% CI
Relative
change, % 95% CI
Effect of CP on SMI admissions
Reported achievement RE 62,882 –0.002 –0.016 to 0.013 –0.04 –0.45 to 0.36
FEa 62,437 0.003 –0.021 to 0.027 0.09 –0.54 to 0.72
Population achievementb RE 55,200 0.025 0.009 to 0.042 0.72 0.26 to 1.19
FEa 54,675 0.037 –0.058 to 0.133 1.02 0.18 to 1.87
Effect of AR on ACSC admissions
Reported achievement RE 23,111 0.002 –0.010 to 0.013 0.44 –2.65 to 3.61
FEa 12,398 0.037 –0.384 to 0.458 3.61 –1.74 to 9.23
FE, fixed effect; RE, random effect.
a FE models are estimated on smaller samples because (1) some practices contribute only 1 year of data and (2) some
practices have > 1 year of contributions but zero SMI admissions in all years.
b The CP population achievement models are estimated on the shorter period 2006/7–2012/13.
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Second, aggregate data do not enable us to specify the nature of individual care pathways or
determine causality. Although we attempted to model all known confounding factors, we were unable
to capture time-variant aspects of the influence of community mental health teams, and could not
account for disease severity (case mix). In addition, we cannot rule out the possibility that there are
other, unknown, biases that impact our findings.
Additional material
Figure 9 shows the rate of care indicators recorded by general practices per patient-year for each
financial year in our sample. This rate is the number of times an indicator is recorded in that year across
all patients, divided by the number of patient-years of observation in that financial year (which takes
into account partial years for patients who were not observed for the full financial year). For example,
in 2007/8 the rate of annual reviews (composite measure) recorded was 1.06 per patient-year.
The CP indicator shows a decline over the study period until 2012/13, when there was an increase in
the threshold of achievement required to attain the maximum payment. The original annual review
indicator shows a marked drop-off after it ceased to be incentivised in 2010/11, whereas the aggregate
indicator composed of the ‘health risk’ checks shows less marked change, but a small increase after the
specific components began to be incentivised in 2011/12. The composite of these two annual review
indicators shows little change in response to the QOF rule changes.
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Appendix 4 The association between
antipsychotic polypharmacy and hospital
care utilisation and mortality
Continuous survival analysis
Complete linkage of primary, secondary and mortality data provides important information about the timing
of APP episodes and the three outcomes. To exploit this rich information, we employ a time-to-event
design. Our modelling choice is also supported by the following three features of the data: (1) patients
enter the study at different times, (2) they may exit the study before the outcome occurs (right censoring),
and (3) APP is a time-varying variable that does not occur at consistent intervals for all patients.
We follow each individual from entry date until the outcome of interest or until censoring. Censoring
may occur because (1) a patient dies, (2) registration with the practice ends or (3) the study period
ends (i.e. the patient is still registered on 31 March 2014). We treat death as censoring rather than a
competing risk because our focus is on the relationship between quality indicators and outcomes,
rather than on the prediction of the probability of an event at a given point in time.182 Although some
patients experience multiple events, we consider only the time to first event.
The hazard function for each outcome is specified as:
hi(t) = λ0(t)expfX i1β1 + . . . + Xikβk + α1APPi(t) + α2NSi(t)g. (12)
It is the product of the baseline hazard, λ0(t), and an exponentiated linear function of time-invariant
covariates, Xi1, . . . , Xik, and the two time-varying variables APP(t) and NS(t), indicating if the patient is
on APP at time t and whether or not the patient is on an antipsychotic medication at time t.
In survival analysis model without time-dependent variables, the baseline hazard cancels out and the
HR between two individuals is constant over time. However, the proportionality of hazards does not
hold in our case, as the time-dependent APP and average length of stay change at different times for
different individuals. Estimation of the Cox model via partial likelihood is still feasible.
Antipsychotic product codes
We downloaded the antipsychotic drug codes list from the ClinicalCodes database [URL: https://
clinicalcodes.rss.mhs.man.ac.uk/ (accessed 12 February 2020)], a web repository of clinical codes developed
by the University of Manchester’s Institute of Population Health.127 The repository holds a collection
of peer-reviewed articles and the associated codes used irrespective of code type (e.g. Read, CPRD
product/medical code, BNF code, ICD-10) and database (e.g. CPRD, The Health Improvement Network).
We used the list of antipsychotic drug codes uploaded by Windfuhr et al.128 The list includes three BNF
chapter headings: (1) first-generation antipsychotic drugs or typical antipsychotics, (2) second-generation
antipsychotics or atypical antipsychotics, and (3) depot antipsychotics. From the list of 33 antipsychotic
substances presented in Table 34, 27 were recorded at least once in our sample.
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TABLE 34 Product codes used to identify antipsychotic substances
Substancea Product code
1 Amisulpride 80139020 68222020 81945020 35008020 35010020 85993020 69302020 68224020 00411021 89950020
85994020 85992020 68217020 80154020 79348020 86000020 86001020 85999020
2 Aripiprazole 91145020 87950020 91147020 87952020 91149020 87954020 88668020 10469020 94973020 91139020
87944020 91141020 87946020 91143020 87948020 88666020 94971020
3 Asenapine 00341021 337021
4 Benperidol 64108020 98282020 64105020 84860020
5 Chlorpromazine 61251020 61249020 61250020 72606020 61237020 58896020 55203020 72588020 55710020 72587020
68531020 55217020 58894020 55204020 66353020 91404020 61244020 65188020 52087020 61238020
72597020 55228020 68532020 60250020 55202020 66356020 91408020 61243020 61264020 56481020
56450020 56444020 56445020 73791020 56446020 56468020 56456020
6 Chlorprothixene 51832020
7 Clozapine 72581020 97149020 72580020 97145020 97153020 72577020 72576020 88169020 97151020 88167020
97147020 97155020 88806020 88804020
8 Droperidol 58513020 72300020 58514020 62878020 62879020 72297020 94599020
9 Flupentixol 48897020 62029020 48900020 91584020 53030020 53031020 89976020 89974020 57938020 89972020
62034020 91582020 68096020 89970020 62033020 62032020
10 Fluphenazine 62037020 62042020 50459020 50472020 92214020 62049020 92200020 92202020 61027020 62048020
62954020 92212020 92204020 92206020 92208020 50445020 92210020 92218020 53053020 92216020
11 Fluspirilene 62066020 51357020
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Substancea Product code
12 Haloperidol 63137020 63136020 58501020 58505020 58502020 58500020 95205020 58506020 63104020 55437020
53896020 54580020 75300020 63108020 99757020 60366020 63114020 511021 00443021 63115020
55438020 53576020 63110020 78059020 63109020 88468020 20065020 20067020 75301020 53575020
75302020 63113020 63118020 59312020 59028020 63105020 53898020 55351020 95203020 99755020
72226020 55346020 91764020 56176020 56181020 56182020 56183020 56175020 56177020 56187020
58510020 58509020 63124020
13 Levomepromazine 87842020 38919020 64327020 64326020 32615020 97323020 87840020 52695020 3365020 52694020
14 Methotrimeprazine 64330020
15 Olanzapine 00719021 81016020 00717021 00715021 87556020 83405020 00727021 55972020 00725021 00723021
59434020 81014020 03580020 00733021 90165020 00731021 00729021 92053020 00713021 81015020
00711021 00709021 83403020 83404020 00589021 87558020 83399020 78913020 58203020 79499020
81008020 92055020 90167020 83397020 78912020 83398020 98278020 98329020
16 Paliperidone 93747020 93739020 93741020 93743020 99845020 99847020 99841020 99843020 99853020 99855020
99849020 99851020
17 Penfluridol 49952020 65318020
18 Pericyazine 50678020 96724020 50677020 96722020 50679020 52648020 65580020 65584020 65579020 65581020
19 Perphenazine 49428020 49429020 53721020 65588020 65592020 65593020 56832020 65589020 56833020 65587020
52047020
20 Pimozide 58519020 58518020 65799020 65798020
21 Pipotiazine 53586020 91989020 91987020 91985020 91981020 65842020
22 Prochlorperazine 68249020 91364020 54878020 66241020 66242020 66237020 54234020 57101020 69868020 60605020
55530020 56337020 66245020 69516020 69517020 72187020 56506020 91368020 58525020 52717020
52716020 51690020 04131020 4128020 04129020 96911020 04123020 51692020 96913020 52248020
52249020
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TABLE 34 Product codes used to identify antipsychotic substances (continued )
Substancea Product code
23 Promazine 72991020 66279020 51749020 72987020 66278020 55705020 72988020 51751020 66277020 66283020
66282020 55706020 72183020 72184020 58296020 52959020 52957020 52958020 52968020 51649020
24 Quetiapine 85204020 97203020 97205020 00209021 00447021 98873020 85207020 94789020 85206020 85203020
42176020 33610020 99745020 94791020 87045020 94793020 94787020 36328020 85202020 85213020
85216020 85215020 85212020 87047020 98875020 95789020 95791020 95793020 95787020
25 Remoxipride 73439020 73440020 73441020 73474020 73475020 84528020
26 Risperidone 49437020 73799020 49438020 49439020 73798020 77749020 73800020 78753020 77550020 82616020
13768020 81545020 77501020 92723020 92725020 88877020 36905020 79476020 53727020 74841020
49490020 86494020 81543020 53728020 86496020 92717020 53729020 92721020 49489020 88875020
77912020 74927020 74786020 65788020 49491020
27 Sertindole 82836020 82837020 82835020 82828020 82829020 82831020 82827020
28 Sulpiride 52921020 52922020 80696020 66836020 60498020 56102020 56529020 59205020 66837020 66838020
59150020 82057020
29 Thioridazine 54413020 67032020 75277020 67027020 67037020 54418020 54411020 67028020 67036020 67038020
54412020 67029020 75276020 55600020
30 Trifluoperazine 51013020 51663020 51681020 51676020 51678020 51687020 51677020 87980020 67148020 67234020
75976020 55747020 75977020 67240020 67235020 55746020 67241020 69003020
31 Trifluperidol 67244020 67245020 67248020 67249020
32 Zotepine 55209020 55210020 50782020 50780020 50781020
33 Zuclopenthixol 48713020 48714020 48712020 90151020 90149020 72839020 61507020 61508020 61506020 90147020
90145020 72836020 91596020 53027020 67405020 91592020 61511020 61512020
a The 27 substances that were recorded at least once in our sample are in bold.
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Calculation of treatment duration
To mark the beginning and end of an APP episode we need information about the prescription date
and the number of days the antipsychotic drug was prescribed. The CPRD therapy file provides the
prescription date but the treatment duration is poorly populated, with 99% missing values for
antipsychotic drugs. The reason is that, in most cases, GPs prescribe the quantity a patient should use
until it runs out and, therefore, they are not interested in recording the duration of the prescription.
To overcome this problem, we calculated the treatment duration as the ratio of the total quantity
entered by the GP for the prescribed product, over the ndd prescribed for the event (drug). As
information on ndd is missing for > 23% of the therapy events, we employ the following imputation
strategy: to events with missing ndd we assigned the most frequent ndd across all events with the
specific product code. Approximately 1% of the therapy events involve a product for which all events
have missing ndd. For these events, we imputed the ndd by assigning the most frequent ndd across all
events with the specific substance.
Estimating the treatment duration as the ratio quantity : ndd was further complicated by another two
issues. First, although pack size or type of the prescribed product is provided (e.g. 560 ml, 21 tablets),
the unit in which ndd is recorded is not, and in some cases it is obvious that quantity and ndd are
recorded in different units (e.g. quantity = 21 tablets, ndd = 300). In these cases, we divided ndd by the
strength of the prescribed substance to impute the true ndd (e.g. ndd = 300/100 mg = three tablets).
Second, < 0.02% of prescription records (245/1,035,856) had an implausibly large calculated duration
and were dropped from the analysis.
Measures of polypharmacy prevalence
We calculated two measures of polypharmacy prevalence. First, the annual prevalence of polypharmacy
as the number of patients with at least one polypharmacy episode in a year divided by the total number
of patients observed during that year. Second, the rate of polypharmacy defined as the sum of all patients’
polypharmacy days in a year over the sum of all patients’ days at risk of polypharmacy in that year.
Our second measure – the rate of polypharmacy – is an improvement over the point estimates of
polypharmacy prevalence often reported in the literature. Point estimates of prevalence show what
fraction of eligible individuals are prescribed polypharmacy on a given day. Average point estimates of
prevalence can be calculated by averaging daily point estimates.
In the following, we prove that the rate of polypharmacy is a weighted average of the point estimates
of polypharmacy on each of the 365 days of the year. Instead of assigning an equal weight to each day
of the year, our measure puts a different weight according to the ratio of patients at risk on that day
over the patients at risk in the entire year.
Let POLnt and POPnt be defined as:
POLnt =
1, if individual n is on polypharmacy on day t
0, otherwise

(13)
POPnt =
1, if individual n is present (at risk) on day t
0, otherwise

(14)
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The average point estimate of polypharmacy prevalence is:
average point estimate =
1
365
∑
365
t = 1
number of patients on polypharmacy on day t
number of patients present (at risk) on day t
=
1
365
∑
N
n = 1
POLn1
∑
N
n = 1
POPn1
+ . . . +
∑
N
n = 1
POLn,365
∑
N
n = 1
POPn,365
0
BBB@
1
CCCA
=
∑
N
n = 1
POLn1
∑
N
n = 1
POPn1
1
365
 
+ . . . +
∑
N
n = 1
POLn,365
∑
N
n = 1
POPn,365
1
365
 
(15)
The rate of polypharmacy is:
rate =
number of polypharmacy days in a year
number of days at risk in a year
=
∑
N
n = 1
∑
365
t = 1
POLnt
∑
N
n = 1
∑
365
t = 1
POPnt
=
∑
N
n = 1
POLn1
∑
N
n = 1
∑
365
t = 1
POPnt
+ . . . +
∑
N
n = 1
POLn,365
∑
N
n = 1
∑
365
t = 1
POPnt
=
∑
N
n = 1
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∑
N
n = 1
POPn1
∑
N
n = 1
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∑
N
n = 1
∑
365
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POPnt
0
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∑
N
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∑
N
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N
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∑
N
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∑
365
t = 1
POPnt
0
BBB@
1
CCCA
(16)
From the Equations 15 and 16 it follows that the two measures differ only in the weights used.
Figure 10 is the same as Figure 5, with the addition of the polypharmacy prevalence calculated on 1
January of each calendar year. The trends of the rate of polypharmacy and the point estimate of
polypharmacy prevalence are very similar (Figures 11 and 12, and Tables 35 and 36).
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FIGURE 10 Measures of polypharmacy prevalence.
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FIGURE 11 Annual prevalence of (antipsychotic) polypharmacy.
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FIGURE 12 Rate of APP.
TABLE 35 Hazard ratios: unplanned all and unplanned SMI admissions
Unplanned admissions Unplanned SMI admissions
HR 95% CI HR 95% CI
APP (time varying) 1.14 0.99 to 1.32 1.19 0.92 to 1.53
No substance (time varying) 1.08** 1.03 to 1.14 1.23*** 1.13 to 1.35
Age (years) at entry into the sample (base: 19–35 years)
36–45 0.95 0.86 to 1.04 0.88 0.76 to 1.02
46–55 0.86** 0.79 to 0.94 0.69*** 0.60 to 0.79
56–65 0.98 0.89 to 1.09 0.56*** 0.47 to 0.67
≥ 66 1.51*** 1.37 to 1.67 0.42*** 0.35 to 0.51
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TABLE 35 Hazard ratios: unplanned all and unplanned SMI admissions (continued )
Unplanned admissions Unplanned SMI admissions
HR 95% CI HR 95% CI
Male 0.99 0.90 to 1.10 1.01 0.87 to 1.16
Age (years) at diagnosis*Male (base: 19–35 years*Male)
36–45*Male 0.94 0.82 to 1.07 0.96 0.81 to 1.16
46–55*Male 1.01 0.88 to 1.17 0.96 0.78 to 1.18
56–65*Male 1.01 0.88 to 1.15 0.92 0.71 to 1.20
≥ 66*Male 1.09 0.96 to 1.25 0.95 0.72 to 1.26
Time (years) since diagnosis (base: < 1 year)
1–5 0.97 0.91 to 1.03 1.22*** 1.11 to 1.34
> 5 0.86*** 0.81 to 0.90 1.15** 1.04 to 1.27
IMD (base: quintile 1)
Quintile 2 1.00 0.93 to 1.08 0.98 0.86 to 1.12
Quintile 3 1.08 0.99 to 1.17 1.01 0.87 to 1.19
Quintile 4 1.11* 1.02 to 1.20 1.03 0.90 to 1.18
Quintile 5 1.21*** 1.11 to 1.31 1.16* 1.01 to 1.33
Ethnicity: white 2.26*** 2.11 to 2.41 2.11*** 1.86 to 2.34
Practice is in rural area 0.96 0.89 to 1.04 0.97 0.82 to 1.15
Minimum distance (km) to acute health services (base: < 3)
3–6 1.03 0.97 to 1.09 1.04 0.91 to 1.18
6–9 0.92 0.84 to 1.01 0.97 0.82 to 1.16
> 9 1.02 0.94 to 1.11 0.98 0.82 to 1.18
Minimum distance (km) to mental health services (base: < 3)
3–6 0.99 0.92 to 1.07 0.96 0.82 to 1.14
6–9 1.03 0.95 to 1.12 1.00 0.84 to 1.20
> 9 0.98 0.90 to 1.06 0.97 0.81 to 1.16
Number of primary care contacts within 12 months prior to diagnosis (base: < 5)
5–9 1.05 0.99 to 1.12 0.88* 0.80 to 0.97
10–14 1.08* 1.01 to 1.16 0.84*** 0.76 to 0.93
15–19 1.18*** 1.10 to 1.27 0.85* 0.75 to 0.96
≥ 20 1.30*** 1.22 to 1.39 0.85** 0.75 to 0.96
Current or ex-smoker 1.08** 1.02 to 1.14 1.04 0.94 to 1.15
Current or ex-alcohol user 0.97 0.93 to 1.02 1.03 0.95 to 1.11
Number of Charlson Comorbidity Index comorbidities 1.22*** 1.18 to 1.25 0.94 0.88 to 1.00
Diagnosis of depression 1.02 0.97 to 1.06 0.84*** 0.77 to 0.90
SMI diagnosis group (base: bipolar disorder or affective psychosis)
Schizophrenia or other psychosis 1.02 0.97 to 1.07 1.10* 1.01 to 1.20
Both 1.20*** 1.12 to 1.29 1.77*** 1.58 to 1.98
*p < 0.05, **p < 0.01, ***p < 0.001.
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TABLE 36 Hazard ratios: mortality and A&E department attendances
Mortality A&E department attendance
HR 95% CI HR 95% CI
APP (time varying) 1.02 0.76 to 1.37 0.95 0.80 to 1.14
No substance (time varying) 1.02 0.94 to 1.10 1.19*** 1.14 to 1.24
Age (years) at entry into the sample (base: 19–35 years)
36–45 2.53*** 1.57 to 4.09 0.86** 0.78 to 0.95
46–55 4.34*** 2.82 to 6.66 0.75*** 0.68 to 0.82
56–65 9.22*** 6.09 to 13.97 0.71*** 0.64 to 0.79
≥ 66 31.72*** 21.38 to 47.05 1.02 0.93 to 1.12
Male 1.98** 1.27 to 3.09 0.97 0.88 to 1.07
Age (years) at diagnosis *Male (base: 19–35 years*Male)
36–45*Male 0.77 0.45 to 1.32 0.97 0.84 to 1.13
46–55*Male 0.74 0.45 to 1.21 1.05 0.91 to 1.20
56–65*Male 0.63 0.39 to 1.02 1.10 0.95 to 1.28
≥ 66*Male 0.60* 0.39 to 0.94 1.03 0.89 to 1.18
Time (years) since diagnosis (base: < 1 year)
1–5 1.01 0.91 to 1.13 0.97 0.90 to 1.05
> 5 0.76*** 0.68 to 0.85 0.90** 0.84 to 0.96
IMD (base: quintile 1)
Quintile 2 0.92 0.80 to 1.06 1.07 0.97 to 1.18
Quintile 3 1.06 0.93 to 1.20 1.11* 1.00 to 1.23
Quintile 4 0.99 0.86 to 1.14 1.18** 1.06 to 1.31
Quintile 5 1.05 0.91 to 1.22 1.31*** 1.17 to 1.47
Ethnicity: white 0.92 0.83 to 1.02 1.49*** 1.40 to 1.58
Practice is in rural area 1.03 0.88 to 1.20 0.85* 0.75 to 0.97
Minimum distance (km) to acute health services (base: < 3)
3–6 1.07 0.95 to 1.20 0.92 0.83 to 1.02
6–9 1.11 0.96 to 1.29 0.90 0.78 to 1.05
> 9 1.17 0.99 to 1.34 0.99 0.85 to 1.17
Minimum distance (km) to mental health services (base: < 3)
3–6 0.95 0.82 to 1.10 1.02 0.90 to 1.16
6–9 0.96 0.82 to 1.12 0.97 0.85 to 1.10
> 9 0.97 0.83 to 1.14 0.88 0.77 to 1.00
Number of primary care contacts within 12 months prior to diagnosis (base: < 5)
5–9 1.04 0.91 to 1.18 1.12** 1.04 to 1.20
10–14 1.06 0.93 to 1.21 1.22*** 1.13 to 1.33
15–19 1.28** 1.10 to 1.48 1.37*** 1.25 to 1.50
≥ 20 1.28*** 1.11 to 1.48 1.59*** 1.46 to 1.73
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TABLE 36 Hazard ratios: mortality and A&E department attendances (continued )
Mortality A&E department attendance
HR 95% CI HR 95% CI
Current or ex-smoker 0.93 0.85 to 1.03 1.07* 1.01 to 1.14
Current or ex-alcohol user 0.83*** 0.76 to 0.92 0.98 0.92 to 1.04
Number of Charlson Index comorbidities 1.43*** 1.37 to 1.49 1.14*** 1.11 to 1.18
Diagnosis of depression 0.89** 0.81 to 0.96 1.07** 1.02 to 1.13
SMI diagnosis group (base: bipolar disorder or affective psychosis)
Schizophrenia or other psychosis 1.42*** 1.29 to 1.56 0.94* 0.89 to 1.00
Both 1.07 0.93 to 1.25 1.02 0.94 to 1.09
*p < 0.05, **p < 0.01, ***p < 0.001.
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